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ABSTRACT 
 
SIRT proteins play an important role in the survival and drug resistance of tumour 
cells, especially during chemotherapy. In this study, we investigated the potency, 
specificity and cellular targets of three recently identified SIRT inhibitors, Sirtinol, 
Salermide and EX527. Our results identify the specificity and cellular targets of 
these novel inhibitors, and suggest that SIRT inhibitors require combined 
targeting of both SIRT1 and SIRT2 to induce p53 acetylation and cell death in 
breast cancer cells. Assessing the role of sirtuins in chemoresistance, cisplatin 
resistant cell lines were developed and characterized. Cisplatin resistant cells 
(CisR) were found to have higher levels of SIRT1, repressing the activation of 
FOXO3a. MCF-7 cells overexpressing SIRT1 were also shown to be protected 
against cisplatin treatment, highlighting its role in resistance.  
 
Sirtuins have many cellular targets, including alpha-tubulin, PARP, ku70 and 
FOXO3a. Because of the similarities between the regulation of p53 and 
FOXO3a, we decided to elucidate the effect of sirtinol treatment on FOXO3a. 
Sirtinol treatment was shown to stabilize FOXO3a, similar to its effect on p53, but 
at lower concentrations. We have shown previously that FOXO3a is an important 
downstream mediator of the cytotoxicity of receptor tyrosine kinase targeted 
therapies. To examine the conjecture whether sirtuin inhibitors could increase the 
proapoptotic potency of lapatinib through stabilization of FOXO3a, lapatinib was 
treated alone and in combination with sirtinol and EX527. Sirtinol was found to 
synergise with lapatinib treatment (in cells containing mutant p53) and this was 
dependent on the presence of FOXO proteins, highlighting the use of sirtuin 
inhibitors in increasing the efficacy of therapies that indirectly target FOXO3a. 
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CHAPTER 1 
 
INTRODUCTION 
 21 
1.1 CANCER 
 
In 2002 the International Agency for Research on Cancer (IARC) published 
figures relating to the incidences of twenty six different types of cancers globally. 
They showed that in 2002, 10.9 million people were diagnosed with cancer, there 
were 24.6 million people alive with cancer (within three years of diagnosis) and 
there were 6.7 million deaths worldwide. Lung cancer and breast cancer are the 
two most prevalent cancers in the world today, with 1.35 and 1.15 million cases 
respectively, although lung cancer has a higher mortality to incidence ratio 
compared to breast cancer due to the relatively more favourable prognosis on 
detection of the disease [1]. Cancer is the second largest cause of mortality in 
the western world after cardiovascular disease. In Europe, 3.2 million cases of 
cancer were diagnosed in 2008 and an estimated 1.72 million people died from 
cancer, 212,000 of these being breast cancer patients. Although lung cancer was 
the most common cause of death from cancer in Europe, in women, the most 
common was breast cancer, 421,000 deaths (28.2% of cancer cases) and the 
leading cause of death in women (129,000 deaths, 17% of total deaths) [2]. In 
the UK, there were 45,822 cases of breast cancer in 2006, over 99% of these 
being women. It is the most common cancer among women in the UK, 
accounting for 31% of all diagnosed cancer cases (Statistical information team, 
Cancer Research UK. Breast Cancer. 2009).   
 
1.1.1 Breast cancer 
 
Breast cancer can develop sporadically throughout a woman’s lifetime; the 
likelihood of developing breast cancer can be increased by factors such as 
obesity, alcohol and exposure to radiation [3]. But an increased risk of developing 
cancer can also be hereditary, 10% of all breast cancers are thought to have a 
strong hereditary link due to a family history of breast cancer [4]. Hereditary 
cancers are predominantly caused by the inheritance of genes that harbour 
mutations that predispose an individual to developing cancer. In breast cancer 
 22 
the two most studied genes that increase the risk of developing cancer are breast 
cancer type 1 susceptibility protein (BRCA1) and breast cancer type 2 
susceptibility protein (BRCA2) [5, 6]. BRCA1 and -2 are located on chromosomes 
17q21 and 13q12.3 respectively, and both function as tumour suppressors, 
regulating responses to DNA damage and repair, maintaining genomic integrity. 
Mutations within BRCA1 and -2 produce truncated proteins that lack appropriate 
function, increasing the likelihood of accumulating mutations due to DNA damage 
and promoting tumourigenesis [7]. Both BRCA1 and -2 are important regulators 
of the estrogen receptor α (ERα), loss of fully functional BRCA1 and -2 can lead 
to its upregulation. Although the effects of loss of BRCA1 and -2 are multifaceted, 
affecting multiple pathways that regulate controlled cell growth. 
 
ERα has been shown to be important in breast, colon, ovarian and endometrial 
cancers [8]. Moreover, 70% of breast cancer cases display an increase in ERα 
expression – termed ERα positive tumours - and a dependence on ERα-driven 
proliferation. ERα is activated by the binding of oestrogen – predominantly 17β 
estradiol – which is produced by the ovaries and the placenta. Once activated 
ERα functions as a transcription factor, translocating from the extracellular 
membrane to the nucleus, binding to promoter regions of genes that contain 
estrogen response elements (EREs), promoting the transcription of genes 
important in proliferation, differentiation and survival [9].  Estrogen is also thought 
to contribute to the accumulation of genotoxic stress by increasing potentially 
damaging factors such as oxidative stress, which can contribute to tumour 
formation. 
 
The expression of ERα provides a therapeutic opportunity to selectively inhibit 
tumour growth with anti-estrogen therapies, such as tamoxifen, ICI 182,720 (also 
known as Faslodex) and aromatase inhibitors, which act as selective ER 
modulators (SERMS), either antagonizing ER activity or targeting it for 
proteasomal degradation, inhibiting ERα-dependent proliferation and survival 
[10]. Unfortunately, prolonged exposure to SERMs can result in tumours that 
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develop ER-independent growth and resistance to SERM therapy. Recent clinical 
trials have shown that therapies that target mechanisms that promote estrogen-
independent growth can induce apoptosis in breast cancer cell lines and breast 
tumours. Moreover, targeted therapies such as lapatinib – which will be 
discussed in more detail later – are able to resensitise tumours to anti-estrogen 
agents and increase their efficacy [11]. 
 
1.2 HALLMARKS OF CANCER 
 
Cancer is a heterogeneous disease, where multiple genetic alterations and 
dysregulated processes lead to the transformation of normal cells into cancer 
cells. The seminal paper from Hanahan and Weinburg outlined the 6 essential 
alternations that cancers have to undergo to transform from normal to cancer 
cells [12]. These steps comprised of self-sufficiency in growth signals, 
insensitivity to growth inhibitory signals, limitless replicative potential, evasion of 
programmed cell death, such as apoptosis, sustained angiogenesis, tissue 
invasion and metastasis [12]. 
 
1.2.1 Oncogenes and tumour suppressors 
 
The genetic alterations observed in the transformation of normal cells to cancer 
cells occur predominantly within two types of genes, termed oncogenes and 
tumour suppressors. 
 
1.2.2 Oncogenes 
 
Oncogenes code for proteins that, when inappropriately modified or activated, 
lead to the transformation of normal cells to undergo tumour development and 
cancer progression. Most normal genes (proto-oncogenes) that become 
oncogenes encode proteins that are important in cell cycle progression, 
proliferation and survival. Oncogenes drive proliferation and survival through their 
 24 
increased activity or expression, for example, the human epidermal growth factor 
receptor 2 (HER2) and the fibroblast growth factor receptor (FGFR) are over 
expressed in 15-20% and 10% of breast tumours respectively, due to their 
chromosomal amplification [13, 14]. The increased expression of these 
extracellular receptors results in the increased activation of pro-survival signalling 
pathways, promoting tumourigenesis.  
 
Oncogenes can also be brought about via chromosomal translocations, this with 
be discussed in more detail later. 
 
1.2.3 Tumour suppressors 
 
Tumour suppressors are genes that when active regulate normal cellular 
processes such as proliferation, but are frequently lost, mutated and/or 
inactivated in cancers, leading to tumour progression. 
 
The protein p53 has been lavished with many titles, referred to as the ‘guardian 
of the genome’ [15] and the ‘policeman of the oncogenes’ [16] and is 
undoubtedly the most well studied tumour suppressor in cancer cell biology to 
date, mostly due to the frequency of mutations found in human cancers - ~50% - 
but also because of the multiple cellular processes that p53 is involved in 
regulating [17].  The primary function of p53 is as a transcription factor, but it is 
also known to exert its effect on the cellular phenotype via transcription-
independent mechanisms such as mitochondrial membrane disruption, but these 
studies are still in their infancy and the exact molecular mechanisms need to be 
more clearly defined [18]. 
 
As a transcription factor p53 is upregulated in response to cellular stresses, such 
as DNA damage, UV radiation, stress and oncogenic processes [19]. p53 
dictates the cellular phenotype by inducing cell cycle arrest (for example, the 
cyclin-dependent kinase inhibitor (CDKN1) p21 [20]), senescence (the 
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plasminogen activator inhibitor 1 – PAI-1 [21]), autophagy (the damage-regulated 
autophagy modulator – DRAM [22]), DNA repair (BTG2 [23]) and programmed 
cell death, apoptosis (the BH3-containing proteins Bid, Noxa and Puma [24, 25]). 
 
Loss of or impaired p53 function is an integral step in cancer development. Li-
Fraumeni syndrome sufferers predominantly have one functional copy of p53 
(~80% of patients), which dramatically increases their susceptibility to develop 
carcinomas of the breast, brain and adrenal glands, as well as other types of 
malignancies [26]. 
 
The increase in cellular expression of p53 is associated with its activation, 
because of this many mechanisms in tumourigenesis have developed to restrict 
or halt this upregulation/stabilisation. The E3 ubiquitin ligase murine double 
minute 2 (mdm2) (along with the other family member, mdm4 [27]), negatively 
regulates the cellular expression of p53, by blocking its transactivation domain 
and facilitating its ubiquitination and subsequent degradation by the proteasome 
[28, 29]. In normal cells, DNA damage results in the disruption of the interaction 
of p53 with mdm2, resulting in the activation and increased cellular expression of 
p53. p53 induces the transcription of genes involved with DNA-damage repair, 
but also the transcription of mdm2, which deactivates p53. This autoregulatory 
loop ensures that p53 is not inappropriately activated [30].  
 
Mdm2 is upregulated in 7% of human tumours and was found to be 
predominantly associated with WT p53 (88%), suggesting that the oncogenic role 
of mdm2 was to suppress normal p53 function [31]. Consequently, because p53 
could still function normally – if it were not repressed - chemical inhibitors have 
already been developed, such as the Nutlins, which bind to the p53-binding 
pocket within mdm2 inhibiting its ligase activity, resulting in an increase in the 
cellular accumulation and activation of p53 [32]. Nutlin compounds (notably 
Nutlin-3) were shown to induce cell cycle arrest and apoptosis in cancer cell lines 
[32] and exhibit tumour growth inhibition and shrinkage in nude mice bearing 
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tumour xenographs [33] highlighting that therapeutically targeting mdm2 could 
provide benefit in tumours that contained inactive WT p53. 
  
p53 is frequently mutated in cancer and is subsequently termed tumour protein 
53 (tp53). Mutations predominantly occur within two regions, the DNA-binding 
domain (DBD) (95%) and the N- and C-terminal regions (5%) [34]. Three-
quarters of the mutations within the DBD are missense mutations, which 
generally produce a full length protein, but their effects either impact on DNA-
binding or overall protein structure [35]. Maintaining functional p53 expression is 
key to controlling cell fate, this is exemplified by the discovery of point mutations 
within p53 – within the DNA-binding domain - that results in its inactivation and 
dysregulation. The core domain of p53 is unstable and has a short half-life of 9 
minutes. Distinct point mutations within p53 destabilize the protein further 
reducing DNA-binding efficiency, cellular expression and ability to activate its 
downstream targets [35]. This loss of function impedes p53s role in maintaining 
genomic integrity, leading to the accumulation of DNA damage, tumourigenesis, 
promoting cancer development. 
 
The activation of the specific subsets of targets of p53 is largely dependent upon 
its posttranslational status and also its association/interaction with known 
cofactors/co-regulators [36], for example, the posttranslational modification of 
lysine residues by acetylation dramatically affects the ability of p53 to activate 
downstream targets involved with inducing a cell cycle arrest and apoptosis. 
Interestingly, the acetylation of eight key lysine residues within p53 was shown 
not to effect DNA-binding ability, but did promote the dissosciation of mdm2 from 
the p53 complex, suggesting that acetylation promoted the stabilisation of p53, 
promoting the full transcriptional potential of p53 [19]. Residues known to be 
acetylated in p53 are lysines 320 and 382. The acetylation of these residues are 
associated with p53 stabilisation and activation, predominantly activating genes 
involved with inducing apoptosis [19]. 
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1.3 MAMMALIAN CELL CYCLE 
 
A eukaryotic cell is required to be able to operate appropriately and maintain the 
function of distinct tissue types. If there is damage to a tissue and new cells are 
required, cells undertake a process called the ‘cell cycle’ to produce two identical 
daughter cells via mitosis. The mammalian cell cycle is a highly ordered process 
and contains four established discreet phases: G1, S, G2 and M phase. The two 
most prominent phases being S phase, where DNA is replicated and M phase, 
where cells undergo mitosis to product two daughter cells. Between these 
phases are gap phases, termed G1 and G2 (G1 follows M phase and G2 follows 
S phase) which allow the cell to prepare for DNA synthesis and cellular division, 
respectively. There is a fifth stage of the cell cycle G0, which occurs during G1. 
Entering into G0 (also known as quiescence) is a reversible process where a cell 
is not actively dividing [37]. This defines G1 as the phase where the cell decides 
whether to undergo mitosis or not i.e. enter G0, predominantly in response to 
extracellular stimuli/growth signals. Once the ‘decision’ has been made, cells are 
committed to progressing through the cell cycle; this is termed the restriction 
point. Once this checkpoint has been passed, even if the favourable pro-cyclic 
stimuli are removed, cells will undergo mitosis [38]. 
 
Transition through the phases of the cell cycle is tightly regulated by 
heterodimeric complexes which contain proteins termed cyclins, and cyclin-
dependent kinases (CDKs) (Figure 1.1) [39]. CDKs are serine/threonine protein 
kinases and as the name suggests, have to associate with specific cyclins to be 
catalytically active and define their substrate specificity [39]. CDK expression 
throughout the cell cycle does not change, whereas the expression of cyclins is 
tightly regulated and is phase specific [40].  
 
To date, twenty CDK-related proteins have been identified in higher eukaryotes 
[41], although only five (CDK1, -2, -3 -4 and -6) are known to be important in cell 
cycle progression [42]. 
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To start from the beginning, mitogenic stimuli promotes the transcription and 
expression of Cyclins D1, -2 and -3, which bind to and activate CDK4 and -6, 
starting the progression through the G1 phase and preparation to synthesize 
DNA [43]. These complexes interact with and partially repress the ‘pocket 
proteins’ or retinoblastoma (Rb) family of proteins by phosphorylating them on 
specific residues. There are three family members, termed Rb/p105, p107 and 
Rb2/p130 [44]. Rb proteins bind to and inhibit the E2F transcription factors. 
Cyclin D/CDK4/6 complexes disrupt this interaction allowing the transcription of 
the E-type cyclins (E1 and -2) which form heterodimeric complexes with CDK2 
which bind to and phosphorylate Rb again, resulting in its complete inactivation 
allowing progression into S phase. Cyclin A is consequently upregulated in S 
phase and associates with CDK2 to drive progression into and through G2 [45]. 
As cells approach mitosis, progression is driven by type-A cyclins and their 
activation of CDK1. Once the nuclear envelope has been broken down and the 
cellular expression of Cyclin A is reduced, CDK1 associates with cyclin B and 
drives cells through mitosis and the formation of two daughter cells [37]. 
 
1.3.1 Cyclin-dependent kinase (CDK) Inhibitors 
 
As with any cellular process there are fail safe mechanisms to protect cells from 
inappropriate progression through the cell cycle, CDK-mediated progression can 
be inhibited by proteins called CDK inhibitors (CDKI), these act at various 
checkpoints throughout the cell cycle to ensure uncontrolled progression does 
not occur. There are two families of proteins that act as CDK inhibitors, the INK4 
(consisting of INK4A, -B, -C, -D) and the Cip and Kip family [42]. 
 
The Cip and Kip family consists of p21Cip1, p27Kip1 and p57 Kip2. Family members 
are predominantly regulated by their cellular expression and phosphorylation. 
Distinct phosphorylation events on specific residues can promote or reduce their 
binding to specific CDK-Cyclin complexes, as well as regulate their subcellular 
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localisation and expression [46]. The CDKI p21 can inhibit CDK1 and -2 but is 
known to predominantly inhibit CDK2. The interaction of p21 with CDK2 reduces 
the ability of CDK2 to interact with its substrates resulting in Rb being active and 
trapping E2F, inhibiting E2F-dependent gene transcription, promoting cell cycle 
arrest [20]. A major regulator of p21 is the tumour suppressor p53, which 
upregulates p21 transcription and expression in response to DNA damage [47]. 
Although p21 is able to promote cell cycle arrest at both G1 and G2, the ability to 
halt the cell cycle at G1 is especially important when there is the possibility of 
transcribing DNA that is faulty or mutated due to damage. p21 expression allows 
the cell time to repair DNA and allow mitosis to continue without propagating 
errors within the genetic material that could promote the development of a 
disease state [48]. 
 
The expression of the CDKI p27 changes throughout phases of the cell cycle and 
is predominantly upregulated in response to the lack of growth signals [48]. p27 
is a potent inhibitor of the CDK2/Cyclin E complex, thus controlling Rb activity 
and G1/S cell cycle transition. Both p21 and p27 promote Rb activity through 
inhibiting CDK/Cyclin complexes. As previously mentioned, the Rb family of 
proteins are integral to the passage from G1 to S phase. Their inhibition by 
hyperphoshorylation by cyclin/CDK complexes is integral to the release of the 
E2F transcription factors. At the G1 checkpoint, active (hypophosphorylated) Rb 
not only binds to and inhibits the pro-transcriptional potency of E2F but also turns 
them into transcriptional repressors by interacting with and inhibiting them when 
they are complexed on promoter regions of pro-proliferative genes, halting gene 
transcription, resulting in an arrest at the G1 boundary [44].  
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Figure 1.1: The mammalian cell cycle (Modified from Malumbres & Barbacid 
2009 and Dehay & Kennedy 2007). 
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1.4 APOPTOSIS 
 
Cell death is an integral function of multicellular organisms during many stages of 
development (embryonic), tissue homeostasis and immunity. There are various 
mechanism of cell death, such as apoptosis, necrosis, mitotic catastrophe and 
autophagy. Apoptosis is the most relevant to this study due to its dysregulation in 
cancer [12] and relevance to the research that was undertaken. 
 
Apoptosis is the process of programmed cell death (PCD) and differs from other 
cell death mechanisms such as necrosis due to its specificity and minimal trauma 
to surrounding cells and tissues. Necrosis, for example, occurs when cells 
undergo trauma from an external source, resulting in membrane damage and 
premature cell death. Necrosis is generally considered to be toxic or detrimental 
to maintaining healthy tissues [49]. Apoptosis, is a highly ordered process and is 
particularly important in embryogenesis and development, for example, an 
embryo will develop both Wolffian and Mullerian ducts, which will become the 
male and female reproductive organs, respectively. Meaning that one or the 
other is redundant in each of the sexes, programmed cell death is implemented 
to removed the structure that will not be required [50]. Moreover, the average 
human body produces 60 billion new cells a day, and due to the fact that 
homeostasis must be maintained, roughly the same number of cells must be 
destroyed [51]. Thus, apoptosis is an indispensible process for higher organisms 
but whose dysregulation could have lethal consequences. 
 
To date two main apoptotic pathways have been described: the extrinsic (death 
receptor) pathway and the intrinsic (mitochondrial) pathway, but due to the 
complexities of these pathways it is becoming clear that they may not necessarily 
be mutually exclusive. Moreover, both pathways are dependent on the caspase – 
cysteine-aspartic acid protease - signalling cascade [52]. Family members are 
expressed as catalytically inactive zymogens, requiring cleavage for activation. A 
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fail-safe mechanism to ensure inappropriate activation of cell death does not 
occur [53]. 
 
1.4.1 Extrinsic pathway 
 
The extrinsic pathway requires the activation of death receptors – named due to 
the presence of an 80 amino acid structure called the ‘death domain’ in each of 
the family members - such as Death Receptor 4 (DR4) and the Fas Receptor 
(FasR) [49]. Expression of the death receptors within the extracellular membrane 
and the presence of their ligands are key to their activation. The Tumour necrosis 
factor (TNF)-Related Apoptosis Inducing Ligand (TRAIL) and Fas Ligand (FasL) 
are ligands for the DR4 and FasR receptor, respectively. Upon ligand binding, 
conformational changes promote receptor activation, inducing the recruitment of 
intracellular adaptor proteins to the cytoplasmic death domains. The Fas-
associated death domain (FADD) protein binds to the activated receptors (TNF 
receptors also require the binding of TRADD – TNF Receptor Associated Death 
Domain), resulting in the recruitment of procaspase-8, forming the death-inducing 
signalling complex (DISC) [54], promoting the cleavage of procaspase-8 to form 
the catalytically active caspase-8. Caspase-8 then activates the caspase 
cascade, cleaving procaspase-3 to form caspase-3. 
 
1.4.2 Intrinsic pathway 
 
The intrinsic pathway is centred around the membrane disruption of the cell 
powerhouse, the mitochondrion. Both positive and negative stimuli influence the 
intrinsic apoptotic pathway by driving the expression of proteins that influence the 
integrity of the mitochondrial membrane, one of the best studied are the Bcl-2 
family of proteins. 
 
The Bcl-2 family of proteins consists of more than 30 members, which can 
promote or inhibit the induction of apoptosis.  Family members contain one or 
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more conserved Bcl-2 Homology (BH) domains termed BH1-4) [55]. Bcl-2 (B cell 
lymphoma gene 1) was the first family member to be identified and was found to 
be anti-apoptotic, able to maintain cell survival when pro-survival stimuli was 
removed, as well as protecting cells from cytotoxic compounds [51], other 
examples of anti-apoptotic members are BCL-XL and MCL-1. Anti-apoptotic 
members contain multiple domains but all contain the BH4 domains, whereas 
pro-apoptotic members can contain either multiple domains, such as Bax and 
Bak, or only the BH3 domain, such as Bim, Bid, Bad, Noxa and Puma [55]. 
 
Family members elicit their function by forming homo- and heterdimers, for 
example, Bcl-2 binds to and sequesters Bax, inhibiting induction of apoptosis. 
Upregulation of Bim – or any other BH3-only protein - preferentially binds with 
Bcl-2, resulting in the release of Bax, promoting apoptosis [51]. Proapoptotic 
members form mitochondrial apoptosis-induced channels (MACs) within the 
mitochondrial membrane, which promotes mitochondrial outer membrane 
permeabilisation (MOMP) [56]. The formation of MACs increase the permeability 
of the mitochondrial membrane, facilitating the release of Smac (second 
mitochondria-derived activator of caspase – also known as Diablo)  and 
cytochrome c into the cytoplasm. Cytochrome c binds to the scaffolding protein 
Apaf-1 and procaspase-9 forming an apoptosome, promoting the accumulation, 
cleavage and activation of caspase-9, which in turn cleaves and activates 
caspase-3 [57]. 
 
Both the extrinsic and intrinsic pathways elicit their proapoptotic function through 
activating initiator caspases (caspase-8 and -9) that activate the effector 
caspase, caspase-3 (along with the other effector caspases -6 and -7) [53, 58]. 
Caspase-3 is thought to be the main regulator of apoptosis and is integral for 
regulating normal development. Caspase-3 knockout mice predominantly die 
soon after birth, displaying abnormal cell numbers in the brain and other organs 
[58]. Although in some instances there does appear to be some redundancy 
between caspase-3 and -7, both have similar substrate specificity and the fact 
 34 
that mice deficient in both caspases die immediately due to cardiac dysfunction 
due to improper development [59]. Although they do appear to have discreet 
roles in apoptosis, caspase-7 is thought to regulate cell viability whereas 
caspase-3 activation is known to regulate DNA fragmentation [60] and cleave key 
cellular components, resulting in morphological changes that are associated with 
apoptosis [57]. But even though this could be the case, caspase-3 and -7 are 
essential for the induction of apoptosis [60]. 
 
As mentioned, caspase-3 promotes DNA fragmentation, supported by the fact 
that caspase-3 defective mice do not display chromatin condensation and DNA 
fragmentation [58]. Moverover, DNA fragmentation potential can be reinstated in 
the MCF7 breast cancer cell line – does not contain caspase-3 – by 
overexpressing caspase-3 resulting in increased apoptosis [61]. Caspase-3 
promotes DNA fragmentation though the activation of the caspase-activated 
Deoxyribonuclease (CAD) – which facilitates DNA fragmentation through its 
Deoxyribonuclease (DNase) activity – by cleaving the carboxy-terminal region of 
the inhibitor of caspase activated DNase (ICAD) which is essential for its activity 
[62]. DNA fragmentation is defective in ICAD null mice, highlighting its 
importance in caspase-3-mediated induction of apoptosis [58]. Although mice 
that lack ICAD expression appear to have no major defects and can still undergo 
apoptosis, suggesting the chromatin condensation and DNA fragmentation are 
dispensable in programmed cell death mechanisms [63]. DNA condensation is 
promoted by the activation of the protein kinase mammalian sterile 20-like protein 
(MST1) through cleavage of its c-terminal domain and its phosphorylation by 
caspase-3 which results in its translocation to the nucleus, where it mediates 
chromatin condensation [64]. 
 
Caspase-3 also cleaves the DNA repair protein poly ADP ribose polymerase 
(PARP) resulting in its inhibition. PARP is important for the repair of damaged 
DNA, although it achieves this by using the cellular pools of energy (NAD and 
ATP). Caspase-3 cleavage of PARP promotes the availability of NAD and ATP 
 35 
that may be important to drive the later stages of apoptosis [59]. Caspase-3 
disrupts structural integrity by cleaving and activating the Rho-associated coiled-
coiled containing protein kinase 1 (ROCK1) resulting in the phosphorylation of 
the myosin light chain and contraction of the actin bundle, weakening the 
cytoskeleton. Moreover, the loss of the cellular scaffold results in the literal 
‘tearing apart’ of the nucleus, promoting apoptosis [65]. 
 
1.4.3 Physiology of apoptosis  
 
While undergoing apoptosis cells shrink, resulting in the organelles being more 
proximal to each other, membrane bledding (irregular budding), collapse of the 
cytoskeletal framework, condensation of nuclear chromatin, chromosomal DNA 
fragmentation and the formation of small membrane-bound compartments, called 
apoptotic bodies [66]. Unlike other forms of cell death, no inflammatory response 
is associated with cells that have undergone apoptosis. For example, cells that 
undergo necrosis predominantly release cellular components such as 
cytochrome c into the local environment due to disruption of the cell membrane, 
promoting an inflammatory response. Due to the organised nature of apoptosis – 
no membrane disruption and cytoplasm is retained in apoptotic bodies - this does 
not occur. Moreover, apoptosed cells are phagocytosed by macrophages or 
surrounding cells, preventing inappropriate inflammation [49]. 
 
Apoptosis is a tightly regulated cellular process; dysregulation can lead to 
multiple disease states, most notably cancer. Suppression of apoptosis is integral 
to the survival of cancer cells. 
 
1.5 PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) PATHWAY 
 
The phosphatidylinositol 3-kinase (PI3K) signalling pathway consists of the family 
of enzymes and phospholipid messengers involved with signal transduction 
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regulating cellular functions such as, cell growth, proliferation, survival and 
apoptosis. 
 
1.5.1 RAS 
 
Ras is a guanosine nucleotide-binding protein (G protein), which is structurally 
related to the Gα subunit of heterotrimeric G proteins (large GTPases) but is 
termed a small GTPase because it consists of a single subunit. Ras, which 
hydrolyses GTP into GDP and phosphate, binds both GTP and GDP [67]. The 
binding of GTP results in a conformational change within Ras, adopting the 
“loaded spring” position due to the additional phosphate that is present on GTP 
and not GDP resulting in Ras activation. Because of this subtle change, bound 
GDP is not able to maintain Ras in the same conformation resulting in its 
deactivation. This change between an on/off state highlights the role of Ras as a 
cellular switch turning on signal transduction pathways. Ras proteins are also 
negatively regulated by GTPase activating proteins (GAPs), which promote an 
increase in Ras GTPase activity resulting in the formation of GDP and its 
deactivation [68]. 
 
Ras activation is known to potentiate extracellular signals through many 
intracellular signaling cascades, most notably the RAF/MEK/ERK signaling 
pathway. Active Ras binds to and activates the serine/threonine kinase RAF (c-
RAF, BRAF and ARAF) [69], leading to its translocation to the plasma membrane 
where it phosphorylates and activates the mitogen-activated protein kinase 
kinases (MAPKKs), MEK1 and MEK2. These in turn phosphorylate and activate 
the mitogen-activated protein kinases (MAPKs), ERK1 and ERK2 (extracellular 
signal-regulated kinase 1 and 2). In addition to activating RAF/MEK/ERK 
signalling cascade Ras also binds directly to and activate the class I PI3K 
proteins [70]. 
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1.5.2 Class I PI3K proteins 
 
PI3K proteins belong to a large superfamily which consists primarily of three 
main classes each containing a range of subunits and isoforms, distinct from 
each other due to their substrate specificity and lipid products [71]. There is also 
a fourth class but these are more distantly related than the other classes. 
Although they are indeed serine/threonine kinases, they are not known to target 
lipids like the other family members [72]. 
 
Class I PI3Ks catalyse the phoshorylation at the 3 position hydroxyl group of the 
inositol ring within lipids, termed phosphatidylinositols (PtdIns) - which are 
present on the intracellular space of the cell membrane – converting 
phosphatidylinositol 4,5-bisphosphate (PIP2) to phosphatidylinositol 3,4,5-
triphosphate (PIP3). PI3K class I proteins are heterodimeric haloenzymes and 
comprise of a p110 subunit that contains the catalytic domain and a p85 subunit 
that contains the regulatory domain. Class I proteins can be further divided into 
two subgroups, IA and IB. Class IA contain three isoforms of the p110 catalytic 
subunit, termed p110α, p110β and p110δ, which are coded by three different 
genes, PIK3CA, PIK3CB and PIK3CD respectively, all structurally similar, 
containing helical and kinase domains and bindings sites for the regulatory 
proteins. Class IA also contains three genes that encode the regulatory subunit, 
PIK3R1, PIK3R2 and PIKR3. Where splice variants of the PIK3R1 encode for the 
p85α, p55α and p50α proteins, and PIK3R2 and PIK3R3 encode for the p85β 
and p55γ proteins, respectively [73].  The p85 subunit contains two Src homology 
2 (SH2) domains which allow binding to the p110 catalytic subunit. Class IB 
contains a p110γ catalytic subunit that binds to a different regulatory subunit, 
termed p101. Unlike class IA, IB PI3Ks are activated by G-protien coupled 
receptors not receptor tyrosine kinases [72]. 
 
Class II PI3Ks are monomeric and do not contain a regulatory subunit. There are 
three isoforms C2α, C2β and C2γ. Class III PI3Ks are more similar to class I 
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PI3Ks because they are heterodimers consisting of a catalytic and regulatory 
subunit. Class I PI3Ks are more extensively studied due to their defined role in 
the development of cancer, where as Class II and III proteins have not yet been 
shown to be linked with oncogenesis [74]. 
 
The class I PI3K proteins are integral to potentiating extracellular signals from 
extracellular growth factor and tyrosine kinase receptors into the intracellular 
environment, regulating transcription factors that activate/inhibit the transcription 
of genes important in a plethora of cellular process, depending on the signal 
being received. 
 
When a growth stimuli is received by the cell through an extracellular receptor, it 
causes the activation and recruitment of the PI3K heterodimer, which primarily 
consists of p110 (the catalytic subunit) and p85 (the regulatory subunit), to the 
plasma membrane where it interacts with and phosphorylates its substrate PIP2, 
generating PIP3. PIP3 generation and accumulation on the plasma membrane 
attracts proteins containing pleckstrin homology (PH) domains such as the AGC 
(cAMP-dependent cGMP-dependent and protein kinase C) family members, 
including the 3’-phosphoinositide–dependent kinase 1 (PDK1)[75]. PIP3 
accumulation also promotes the binding of another AGC family member, the 
serine/threonine kinase AKT (also known as PKB), to the intracellular space on 
the plasma membrane, where it is phosphorylated by PDK1 on threonine residue 
308, which is within the catalytic site (activation loop) of AKT, leading to its 
activation and release of AKT into the intracellular space to phosphorylate its 
downstream targets [76, 77].  
 
AKT is also phosphorylated on serine 473, within the c-terminal hydrophobic 
motif (HM), by the mammalian target of rapamycin (mTOR) complex 2 [78]. AGC 
family members are dependent on their phosphorylation to be catalytically active 
[79, 80]. Dually phosphorylated AKT (308 and 473) is known to have an 
increased catalytic activity in vitro [81, 82] highlighting the importance of both 
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phosphoryation sites on activity, thus it is rationalised that the phosphorylation of 
both sites is required to elicit its full activity in vivo, but the exact implication of 
differential phosphorylation on these sites has not been fully elucidated. Jacinto 
et al and Guertin et al both showed rather eloquently that differential 
phosphorylation on serine 473 only affected a subset of AKT downstream 
targets, most notably the forkhead transcription factors [78, 83, 84]. 
 
1.5.3 AKT/PKB 
 
AKT is considered to be one of the most important effectors of the PI3K 
signalling cascade and has been conserved throughout evolution, from 
Caenorhabditis elegans (C.Elegans), Drosophila to humans [73]. The 
maintainance of this signalling axis has lead to a wealth of study of the 
downstream effector AKT. In mammals there are thee AKT isoforms or family 
members, termed AKT1 (PKBα), AKT2 (PKBβ) and AKT3 (PKBγ) [73, 85]. Each 
containing an N-terminal PH domain, a C-terminal region that contains the HM 
domain and a central kinase catalytic domain (CAT) responsible for the 
serine/threonine phosphorylating potential of all the AKT isoforms [86].  
  
In humans, AKT1 and AKT2 are expressed in all tissue and cell types, whereas 
AKT3 expression appears to be more exclusive, predominantly found in the 
brain. Knockout mice highlighted the different phenotypes that arise from loss of 
one AKT isoform. AKT1(-/-) mice display placental hypotrophy as well as 
impaired growth and reduced bodyweight, AKT2(-/-) are hyperinsulemic and 
hyperglycaemic and AKT3(-/-) have impaired brain development. But all knockout 
mice are viable and thrive suggesting that compensatory mechanisms exist 
between the AKT isoforms (reviewed in [87]). 
 
Upon activation (as described above), AKT relocates to the nucleus where it 
phosphorylates its downstream targets, such as forkhead transcription factors 
[84], the proapoptotic BH3-containing protein BAD [88], the E3 ubiquitin ligase 
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MDM2 [89], and many others. All established AKT downstream targets to date 
have been shown to require the R-X-R-X-X-S/T-B motif (X represents any amino 
acid, B represents bulky hydrophobic residue) [90, 91].  
 
1.5.4 Phosphatase and Tensin homolog deleted on chromosome 10 (PTEN) 
 
PTEN, a 3’phosphatase stringently controls the cellular levels of PIP3 by 
dephosphorylation, converting PIP3 back to PIP2, reducing the recruitment of PH 
containing proteins to the plasma membrane, inhibiting the potentiation of the 
PI3K signal [77]. Although there are other PIP3 phosphatases, notably SHIP1 
and SHIP2 (SH2-containing inositol polyphosphate-5-phosphatase), knockout 
mice which lack PTEN develop cancer, whereas SHIP1 knockout mice develop 
myeloproliferative syndromes - possibly due to the fact that SHIP1 reduces PIP3 
to PIP2 by removing the phosphate group from the 5-position, not the 3-position 
of the inositiol ring – establishing PTEN as a true tumour suppressor [73, 92, 93]. 
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Figure 1.2: The PI3K signaling cascade. A summary of the PI3K cascade and 
its regulation of the subcellular localisation of the FOXO transcription factors. 
Post-translational modifications of key signalling components is displayed, 
phosphorylation (P - red) and acetylation (A - green). 
 42 
1.5.5 PI3K in cancer 
 
Dysregulation of the intracellular signalling profiles of cells is a prominent feature 
in the development of cancer. There are many changes that occur to the PI3K in 
cancer, here I will outline a few that are the most well known and relevant to this 
study. 
 
Many different extracellular growth factor and tyrosine kinase receptors can 
activate the PI3K signalling cascade. Due to this redundancy, the PI3K is 
frequently dysregulated in tumour formation and cancer development. 
 
1.5.5.1 Epidermal growth factor receptor (EGFR, also known as ERBB) 
 
The receptor tyrosine kinase EGFR was one of the first growth factor receptors to 
be characterised and with the other structurally related ERBB family members 
HER2 (ERBB2, neu), HER3 (ERBB3) and HER4 (ERBB4) form homodimeric and 
heterodimeric complexes. Each family member contains an extracellular ligand-
binding domain, a trans-membrane region and an intracellular tyrosine kinase 
domain, although HER3 lacks intrinsic kinase activity due to its lack in ability to 
bind adenosine triphosphate (ATP) [94-96]. 
 
Ligand binding promotes receptor homo/heterodimerisation and phophorylation 
on lysine 721 (K721) of the EGFR receptor, this in turn promotes ATP binding 
and activation of the tyrosine kinase domain [95]. Receptor activation results in 
the recruitment of intracellular proteins important in signal transduction such as 
proteins involved in the PI3K/AKT signalling cascade, regulating a plethora of 
cellular processes such as differentiation, proliferation and survival [97, 98].  
 
In cancer, the ERBB family of receptors are activated by a range of mechanisms 
including activating mutations, overexpression and the autocrine or paracrine 
production of their activating ligands [96].  The study of 5,232 breast cancer 
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cases showed 48% to be EGFR positive affirming the importance of EGFR in 
breast cancer development [99].  
 
In non-small cell lung cancer, anti-EGFR target therapy leads to the development 
of resistance through mutations in the receptor. The T790M (residue 790 
threonine to methionine) mutation increases the binding affinity of the receptor to 
ATP, as well as sterically hinder the binding of targeted small molecule inhibitors. 
Moreover, the mutation results in the preferential activation of the PI3K-AKT 
cascade over that of the RAS-MAPK signaling pathway, suppressing pro-
apoptotic mechanisms [100]. Recent publications have shown that the T790M 
mutation is present in EGFR before the use of targeted therapy [101], 
highlighting that maintenance of EGFR driven proliferation provides a selective 
advantage in a heterogeneous tumour environment. 
 
Although EGFR expression does not inversely correlate with patient survival, 
recent publications are starting to unravel its importance, suggesting that its 
subcellular localisation is important in breast cancer, showing nuclear 
accumulation of EGFR is inversely correlated with patient survival suggesting 
that EGFR has a role in tumourigenesis beyond the activation of intracellular 
signaling pathways such as the PI3K [102]. 
 
1.5.5.2 Human epidermal growth factor receptor 2 (HER2) 
 
Another growth receptor HER2 is implicated in various cancers. The oncogenic 
tyrosine kinase receptor is overexpressed in 25% of breast cancer cases and is 
predominantly due to gene amplification [14]. Unfortunately these tumours are 
more prevalent in premenopausal women and ultimately lead to a poorer clinical 
outcome. Although its overexpression does present the opportunity to exploit 
tumour dependence on HER2 driven proliferation by developing HER2 targeted 
therapies [14]. 
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Transgenic mice overexpressing an active form of the rodent HER2 homologue 
NEU were shown to rapidly develop multiple mammary tumours [103]. Further 
studies showed that human HER2 expression in transgenic mice also promotes 
mammary tumour formation [104]. 
 
Recent studies have shown that 20% of breast cancers also express a splice 
variant of HER2 which lacks a 16 amino acid sequence that codes for the 
juxtamembrane domain. The truncated form of HER2 is constitutively active due 
to the fact that it can form homodimers [105]. Furthermore, overexpression of the 
truncated form of HER2 in mice causes the development of aggressive and 
invasive mammary tumours [106]. 
 
HER2 overexpression is intimately linked with estrogen receptor (ER) endocrine 
signaling, less than 10% of ER+ tumours have high HER2 expression [107]. 
Furthermore, increasing HER expression is linked with ER-independent 
proliferation and resistance to endocrine therapy [108]. 
 
1.5.5.3 RAS 
 
Mutations within the RAS family of proteins, most notably, HRAS, KRAS and 
NRAS - which are structurally similar, containing 85% sequence homology - are 
found in 25% of all human cancers [109]. Mutations within the different family 
members is found in different cancer types, for example, HRAS mutations can be 
found in bladder and renal cancer; KRAS mutations can be found in pancreatic, 
colorectal and non-small lung cancer; and NRAS mutations can be found acute 
myelogenous leukemia, melanoma and hepatocellular cancer [110]. 
Modifications of Ras in cancer are predominantly somatic missense mutations at 
positions 12, 13 and 61, reducing its GTPase activity and promoting resistance to 
GAP proteins, resulting in Ras hyperactivation [68]. Although generally lone 
mutations within Ras do not lead to tumourigenesis, in combination with other 
processes, Ras overactivation promotes tumour development by activating 
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prosurvival downstream signaling cascades such as the Raf/MEK/ERK and PI3K 
signaling pathways [109]. 
 
1.5.5.4 PIK3CA 
 
Mutations in the catalytic subunit of class 1A PI3K (PIK3CA) - which encodes the 
p110α protein - have been found in breast and other tumours [111]. Eighty 
percent of the mutations found in PIK3CA are located in three main coding 
regions, two within the helical domain of p110α and one in the kinase domain 
[112], these mutations result in an increase in activity, highlighting the oncogenic 
potential of p110α, and its ability to drive PI3K-dependent proliferation and 
cancer progression. Moreover, mutations within PIK3CA have been found in 
approximately 30% of ductal carcinomas in situ (DCIS) and invasive ductal 
breast carcinomas (IDC), highlighting the frequency of loss of functional PIK3CA 
in breast cancer but also that it occurs as a relatively early event, promoting 
tumour development, rather than being involved in the development of resistance 
and metastasis [113]. 
 
Mutations within PIK3CA are associated with KRAS mutations [77] and HER2 
overexpression, suggesting that multiple constituents of PI3K signalling are 
dysregulated in cancer, highlighting the importance of the PI3K signalling 
cascade in promoting tumour survival. 
 
1.5.5.5 PTEN 
 
PTEN is essential at controlling PI3K signalling via its regulation of PIP3, 
inhibiting prosurvival mechanisms such as proliferation and differentiation. 
Because of its role as a sentinel on the internal surface of the extracellular 
membrane, guarding the release of serine threonine kinases into the intracellular 
environment, PTEN was identified in 1997 as a major tumour suppressor [114, 
115] and was subsequently found to be frequently mutated in many different 
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cancers such as lung, prostate, ovarian and breast [116] and to be the main 
contributing factor to the autosomal dominant syndrome known as Cowdens 
disease, where 80% of sufferers contain inactivating mutations (up to 70 have 
been identified) within the PTEN gene [114]. In 2010, 211 sufferers were 
assessed and 89% were found to be diagnosed with cancer within their lifetime 
and 81% of female cowden disease suffers developed breast cancer [117]. 
Seventy five percent of patients (both sexes) also developed benign breast 
tumours [118]. Its mutation results in a non-functioning PTEN protein resulting in 
the hyperactivation of the PI3K pathway.  
 
PTEN is deleted in 30-40% of human tumours [119] and is considered one of the 
most important tumour suppressors known in cancer cell biology to date, 
matched in frequency by key regulators of cell fate, such as p53 which is mutated 
in 50% of human cancers [17].  PTEN was found to be mutated in 6% of breast 
cancer cell lines and xenographs [115]. 48% of breast cancer tissue samples 
were shown to have lost PTEN expression and this loss correlated with lymph 
node status (metastasis), loss of ER expression and disease-related death [120]. 
 
Loss of PTEN activity results in the hyperactivation of the PI3KAKT signalling 
axis 
 
1.5.5.6 AKT/PKB 
 
AKT is frequently hyperactivated in cancer through the deregulation of the PI3K 
signalling cascade. Overexpression of RTKs, loss of function mutations within 
PTEN and activating mutations within PIK3CA all lead to increased AKT activity 
which promotes tumour survival and cancer progression. 
 
More recently, somatic mutations within AKT1 were found in 8% of breast cancer 
patients. The mutation, E17K – within the PH domain – was found to allow 
binding of AKT to the extracellular membrane without the need of PIP3 
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accumulation, promoting the phosphorylation of AKT on S473 (no change in 
T308 was observed) [121]. 
 
Loss of AKT1 expression inhibits the development of Neu-induced tumours in 
mice, whereas loss of AKT2 accelerated tumour development. Moreover AKT1(-
/-)Neu-induced tumours in mice were more invasive than AKT2(-/-)Neu-induced 
tumours [122] and recently, it has been shown that the dual overexpression of 
HER2 and AKT2 in mammary epithelial resulted in a markedly increased 
pulmonary metastasis whereas AKT1 did not [123]. Moreover, the reduction of 
AKT1 expression using siRNA enhanced migration in cancer cell lines. This 
finding was reaffirmed using specific short hairpin RNAs (shRNAs) targeting 
AKT1 and AKT2 specifically. AKT1 silencing enhanced insulin growth factor 1 
(IGF-I) and epidermal growth factor (EGF) dependent migration, and AKT2 
silencing reduced IGF-I dependent proliferation and survival [85]. Together, these 
results suggest that the differential expression of the AKT isoforms are linked 
with different stages of cancer progression and metastasis and that due to 
redundancy and compensatory mechanisms the distinct inter-regulatory roles of 
AKT isoforms in cancer need to be more clearly defined, especially with the 
advent of AKT targeted compounds. Establishing their pre-clinical efficacy will be 
crucial to achieving patient benefit and increased survival. 
 
1.6 FORKHEAD BOX TRANSCRIPTION FACTORS  
 
Forkhead box proteins are a large family of transcriptional regulators which share 
an evolutionarily conserved DNA-binding domain (DBD) named the winged helix 
domain. It consists of three tightly packed α-helical domains at the N-terminal 
region and three β-sheets and two large loop regions located at the C-terminal 
end, forming a structure which is similar in appearance to the wings of a butterfly 
[124, 125].   
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Since 1989 more than 150 forkhead transcription factors have been identified, 
including more than 41 in humans [126]. Due to the rapid discovery of forkhead 
family members Kaestner et al outlined a unified nomenclature to minimise 
confusion, proteins became known as FOXs, named after their ‘forkhead box’. 
Forkhead proteins in chordates were divided into 15 classes or subgroubs, which 
has since been expanded to 19, each class termed A-S, based on their 
sequence similarity and structure, not their function [127]. Outside of the DBD, 
forkhead proteins families vary significantly, in part, leading to their differential 
roles and regulation in many cellular processes including, metabolism, 
proliferation, development, migration, invasion, apoptosis and longevity [126, 
128]. Of the subgroups, the role and regulation of some are more well defined 
than others and are established in distinct cellular processes, for example cell 
cycle proliferation, angiogenesis, cell cycle arrest and apoptosis. 
 
1.6.1 Forkhead subgroup C (FOXC) 
 
FOXC2 (previously known as Mesenchyme Forkhead 1- MFH1) is known to be a 
critical regulator of angiogenesis, controlling vascular development, remodelling 
and migration [129]. FOXC2 is also known to be important in lymphatic 
development, loss of functional FOXC2 is known to be associated with the 
inheritable disease Lymphedema-distichiasis, which causes swelling in the lower 
limbs and irregular eyelash growth [130]. As a transcription factor FOXC2 binds 
to forkhead-response elements within the promoters of its target genes driving 
their expression. Established targets of FOXC2 are the chemokine receptor 4 
(CXCR4), integrin β3 and the vascular endothelial growth factor receptor 2 
(VEGFR2), all which promote endothelial cell migration and angiogenesis [131].  
 
The overexpression of FOXC2 is observed in breast cancer – 85% of invasive 
breast carcinomas - and has been shown to be a key mediator of epithelial-
mesenchymal transition (EMT) [132], which is an essential step in metastasis, 
allowing cells from the primary tumour to spread and establish themselves in 
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secondary sites throughout the body [133]. Moreover, it has been shown that 
inhibiting FOXC2 using small hairpin RNA reduced their metastatic potential, 
highlighting FOXC2 – and its downstream targets - as a viable target for anti-
metastatic targeted therapy [132]. 
 
1.6.2 Forkhead subgroup M (FOXM) 
 
FOXM1 is a crucial regulator of cell cycle progression through the transcription of 
the pro-proliferation genes, cyclin B [134], polo-like kinase-1 (PLK1) [135] and 
cell division cycle protein 25b (CDC25b) [136], and suppression of CDKIs p21 
and p27 through its interaction, promoting their cellular degradation [137, 138]. 
 
FOXM1 is only expressed in cells progressing through the cell cycle; it is almost 
undetectable in quiescent cells. Its expression increases through S phase and 
continues to increase into G2 and mitosis. FOXM1 is also regulated by its 
phosphorylation status which positively affects its activity. FOXM1 is known to be 
phosphorylated by the Raf/MEK/ERK signalling cascade [139] and the CDK2-
Cyclin E complex [136], its phosphorylation peaking in G2, reaffirming the role of 
FOXM1 at modulating the progression of cells into mitosis. Moreover, in 
development FOXM1-null embryos fail to survive in utero past E18.5 due to 
inability to enter into mitosis [140].  
 
The overexpression of FOXM1 has been identified in many different cancer 
types; brain, breast, lung, liver and prostate [141] and has been shown to 
promote tumourigenesis, angiogenesis and metastasis [126]. Recently it has 
been shown that antibiotic compounds siomycin A and thiostrepton inhibit 
FOXM1 activity and induces cell death in breast cancer cell lines but not 
untransformed breast epithelial cells [141]. 
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1.6.3 Forkhead subgroup O (FOXO) 
 
Mammalian FOXO proteins are orthologues of the transcription factor DAF-16 
(abnormal DAuer Formation 16) identified in the nematode Caenorhabditis 
elegans (C.Elegans), which was found to be an integral component of metabolic 
insulin signalling and longevity [142]. The FOXO class of proteins consists of four 
members, FOXO1 (FKHR), FOXO3a (FKHRL1), FOXO4 (AFX) and FOXO6, 
which are mostly regulated by the PI3K signalling cascade effector protein AKT 
[84]. FOXO1, -3 and -4 are ubiquitiously expressed although can differ between 
different tissue/organ types. FOXO1 is expressed more highly in adipose tissues, 
FOXO3a is expressed highly in the liver, and FOXO4 is highly expressed in 
skeletal muscle. FOXO6 is predominantly found in the brain [76, 124]. 
 
FOXO proteins consist primarily of four domains, the DNA binding domain (DBD) 
that defines all forkhead proteins, a nuclear localisation signal (NLS) downstream 
of the DBD, a nuclear export sequence (NES) and a C-terminal transactivation 
domain (Figure 1.3). FOXO1 and FOXO3 are similar in length (655 and 673 
amino acids, respectively) while FOXO4 and FOXO6 are moderately shorter (501 
and 559 amino acids, respectively) [143] As well as sequence homology within 
the DBD, FOXO family members also retain sequence homology that is integral 
to regulating their subcellular location and consequently, their activity. This will be 
more clearly defined later. 
 
As transcription factors, FOXO proteins elicit their effect on the cellular 
phenotype by activating the transcription of their target genes, which differentially 
effect cell fate in a downstream target-specific manner. FOXO proteins 
predominantly bind to the consensus motif (also known as forkhead response 
element) 5’-TTGTTTAC-3’ via their DBD (more specifically, through the third α-
helix) within the promoter sequences of their downstream targets [142, 144]. 
Once bound the c-terminal transactivation domain initiates gene transcription. 
FOXO proteins have also been shown to be keen transcriptional repressors, its 
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activation halting the expression of the cell cycle progression proteins Cyclin D1 
and -2 [145]. Due to the fact that FOXO proteins have a role in a plethora of 
physiological activities, it is best to outline these subsets of genes within the 
context of each cellular process. 
 
1.6.3.1 FOXO in oxidative stress 
 
FOXO proteins have also been found to be key sensors of oxidative stress 
through the regulation of genes involved with detoxification and DNA repair. 
Reactive oxidative species (ROS) – which includes oxygen free radicals, nitric 
oxide and hydrogen peroxide - are produced as byproducts from exogenous 
sources such as, ultra-violet (UV) and ionising radiation [146] or metabolic 
processes that take place within the mitochondrion [147]. ROS has been shown 
to be important in some cell signalling pathways and cell cycle progression, but 
excessive ROS accumulation can be detrimental to the cell and can lead to the 
induction of apoptosis and cell death. If these cellular processes are perturbed 
disproportionate ROS accumulation can damage proteins, lipids and DNA 
leading to cellular transformation, tumourigenesis and cancer [148]. 
 
In 1999 Honda & Honda showed in C.Elegans that the DAF-2/DAF-16 signalling 
pathway (homologues of mammalian IGFR/FOXO) regulated the expression of 
SOD-3 – which facilitates the conversion of superoxide into oxygen and 
hydrogen peroxide [149] - playing a central role in ROS detoxification, having a 
drastic effect on lifespan [150]. Furthermore, it was shown that this regulation 
was direct due to the discovery of DAF-16 binding sites within the sod-3 promoter 
[144]. It was later shown that this pathway was conserved in mammals, FOXO3a 
being able to upregulate the mRNA and protein expression of manganese 
superoxide dismutase (MnSOD – homologue of SOD-3) in response to ROS 
accumulation, promoting cell survival, and that crucially, this mechanism was 
observed in cancer cells as a mechanism of evading apoptosis [151, 152]. 
Subsequently, FOXO3a has been found to be upregulated in response to ROS 
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accumulation and that this coincided with an increase in the expression of its 
downstream transcriptional targets [153]. Also, it was shown that FOXO4 could 
also regulate mnSOD expression in response to ROS accumulation and TNFα 
treatment, reaffirming the role of FOXO family members in regulating cellular 
stress [146].  
 
FOXO was also found to regulate catalase in response to oxidative stress [154]. 
Catalase, as the name suggests, catalyses the reaction of breaking down 
hydrogen peroxide into oxygen and water [155] and was originally identified in 
C.Elegans at being important at regulating longevity via the DAF-16 pathway 
[154]. It was subsequently shown that hydrogen peroxide treatment in 
mammalian cells resulted in the activation of FOXO3a and an increase in 
transcriptional activity. Moreover, FOXO3a bound to the catalase promoter, 
activating its transcription, but this activation was lost when a FOXO3a inactive 
mutant was overexpressed [156]. 
 
Although mnSOD and catalase are located in different cellular compartments, the 
mitochondria and peroxisomes respectively, suggesting they have distinct roles 
in regulating cellular stress [157], they are key transcriptional targets of FOXO 
proteins and highlight the concerted role of FOXOs in regulating ROS 
scavengers, driving detoxification and promoting survival. Recently, Tothova et al 
have shown rather excellently that FOXO1,-3 and -4 negative hematopoietic 
stem cells (HSCs) have marked increases in ROS and a decrease in expression 
of a subset of genes that regulate ROS accumulation, resulting in dysregulation 
of the cell cycle and induction of apoptosis, having drastic consequences on self-
renewal and differentiation of the HSC pool. Moreover, this phenotype was fully 
reversible by the treatment of an antioxidant compound, showing that loss of 
FOXO proteins effect the cellular phenotype predominantly by regulating ROS 
[158]. Together, these data support the role of FOXO proteins in regulating ROS 
accumulation and their attempt to maintain normal cell cycle progression through 
 53 
the transcription of genes important in regulating ROS, dictating the cellular 
consequences and influencing cell survival. 
 
1.6.3.2 FOXO in DNA repair 
 
FOXO proteins have been shown to protect cells from ROS accumulation by 
upregulating genes involved with detoxification, but FOXO family members also 
upregulate the expression of genes known to be important in DNA-damage 
repair, such as the growth arrest and DNA damage 45 (Gadd45) protein. 
 
Gadd45 acts as a sensor to cellular stress and is known to interact with the 
cdc25/Cyclin B complex and the CDKI p21, both known to be important in G2-M 
cell cycle transition. Their interaction with Gadd45 promotes the activation of the 
G2-M cellular checkpoint, allowing DNA repair mechanisms to be initiated [159]. 
Gadd45 is also known to interact with the proliferating cell nuclear antigen 
(PCNA) protein, which is important in DNA-damage repair, maintaining genetic 
integrity, promoting cell survival [160]. 
 
FOXO3a was shown to be activated in response to UV radiation and delay 
progression of cells through G2-M, increasing the mRNA and protein expression 
of Gadd45, allowing DNA-repair mechanism to be undertaken [161]. A 
subsequent study reiterated the importance of FOXO3a in regulating Gadd45 
expression and showed that FOXO4 could also promote Gadd45 expression and 
initiate DNA repair mechanisms [162]. The ability of FOXO proteins to induce 
DNA-damage repair highlights their role at maintaining genomic integrity, 
reducing the accumulation of possible oncogenic mutations that could drastically 
alter cell fate. 
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Figure 1.3: Structure and post-translational modification sites of FOXO 
protein. The basic structure and location of post-translational sites of FOXO 
family members. The position of the forkhead DNA-binding domain (DBD - 
purple), nuclear localisation sequence (NLS - blue), nuclear export sequence 
(NES - orange) are represented diagrammatically. Key post-translational sites 
such as phosphorylation (P)(red – AKT sites, blue – other) and acetylation (A - 
green) are also designated. Adapted from Greer and Brunet 2005 [143]. 
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1.6.3.3 FOXO in the cell cycle  
 
FOXO proteins are key regulators of cell cycle inhibition, predominantly 
responsible for controlling progression through transition of the G1-S phases – 
but also G2-M - of the cell cycle. FOXO has been shown to regulate both p21 
and p27 CDKIs from the Cip/Kip family, as well as INK4 family members [163]. 
 
FOXO family members FOXO1, -3 and -4 (predominantly FOXO3a) were show  
to bind to the p21 promotor in a Smad-dependent manner, promoting its 
transcrption in response to the cytostatic transforming growth factor β (TGF-β) 
cytokine signal. Furthermore, when FOXO activity was inhibited using targeted 
short interfering RNA or the overexpression of a functionally inactive FOXO 
mutant, p21 expression was lost following TGF-β treatment while other 
downstream targets remained unchanged [164]. 
 
The overexpression of FOXO3a and FOXO4 were shown to induce the 
expression of p27, disrupting the cyclin E-cdk2 complex causing a cell cycle 
arrest at the G1 cellular check point. Furthermore, this arresting potential was 
significantly decreased in p27-/- cells, compared to WT cells, due to the fact that 
loss of cell cycle control is a common feature of cancer development, the 
hyperactivation of the PI3K/AKT axis was linked to inhibition of FOXO family 
members and consequently uncontrolled cell growth [165]. The overexpression 
of a constituitively active FOXO4 was also able to positively regulate the 
expression of p27 by promoting its stabilization [166]. Moreover, the pro-
oncogene c-myelocytomaosis (c-MYC) was shown to repress FOXO3a activity 
leading to loss of p27 expression, an event which is observed in B-cell 
lymphomagenesis [167]. The regulation of p27 by FOXO3a was also shown to be 
important in the induction of apoptosis in both B and T cells through loss of 
Interleukin 3 (IL-3) and Interleukin 2 (IL-2) mediated survival, respectively [168, 
169]. 
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FOXO proteins were also shown to regulate cell cycle inhibition by driving the 
transcription of the Rb family member, p130. FOXO3a and FOXO4 were shown 
to bind to the p130 promoter and increase its cellular expression, as well as 
influence its phosphorylation status and interaction with E2F transcription factors. 
FOXOs activation of p130 promoted the exit from the cell cycle and entering into 
a reversible quiescent state and is thought to complement p27 upregulation (p27 
inducing a cell cycle arrest and p130 promoting exit from the cell cycle) [170]. 
 
As well as upregulating proteins involved with cell cycle inhibition FOXO proteins 
are also known to repress proteins involved with promoting cell cycle 
progression. FOXO proteins are known to decrease CDK/Cyclin D complex 
activity by upregulating p27 expression, but it has also been shown that they are 
able to decrease the cellular expression of Cyclin D1 by inhibiting promoter 
activity in a p27 independent manner. Overexpression of Cyclin D1 was also 
sufficient to overcome the FOXO induced cell cycle arrest reasserting the 
transcriptional control that FOXO proteins have over Cyclin D1 expression [171]. 
 
1.6.3.4 FOXO in cell death and apoptosis 
 
1.6.3.4.1 Extrinsic apoptosis 
 
FOXO family members are also known to regulate a distinct subset of genes that 
facilitate the induction of programmed cell death, apoptosis. FOXO3a is known to 
regulate the expression of components of the extrinsic apoptotic pathway. The 
activating ligand, tumour necrosis factor (TNF) cytokine family member, FasL 
(Fas ligand) was one of the first identified targets of the AKt/FOXO signalling 
pathway [84]. FasL binds to the Fas receptor, activating the caspase-8 
dependent proapoptotic pathway [172]. FOXO3a was also found to positively 
drive the direct transcription of TRAIL, also a member of the TNF super family. 
Once cleaved, TRAIL forms homo-trimeric structures which activate apoptosis 
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through binding to the death receptor 5 (DR5) and DR4, activating a caspase-8-
dependent proapoptotic mechanism [173, 174]. 
 
1.6.3.4.2 Intrinsic apoptosis 
 
In addition to regulating proapoptotic extracellular receptors, FOXO proteins also 
regulate the expression of genes involved with destabilizing the mitochondrial 
membrane, namely the Bcl-2 family members - BH3-only proteins -  Puma [175] 
and Bim [176], promoting the intrinsic activation of apoptosis. 
 
The proapoptotic protein Bim was initially discovered to be a downstream target 
of FOXO3a in the mouse pro-B cell line Ba/F3, after FOXO3a activation due to 
cytokine deprivation (IL-3). Moreover, Bim -/- leukocytes were shown to be more 
resistant to cytokine withdrawal and apoptosis, highlighting the importance of Bim 
at initiating apoptosis [176, 177]. IL-2 deprivation in the murine T cell line CTLL-2 
also led to the induction of Bim and p27. Interestingly, the induction of Bim was 
preceded by an increase in p27, which coincided with the induction of a cell cycle 
arrest, then apoptosis, suggesting that the differing downstream targets of 
FOXO3a cooperated to elicit their effect on the cellular phenotype [169]. 
Subsequent studies also showed FOXO3a-dependent induction of Bim in 
neuronal cell lines [178], endothelial progenitor cells (EPC) [179] and 
osteosacroma cells [180]. The latter study being of particular interest due to the 
fact that it showed the UV-induced apoptosis was independent of functional p53, 
highlighting FOXO proteins as keen inducers of apoptosis in response to DNA 
damage [180]. 
 
Further studies into the regulation of Bim by FOXO3a showed that it was 
possible for the pro-apoptotic function of FOXO proteins to be exploited 
therapeutically. Chronic myelogenous leukemia (CML) cell lines – which are 
driven by the Bcr-Abl chimeric oncogene [181] – and cell lines over expressing 
Bcr-Abl, upon treatment of the Bcr-Abl inhibitor STI571, caused the activation of 
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FOXO3a and increased FOXO3a-dependent Bim expression resulting in the 
induction of apoptosis. Moreover, the induction of Bim expression by STI571 
treatment was lost when the cellular pool of FOXO3a was reduced using siRNA, 
the cells maintaining a cell cycle arrest rather than undergoing apoptosis. 
Furthermore, Bim silencing with siRNA also abrogated the induction of apoptosis 
in STI571 treated cells [182]. Subsequent studies in the breast cancer cell line 
MCF-7 have shown that FOXO3a also drives the expression of Bim in response 
to the chemotherapeutic DNA-damaging agent paclitaxel, inducing apoptosis 
[183].  
 
The BH3-only protein PUMA has recently be also shown to be regulated by 
FOXO3a in p53-dependent and independent mechanisms. MEFs which were 
negative for PUMA and BAX were used to show that the proapoptotic potency of 
FOXO3a was dependent on their cellular expression [184]. Moreover, it was 
shown that FOXO3a induced apoptosis in T-cells following IL-2 withdrawal 
through the transcriptional activation of Bim and PUMA. Although it was 
hypothesised that loss of Bim had a more drastic effect on cell fate due to both 
transcriptional and post-translational regulation, whereas PUMA was only 
regulated transcriptionally [175].  
 
Bim and PUMA induce apoptosis by binding to Bcl-2, facilitating the release of 
Bax, which reduces the integrity of the mitochondrial outer membrane, facilitating 
the release of factors that activate the caspase cascade, inducing apoptosis 
[185]. These findings highlight the importance of FOXO3a-mediated induction of 
apoptosis and the central role FOXOs pro-apoptotic targets play in dictating cell 
survival. 
 
1.6.4 Regulation of FOXO proteins 
 
As discussed previously the FOXO transcription factors have a diverse range of 
transcriptional targets involved in different cellular processes such as, cell cycle 
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regulation (e.g., p21, p27, p130(RB2), cyclin D), apoptosis (e.g., Bim, Fas-ligand 
and TRAIL) and oxidative stress (e.g., mnSOD and Catalase) [84, 151, 156, 165, 
170, 171, 173, 176]. To achieve successful regulation of this repertoire of target 
genes, the activity of FOXO transcription factors is regulated by a range of 
posttranslational processes including phosphorylation, ubiquitination, acetylation, 
which allows the activation of specific subsets of genes that influence cell fate 
[126]. 
 
1.6.4.1 Phosphorylation 
 
Phosphorylation is the chemical modification of serine, threonine and tyrosine 
(although the latter is the least common) residues by the addition of a phosphate 
group. The post translational status of proteins is a dynamic process, the 
modification of residues is regulated by kinases and phosphatases which 
phosphorylate and dephosphorylate protein substrates, respectively. The 
phosphorylation status of proteins is predominantly linked heavily with their 
activity, phosphorylation promoting its activity or reducing it, in a substrate 
specific manner. FOXO3a is known to be phosphorylated by  the oncogenic 
kinases AKT, IKK and ERK, all three commonly activated in cancer [186]. 
 
All FOXO family members contain multiple AKT consensus sequences meaning 
they are prime cellular targets for phosphorylation by AKT. Moreover, these 
phosphorylation sites are conserved throughout evolution, from C.Elegans to 
mammals. AKT and other closely related kinases, such as the serum and 
glucocorticoid inducible kinase (SGK) phosphorylate FOXO3a on Threonine 32, 
Serine 253 and Serine 315. The phosphorylation of FOXO3a on these residues 
results in an increased interaction with the chaperone protein 14-3-3, and the 
rapid export of FOXO3a from the nucleus into the cytoplasm, inhibiting FOXO3a 
activity [143]. The 14-3-3 family of proteins are actively involved in 
nuclear/cytoplasmic shuttling processes, transporting proteins from one 
compartmentalised space to another, they are predominately found within the 
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cytoplasmic space. 14-3-3 proteins form homo and heterodimeric U-shaped 
structures and bind to their targets via the central channel. Phosphorylation 
within the NES sequence of FOXO promotes the interaction with the 14-3-3 
complex; this binding decreases the binding affinity of FOXO proteins to DNA 
and possibly obscures the NLS sequence [187-189]. The nuclear export of the 
FOXO:14-3-3 complex is facilitated by chromosomal region maintenance 1 
(CRM1) and Ran GTPase [152].  
 
The loss or withdrawal of growth stimuli results in the inactivation of the PI3K 
signalling cascade. Inactive AKT and other AGC family members are unable to 
phosphorylate FOXO3a and prolong cytoplasmic retention. Thus, 
unphosphorylated FOXO3a translocates to the nucleus where it activates its 
downstream targets. 
 
Hu et al elucidated the complex nature of the AKT/FOXO axis by showing in 
breast tumour samples that indeed AKT phosphorylation did correlate with the 
cytoplamic retention of FOXO3a, but there were also a significant proportion of 
samples that did not, suggesting the subcellular location of FOXO3a was 
regulated by other pathways. Investigating this further they showed that FOXO3a 
cytoplasmic retention correlated with the upregulation of the inflammatory 
pathway protein IKKβ and showed that it directly interacted with FOXO3a, 
phosphorylating it on serine 644 promoting its exclusion from the nucleus and 
degradation by the proteasome. Moreover, this regulation was independent of 
AKT, suggesting multiple mechanisms such as increased IKK signalling – which 
also occurs in cancer – is increased to inhibit the tumour suppressor function of 
FOXO family members [190-192]. 
 
The downstream effector of the RAS-MEK pathway ERK, has also been shown 
to regulate the phosphorylation status of FOXO3a. ERK phosphorylation on 
Serine 294, Serine 344 and Serine 425 promotes the dissemination of FOXO3a 
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throughout the cytoplasm where the likelihood of interaction with mdm2 is 
increased, reducing the cellular expression of FOXO3a [193]. 
 
1.6.4.2 Ubiquitination 
 
When located in the cytoplasm, FOXO3a is exposed to mechanisms that 
regulate the cellular of accumulation of proteins, one such way is ubiquitin-
dependent proteasomal degradation.  
 
There are two types of ubiquitination, monoubiquitination, which is reversible and 
polyubiquitination which is not. Polyubiquitation results in degradation via the 
proteasome, a process known as the ubiquitin-proteasome system (UPS) [194].  
The UPS is essentially a two step process, firstly, the covalent attachment of 
ubiquitin molecules to a particular cellular substrate – this is facilitated by a 
ubiquitin-activating enzyme (E1), a ubiquitin-conjugating enzyme (E2) and a 
ubiquitin ligase (E3) - and then the degradation of this protein via the 26S 
proteasome complex [195]. The 26S proteasome complex can be located in 
either the nucleus or cytoplasm (proximal to centosomes, endoplasmic 
recticulum and cytoskeletal structures) and has been shown to be active in both 
compartments [196]. Entry to the nucleus can be obtained via nuclear pores or 
during the reassembly of the nuclear envelop after cells have undergone mitosis 
[197]. 
 
The phosphorylation of FOXO1 by AKT results in its nuclear exclusion but also 
promotes the interaction with the F-box protein Skp2, which as its predominant 
E3 ubiquitin ligase, facilitates its polyubiquitination. Although to date, this 
regulation is not believed to be shared by the other family members [198].  
 
Although FOXO3a was known to be regulated by the proteasome [199], it was 
not until Yang et al displayed definitively that FOXO3a was regulated by the E3 
ubiquitin ligase mdm2 - that interestingly is also, in part, responsible for 
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regulating the cellular accumulation of the tumour suppressor p53 [28] - that the 
process became more apparent. ERK phosphorylation on Serine 294, Serine 388 
and Serine 425 promotes the localisation of FOXO3a to the cytoplasm where the 
interaction with mdm2 is increased. Polyubiquitination by mdm2 results in the 
degradation by the proteasomal pathway [193]. 
 
Van der Horst et al showed rather eloquently that FOXO4 – and possibly other 
family members – is monoubiquitinated in response to oxidative stress, resulting 
in its translocation to the nucleus and an increase in transcriptional activity and 
that this was negatively regulated but the herpesvirus-associated ubiquitin-
specific protease (HAUSP) [200]. HAUSP had previously been identified as a 
regulator of p53 ubiquitination, competing with mdm2 at modulating its post-
translational status, again reiterating the similarities of FOXO regulation with p53 
[201, 202] 
 
1.6.4.3 Cytosolic FOXO 
 
New research is bringing to light the possible transcriptionally-independent role 
for FOXO1 taking place within the cytoplasm. Zhao et al have shown that 
acetylated cytoplasmic FOXO1 activates the autophagy regulating protein 7 
(Atg7), promoting the induction of autophagy, having a dramatic effect on cell 
fate independent of its transcriptional potential [203]. This study highlights the 
need for more research into the many ways in which FOXO family members can 
dictate cell fate, and how these mechanisms could be important in different 
disease states, such as cancer [204]. 
 
1.7 THE DYNAMIC REGULATION OF THE ACETYLATION STATUS OF 
PROTEINS 
 
Acetylation is the chemical modification of the ε-amino group of lysine residues 
where an acetyl group from the acetyl co-enzyme is transferred to the lysine 
 63 
residue on the target protein [205]. Acetylation can occur on a range of proteins 
with diverse cellular functions, most notably histones, due to the fact that they 
were the first cellular components found to be acetylated in the late 1960s [206]. 
Because of this fact, proteins that control the acetylation status of histone and 
non-histone proteins are called histone deacetylases (HDACs) and histone 
acetyltransferases (HATs). The acetylation of histone and non-histone proteins is 
controlled by the dynamic interaction of HDACs and HATs in a substrate specific 
manner. 
 
Highly conserved throughout evolution, histone proteins package and arrange 
DNA into nucleosomes, giving them protection, structure and order. 
Nucleosomes consist of 146 base pairs of genomic DNA wrapped around a 
histone octamer (consisiting of two pairs of H2A, H2B, H3 and H4). The amino-
terminal and carboxyl-terminal ends of histones project out of the main ‘bead-like’ 
structure of the nucleosome earning them the name ‘histone tails’ [207].  
 
Nucleosomes coupled with DNA are the main constituents of chromatin, which 
make up chromosomes. The modification of the acetylation status of these 
histones can alter chromatin structure which in turn leads to alterations in gene 
expression [208]. Acetylation neutralizes the charge of the histone tails, resulting 
in the decreased ability of the histone to interact with DNA, meaning the tight 
DNA-nucleosome structure is relaxed forming euchromatin, allowing the access 
of transcription factors and other associated proteins that can initiate gene 
transcription. When histones are not acetylated their affinity to interact with DNA 
is not reduced meaning they can form tightly packed heterochomatin, which limits 
the ability of factors to bind and interact with the DNA, leading to silencing of 
genes [209, 210]. 
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1.7.1 Histone Acetyltransferases (HATs) 
 
There are several different HAT protein families, based on conserved structures 
within each of the members. The three most established families are Gen5-
related N-acetyl transferase (GNAT), p300/CBP (CREB binding protein) and 
MYST, which is named after founding members monocytic leukaemia zinc finger 
protein (MOZ), YBF2/SAS3, SAS2 and TAT-interactive protein-60 (TIP60) [209, 
211] 
 
HATs are known to regulate the acetylation status of both histone and non-
histone proteins, for example, p300/CBP regulates the acetylation status of p53 
and FOXO family members [212], influencing their cellular accumulation and 
activity. 
 
1.7.2 Histone Deacetylase (HDAC) class I and II 
 
There are four classes of HDACs, class I, II and IV are zinc-dependent and 
known as the ‘classical’ family. Class III being the relatively new family of 
HDACs, which are termed Sirtuins and are NAD+ (nicotinamide adenine 
dinucleotide-positive) dependent [206]. 
 
Class I members are evolutionarily homologous to the yeast protein Rpd3 and 
comprises of HDAC1, -2, -3 and -8, all containing a high degree of sequence 
homology to Rpd3 (HDAC1 and –2 being the most closely related and 
structurally similar). Class I HDACs are ubiquitously expressed in all cells [213] 
and are predominantly found in the nucleus [214]. Class I HDACs predominantly 
elicit their effect on their substrates and the cellular phenotype through regulating 
gene transcription as members of large mutliprotein complexes, for example, the 
Sin3 complex can act together to facilitate the function of the individual 
components that on their own cannot interact with DNA and inhibit gene 
transcription. Sin3 does not contain a DNA interacting domain, requiring other 
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proteins to perform this function [215]. One protein that can fulfil this role is the 
transcription factor mitotic arrest deficient-like 1 (Mad1), which was the first 
transcription factor found to interact with Sin3. Sin3 binds to Mad1 using its 
paired amphipathic alpha-helic domain (PAH) two (PAH2) [216]. HDAC1 and -2 
have been shown to directly interact with Sin3 through a HDAC interacting 
domain (HID) and one is required to repress transcription in a Mad1-dependent 
manner. Although HDAC1 and -2 cannot interact with Mad1 directly, requiring 
Sin3 to facilitate complex formation [217]. The aggregation of proteins into 
complexes also aids defining substrate specificity, for example, the inhibitor of 
growth protein 2 (ING2) binds to the mSin3a-HDAC1 complex in response to 
DNA damage and interacts with a discreet subset of genes involved with 
promoting proliferation. The binding of mSin3a-HDAC1 represses gene 
transcription halting cell proliferation allowing the cells to mediate DNA repair 
mechanisms [211, 218].  
 
HDAC3 is a major component of the nuclear receptor corepressor (NCoR) and 
the silencing mediator for retinoid and thyroid hormone receptor (SMRT) 
transcriptional repressor complexes [219]. 
 
Class II HDACs are evolutionarily derived from the yeast protein, Hda1 and are 
subdivided into two subclasses, IIa and IIb. Class IIa containing HDAC4, -5, -7 
and -9, class IIb containing HDAC6 and -10 [206, 220]. Although derived from 
Hda1, class II HDACs only share homology within the coding of the catalytic 
domains but vary significantly in other structures and their overall functions [219] 
(Not unlike the forkhead family of proteins). Class II HDACs are predominantly 
located in the cytoplasm but are thought to translocate to the nucleus when 
required for transcriptional repression [220]. 
 
The fourth class has only one member, HDAC11 and is distinct from classes I 
and II due to the fact that it contains structural features similar to both Rpd3 and 
Hda1 [221]. 
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1.7.3 Histone Deacetylase (HDAC) class III, also termed Sirtuins 
 
Sirtuins are the most recently discovered HDAC class and are different to other 
families due to the fact they require NAD+ and are resistant to compounds that 
target and inhibit class I and II HDACs. Moreover, HDACs are known not to 
solely regulate the acetylation status of histones but also regulate the acetylation 
status of non-histone proteins. Sirtuins are a perfect example of this, influencing 
the posttranslational status and activity of proteins key to maintaining cell 
viability, such as p53 [222], FOXO family members [223] and the DNA-repair 
protein Ku70 [224]. 
 
There are seven human orthologues of silent information regulator 2  (sir2), 
termed SIRT1-7, which possess primarily histone deacetylase (SIRT1, -2, -3, -5) 
or mono-ribosyltransferase activity (SIRT4 and SIRT6) [225, 226], the enzymatic 
ability of SIRT7 is yet to be fully determined (Figure 1.4) . 
 
Sirtuins are ubiquitously expressed although they occupy distinct subcellular 
localisations and consequently interact with different intracellular targets – 
suggesting that their main role is mediating the acetylation status of non-histone 
proteins, otherwise they would all be located in the nucleus - for example, SIRT1 
is primarily located in the nucleus – but can also be found in the cytoplasm -
whereas SIRT2 is predominantly found in the cytoplasm [227, 228]. SIRT3, -4 
and -5 are located in the mitochondrion [229], although recently SIRT3 has also 
be found in the nucleus [230]. SIRT6 and -7 are also located in the nucleus, 
although they are predominantly found in distinct regions, SIRT6 is associated 
with heterochromatin, whereas SIRT7 is found in the nucleoli [231]. 
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Figure 1.4: The structure of mammalian sirtuins. The basic structure of Sirtuin 
proteins, displaying the NAD+ binding site (dark blue), HDAC catalytic domain 
(pink) and sumoylation site (green). Only SIRT1, -2, -3 and -5 are known to 
possess histone deacetylase activity. Adapted from Yamamoto et al 2007 [232]. 
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1.7.3.1 SIRT1 
 
SIRT1 is the most studied sirtuin family member, it being the most homologous to 
Sir2, the first sirtuin to be discovered in Saccharomyces cerevisiae 
(S.cerevisiae). Sir2 was found to promote longevity, increasing lifespan by 30% 
when an extra copy was integrated into the genome. Moreover, deletion of Sir2 
resulted in a drastic shortening of lifespan [233]. Further interest was sparked 
when Sir2.1 - sharing 31% sequence similarity in the ‘conserved core’ domain 
[234] - was found to increase lifespan in C.Elegans by 50% when its expression 
was increased due to gene duplication. Moreover, Sir2.1 was able to promote 
longevity in response to caloric restriction (CR). The increased availability of 
NAD+ during CR facilitated an increase in Sir2.1 activity, driving survival [234]. 
Furthermore, transgenic mice overexpressing SIRT1 showed traits associated 
with caloric restriction, for example, reduced body weight, lower blood 
cholesterol, increased metabolic rate, lower body fat and improved physicality 
[235]. Mice deficient in SIRT1 were shown unable to develop these traits under 
conditions of CR, suggesting that SIRT1 is indispensible for regulating CR in 
mice [236]. In mammalian cells SIRT1 – along with SIRT2 and -3 [237] - were 
also found to be activated in response to CR, reducing stress induced apoptosis 
and promoting longevity, suggesting that sirtuins can cooperate in deciphering 
cell fate in response to different forms of stress [238].  
 
SIRT1 is known to regulate the acetylation status of histones H2A, H2B, H3 and 
H4, although it shows preference to regulating the specific lysine residues 
histone 3 lysine 9 (H3K9), histone 3 lysine 14 (H3K14) and histone 4 lysine 16 
(H4K16) . H4K16 is an important posttranslational modification, it has been 
shown to regulate chromatin structure, acetylated H4K16 disrupting the formation 
of compact chromatin, a trait not shared by other lysines residues on histones 
[239]. SIRT1 is a key modulator of H4K16, its overexpression able to decrease 
H4K16 in response to various cytotoxic agents [240]. 
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SIRT1 is known to be involved in deciphering cell fate through its negative 
regulation of p53. Acetylation is essential for p53 activation [36] as well as 
potentiating its activation by increasing the cellular accumulation of p53 by 
inhibiting its mdm2-dependent degradation by the proteasome. The deacetylation 
of p53 by SIRT1 suppresses its stabilization and transcriptional activation, 
inhibiting p53s ability to activate targets involved with cell cycle arrest and 
apoptosis, such as p21 and BAX [241]. Moreover, acetylation has been shown to 
be crucial for the transcription-independent activation of BAX by p53, suggesting 
that the effect of acetylation on p53 is complex, but ultimately the effect on cell 
fate is the same, p53 acetylation promotes the induction of programmed cell 
death [242]. 
 
1.7.3.2 SIRT2 
 
SIRT2 is a major regulator of cytoskeleton dynamics, predominantly through its 
deacetylation of α-tubulin and microtubule regulation influencing processes such 
as cell division, intracellular transport and motility [243]. Validating α-tubulin as an 
important downstream target of SIRT2, the knockdown of SIRT2 using siRNA in 
293T cells resulted in the hyperacetylation of tubulin [243]. Although SIRT2 is 
predominantly cytoplasmic protein it is also known to regulate the acetylation 
status of H4K16 and H3K9, although this is thought to only occur during mitosis 
when the nuclear membrane has disassembled allowing cytoplasmic proteins to 
interact with chromatin. SIRT2 deactylation encourages progression through the 
G2-M phase of the cell cycle by promoting chromatin condensation which 
precedes chromatin segregation in cells undergoing mitosis [244, 245]. 
Supporting this function of SIRT2, H4K16 acetylation levels decrease when 
SIRT2 is seen to associate with chromatin in G2-M cell cycle progression. 
Moreover, SIRT2-/- MEFs displayed an inability to deacetylate H4K16, 
hyperacetylation was observed in cells undergoing mitosis, delaying the entry 
into s phase suggesting SIRT2 as an important regulator of cell cycle progression 
[244, 246]. 
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1.7.3.3 Mitochondrial Sirtuins (SIRT3, -4 and -5) 
 
The role of sirtuins in mitochondrial biology and the consequent influence on cell 
fate is particularly interesting when you consider that a significant proportion of 
mitochondrial proteins can be acetylated (at least 20%) [247]. Furthermore, 
SIRT3-/- null mice (but not SIRT4-/- or SIRT5-/-) display hyperacetylation of 
mitochondrial proteins which can be reduced by reinstating SIRT3 expression, 
suggesting that it plays a major role in regulating the posttranslational status of 
this compartmentalized pool of proteins.  
 
It has been shown that SIRT3 - the most well defined mitochondrial sirtuin - is 
found in both the mitochondrion and the nucleus. Although recent publications 
have shown that full length SIRT3 can be found in the nucleus, SIRT3 is 
translocated to the mitochondrion where it undergoes proteolytic cleavage [248]. 
Furthermore, all mitochondrial sirtuins contain N-terminal sequences that 
promote their localization to the mitochondrion where they undergo proteolytic 
cleavage [249]. Moreover, full length SIRT3 has been found to lack deacetylase 
activity and can only possess deacetylase activity once it has been cleaved, 
suggesting that the translocation of SIRT3 to the nucleus must only occur under 
specific types of physiological stress.  
 
SIRT3 is known to deacetylate the mitochondrial matrix protein acetylcoenzyme 
A synthase 2 (aceCS2) on residue K642 increasing its enzyme activity [250]. 
AceCS2 facilitates the formation of acetyl-CoA from acetate, CoA and ATP, 
which can be used to generate energy through the tricarboxylic acid (TCA) cycle 
[251]. SIRT3 also associates with components of Complex I of the electron 
transport chain, promoting its activity and the generation of ATP [252]. These two 
intracellular targets reiterate the intimate role of SIRT3 at regulating the cellular 
availability of metabolic energy. SIRT3 expression is also known to positively 
correlate with the expression of mnSOD [237]. Also, SIRT3 corroborates with 
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SIRT4 to regulate NAD+ levels in mitochondria following stress, promoting cell 
survival [253]. 
 
SIRT4 does not possess HDAC activity but acts as an ADP-ribosyltransferase, 
depositing ADP-ribose from NAD+ onto its target proteins [254]. One of known 
cellular targets being glutamate dehydrogenase (GDH), which converts 
glutamate to α-ketoglutarate and ammonia, promoting the production of ATP and 
secretion of insulin. SIRT4 negatively regulates the activity of GDH, and SIRT4s 
regulation of insulin secretion is GDH-dependent [255]. To confirm GDH as an 
important cellular target of SIRT4, pancreatic islets from SIRT4-/- mice displayed 
increased insulin secretion and significantly elevated insulin levels in the blood 
compared to WT mice [249].  
 
SIRT5 does display weak HDAC activity and is able to deacetylate H4 in vitro 
[256] and to date, is known to regulate the acetylation status of two mitochondrial 
proteins, cytochrome c - which is integral to the induction of apoptosis – and 
carbamoyl phosphate synthase 1 (CPS1) [257]. The deacetylation of CPS1 
increases its activity, promoting the activation of the urea cycle and reduction in 
accumulation of ammonia. SIRT5-/- mice displayed increased ammonia levels 
after prolonged fasting, suggesting that SIRT5 is a major regulator of ammonia 
accumulation [258]. 
 
1.7.3.4 SIRT6 
 
SIRT6-knockout mice are susceptible to genotoxic insults, genomic instability 
and the development of premature aging [259]. Although SIRT6 was initially 
identified to contain ADP-ribosyltransferase activity [226], it has recently been 
shown that SIRT6 also possesses histone deacetylase activity and that this may 
be responsibly for its ability to regulate cell survival [260]. Supported by the fact 
that SIRT6 is located in the nucleus, it appears to protect cells from senescence 
and aging by deacetylating H3K9 at the terminal telomeric regions of chromatin, 
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maintaining telomere structure and reducing the development of abnormal 
chromosomal aberrations [261]. SIRT6 also interacts with components of the NF-
κB complex, where upon binding to the promoters of its target genes modulated 
the acetylation of H3K9 inhibiting gene transcription. Moreover, SIRT6 null mice 
were found to contain increased expression of NF-κB regulated genes [258, 261]. 
 
1.7.3.5 SIRT7 
 
SIRT7 deficient mice have been developed and shown to have a decreased 
lifespan due to cardiac dysfunction. Mice lacking SIRT7 have an increase in p53 
activity and apoptosis in cardiomyocytes, whereas SIRT7 overexpression 
increase stress resistance and reduces the induction of apoptosis [262]. SIRT7 
also is known to regulate ribosomal RNA transcription by directly binding to RNA 
polymerase I (Pol I), increasing its activity [263], which is in contrast to SIRT1 
which competes with the HAT PCAF to negatively regulates the acetylation 
status – and activity - of the TATA box-binding protein associated factor 68 
(TAF68) which promotes Pol I transcription [264]. 
 
1.8 FOXO AND ACETYLATION 
 
The origins of interest in the regulation of FOXO by sirtuins came from the 
studies in C.Elegans, which showed that Sir2.1 was able to promote longevity 
and survival, and appeared to corroborate with the DAF-16 signalling pathway to 
achieve this [234]. In 2004 Brunet et al and Motta et al both showed that SIRT1 
directly interacted with FOXO3a. Motta et al elucidated the mechanism by which 
SIRT1 counteracted the HAT p300 in dynamically regulating the acetylation 
status of FOXO3a (and FOXO4). The deacetylation of FOXO3a by SIRT1 
inhibiting its ability to activate the downstream targets p27 and Bim, inhibiting the 
induction of apoptosis [265]. Brunet et al showed rather eloquently that SIRT1 
regulated the acetylation of FOXO3a in response to hydrogen peroxide induced 
oxidative stress, promoting the transcription of genes favouring a cell cycle arrest 
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and DNA damage repair phenotype, such as p27 and Gadd45 [223]. Although 
the papers have differing opinions on the regulation of p27 by acetylated 
FOXO3a, they both concur with the fact that SIRT1s deacetylation of FOXO3a 
promoted survival and suppressed a FOXO3a-dependent induction of apoptosis. 
Subsequent publications later that year also showed that SIRT1 deacetylated 
FOXO4, competing with CBP to control its acetylation status. SIRT1-mediated 
deacetylation increased the transcriptional activity of FOXO4 [266]. Moreover, 
mouse Sir2 was found to compete with CBP to control the acetylation of FOXO1, 
deacetylating FOXO1 on lysines 242, 245 and 262, potentiating its transcriptional 
activity, promoting the upregulation of p27 and mnSOD [267].  Furthermore, 
Matsuzaki et al showed that the acetylation of these residues decreased DNA-
binding affinity of FOXO1, increasing its phosphorylation at a proximal residue - 
serine 253 – which is controlled by AKT, promoting its nuclear exclusion and 
inhibition by cytoplasmic retention [268]. 
 
Subsequent publications have also shown that SIRT2 and SIRT3 interact directly 
with FOXO3a regulating its acetylation status and ability to regulate cellular ROS 
accumulation [269, 270]. A particularly interesting study showed that SIRT3-/- 
mice displayed cardiac dysfunction and that overexpression of SIRT3 inhibited 
this in a FOXO3a-dependent manner via the upregulation of genes involved with 
decreasing ROS accumulation and reducing cellular stress [271]. Although, these 
studies do require further examination to determine the exact consequence on 
cell fate of multiple SIRTs interacting with FOXO3a. The regulation of the 
acetylation status of p53 is also regulated by multiple sirtuins, SIRT1, -2 and -3, 
suggesting that there is redundancy between family members and that sirtuins 
play a central role at regulating cell fate [272-274]. 
 
When considering the acetylation of FOXO3a most publications centre on the 
regulation of lysines within the DBD. The general consensus is that the 
deacetylation of FOXO3a promotes the activation of a subset of genes 
predominantly involved with survival, promoting the transcription of genes 
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involved with responding to stress and inhibiting the induction of apoptosis [143]. 
This suggests that the acetylation of FOXO3a could promote the transcription of 
genes involved with initiating apoptosis.  In support of this hypothesis, Yang et al 
2009 recently showed that the class I and II HDAC inhibitor depsipeptide caused 
the acetylation and increased cellular accumulation of FOXO1 in human lung 
cancer cells. Moreover, depsipeptide treatment resulted in FOXO1-dependent 
induction of Bim, resulting in the induction of apoptosis [275]. Also, Brunet et al 
did show that inhibition of SIRT1 with the pan inhibitor nicotinamide did reduce 
the transcription of p27 and mnSOD and an increase in Bim expression. 
However they did not suggest whether this was due to changes of chromatin 
structure due to HDAC inhibition, or the direct aceylation of FOXO [223]. In 
pancreatic β cells the acetylation of FOXO1 inhibits its polyubiquitation and 
subsequent degradation by the proteasome. Moreover, its acetylation promotes 
the interaction with promyelocytic leukemia (PML) protein and PML bodies within 
the nucleus, not promoting its phosphorylation and nuclear exclusion [276]. This 
is particularly interesting when you consider that this is the same subcellular 
location where p53 accumulates [274] and that PML bodies are associated with 
increased cellular stress and apoptosis, particularly Fas and TNF mediated cell 
death [277]. 
 
Smith & Shanley have investigated the posttranslational status of FOXO proteins 
in response to various regulatory factors using mathematical models and found 
that acetylation protected FOXO proteins from degradation [278]. Furthermore, 
although acetylated FOXOs transcriptional activity was lower than the non-
acetylated form, this could have been a result of monitoring only a subset of 
downstream targets [278]. 
 
Research into the effect of acetylation on FOXO3a is still in its infancy and 
requires more investigation to prove a consensus of how the modulation of 
specific lysine residues affects the role of FOXO proteins in determining cell fate. 
One way to examine this would be to perform ChIP-seq. Although, an 
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appropriate cellular system would have to be found where you would not have 
compensation from other forkhead family members. CHIP-seq would allow the 
assessment of the activation/repression of all FOXO3a target genes (established 
and novel), taking into account cofactor binding and promoter architecture. The 
one caveat would be producing site-specific mutants of acetylation mimic and 
non-acetylatable FOXO that reflected the acetylation status found in vivo through 
HAT/HDAC regulation. 
 
1.9 FOXO IN CANCER 
 
Three of the four group members were initially identified in humans because they 
were found at chromosomal translocations in tumours, suggesting that they may 
play a role in tumour development [143]. FOXO1 was found to be fused to PAX 
proteins 3 and 7, in two translocation sites, t(2;13) and t(1:13) respectively,  in a 
number of alveolar rhabdomyosacromas (ARMS) [124]. PAX proteins – named 
because of the presence of the ‘paired box’ DNA-binding domain within each 
family member - are transcription factors that are important in cellular 
differentiation and tissue development, most notably, skeletal muscle. They 
promote cell proliferation, migration and survival [279]. 
 
The PAX3-FOXO1 chimeric protein contains the potent FOXO transactivation 
domain and the PAX3 DNA-binding domain, which results in the fusion protein 
being more transcriptionally active than the normal PAX3 protein. The PAX3-
FOXO1 protein is constitutively active and localised solely in the nucleus where it 
can activate its downstream targets more readily, leading to oncogenic 
transformation and tumour development [280]. Moreover, the presence of the 
PAX3-FOXO1 protein results in a loss of expression of endogenous FOXO1, 
which is a critical mediator of cell cycle control in normal tissues. This loss of 
expression could be a key event in the development of tumourigenesis [76]. The 
loss of FOXO1 though chromosomal deletion (13q14) can be found in different 
prostate cancer types and its loss is known to promote tumourigenesis and the 
 76 
development of androgen independence [281]. Furthermore, the PAX3-FOXO1 
protein promotes transcription of platelet-derived growth factor alpha (PDGFα), 
which is neither a target of PAX3 or FOXO1, suggesting that the fusion protein 
could have distinct downstream targets to that of the individual transcription 
factors. PDGFα activates the PI3K cascade, negatively regulating FOXO1 
transcriptional activity, promoting tumour progression [128]. Of course, in vivo the 
development and progression of ARMS is likely to be far more complex, involving 
a combination of all known and other yet unknown mechanisms that provide the 
tumour with a select advantage over its environment, but what is clear is FOXO 
dysregulation can provide this advantage. In metastatic ARMS patients, half the 
patients display metastasis to the bone barrow and a quarter present with 
metastasis to the lungs. Ultimately this leads to a poor clinical outcome, only 8% 
of sufferers having a 4-year survival rating [279, 282]. 
 
FOXO proteins function as tumour suppressors in a range of cancers, including 
lung, prostate and breast cancers [76]. The loss of expression or dyregulation of 
FOXO proteins can have drastic effects on cell fate. The loss of functional FOXO 
has been investigated using triple knockout mice - who do not express FOXO1, -
3 and -4 – the lack of the three principal FOXO proteins leading to the 
development of hemangiomas and lymphoproliferative disease [283, 284]. The 
loss of FOXO3a mRNA and protein expression has been observed in lung 
adenocarcinoma (LAC) and non-small cell lung cancer (NSCLC). In 24.2% of 
LAC samples, FOXO3a expression was lost due to homozygous deletion and a 
further 60.6% displayed a significant loss of FOXO3a expression [285], 
supporting the hypothesis that FOXO3a functions as a tumour suppressor. 
Decreased expression of FOXO3a has also been observed in human prostate 
cancer cells when developing androgen-independent growth [286]. Furthermore, 
prostate cancer clinical samples displayed a decreased transcriptional 
expression of FOXO3a in high grade prostate tumours [287]. Interestingly, it was 
also shown that in low grade tumours, FOXO3a expression was comparable to 
benign tissue samples but in low grade prostate tumour samples, FOXO3a was 
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retained in the cytoplasm, suggesting that FOXO3a inactivation is an early step 
in prostate cancer development, followed by loss of FOXO3a expression in high-
grade tumours [287]. 
   
Not only does its loss of expression lead to increased tumourigenesis but recent 
studies have shown that its subcellular location is integral to its role at regulating 
cell fate. The cytoplasmic retention of FOXO3a has been observed in breast 
cancer and shown to be due to the hyperactivation of regulatory kinases, such as 
PI3K/AKT, RAS/MEK/ERK and IKK [186, 190]. Activation of these pathways 
through loss of functional PTEN, PIK3CA and increased expression of 
extracellular receptors all lead to the inactivation of FOXO3a and its retention in 
the cytoplasm. The suppression of FOXO3a activity through overactivation of 
upstream regulatory pathways has been implicated in breast cancer tumour 
progression, for example, in tumour cell lines that harbour PTEN mutations, 
FOXO1 and -3a are retained in the cytoplasm resulting in their inhibition. 
However, the reintroduction of functional PTEN or overexpression of FOXO 
family members resulted in a G1 cell cycle arrest and induction of apoptosis, 
highlighting the importance of PI3K hyperactivation in breast cancer and its 
suppression of FOXO proteins, promoting tumour progression and survival [165, 
288]. Moreover, hyperactivation of the IKK inflammatory pathways has also been 
shown to inversely correlate with the active/nuclear FOXO3a in breast cancer.  A 
total of 131 breast cancer tumours were examined, 113 (86%) were found to 
positively express FOXO3a and that it was located in the cytoplasm and that this 
repression of FOXO3a positively correlated with a poor clinical outcome [190]. 
The retention of FOXO3a in the cytoplasm inhibits its ability to transcribe its 
downstream targets – which are predominantly involved with regulating cell cycle 
progression – resulting in tumour progression and resistance to apoptosis. 
Combined these data support the hypothesis that suppression of proapoptotic 
potential of FOXO3a can play a pivotal role in tumour progression and survival. 
What is clear is, dysregulation of the normal function of FOXO proteins is a 
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frequent event in cancer and restoring their activity could reinstate proliferative 
control. 
 
1.9.1 Therapeutic approaches to targeting the PI3K and FOXO family 
members in cancer 
 
Due to the fact that the activity of FOXO proteins is regulated by signalling 
pathways that are positioned upstream of the transcription factors and that these 
pathways are frequently hyperactivated in cancer, compounds that impede this 
hyperactivation are potent activators of FOXO proteins, for example, PI3K 
inhibitors have been identified using large-scale screens that specifically assess 
the ability of compounds to promote the translocation of FOXO3a to the nucleus, 
inhibiting proliferation in human cancer cell lines [289].  
 
In recent years, a fervour of research into the development of smart therapies or 
targeted therapies has produced a myriad of specifically targeted compounds 
and monoclonal antibodies that inhibit various constituents of the PI3K signalling 
system, ranging from the extracellular receptors to the intracellular signalling 
machinery. Probably the most widely known and clinically tested therapies are 
gefitinib, lapatinib and herceptin which target EGFR, EGFR and HER2, and 
HER2 respectively, resulting in the inhibition of the PI3K cascade, inhibiting 
tumour growth.  
 
Lapatinib is a potent proapoptotic compound, inducing cell cycle arrest and 
apoptosis in cell lines or xenographs that are dependent on EGFR or HER2-
driven proliferation [290, 291]. We and others have shown that FOXO3a is 
indirectly activated in response to lapatinib and gefitinib treatment, and that its 
activation is integral to modulating the induction of apoptosis [98, 292, 293]. 
Moreover, since HER2 overexpression is predominantly linked with ER-
independent growth and resistance to anti-estorogens, such as tamoxifen, 
lapatinib treatment can resensitises cell lines to anti-estrogen therapies. 
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Emphasizing this fact, a recent phase III study showed that lapatinib in 
combination with the anti-estrogen aromatase inhibitor letrozole, significantly 
reduced the risk of disease progression, while increasing the progression free 
survival of metastatic breast cancer patients that had ER+/HER+ disease [294, 
295]. Furthermore, the ability of lapatinib to resensitise breast cancer cell lines to 
anti-estrogens is dependent on FOXO3a-mediated transcription of the estrogen 
receptor [291], highlighting the important role FOXO3a plays in modulating cell 
fate in response to cytotoxic agents. Further understanding of the regulation of 
FOXO3a is needed so that its role in the efficacy of combinatorial therapies can 
be exploited more effectively. 
 
1.9.2 HDACs in cancer 
 
Disruption of the acetylation profile of cellular components through the disruption 
of HATs and HDACs is thought to lead to the development of cancer. The loss of 
aceylation of H4K16 is frequently observed in cancer development (In total 25 
cancer cell lines were tested, including breast, colon, lung and leukaemic cell 
lines relative to the nontransformed controls) [296], suggesting that increased 
HDAC expression/activity or reduce HAT expression/activity is a feature of 
tumourigenesis. Complementing this research, another study performed by 
Suzuki et al showed that H4 hypoacetylation is associated with breast cancer 
progression from normal epithelium to invasive cancer, and that interestingly this 
was most marked between normal epithelium samples and the development of a 
ductual carcinoma in situ (DCIS) suggesting that loss of H4 acetylation is an 
early even in cancer development [297]. Interestingly sirtuins, predominantly 
SIRT1, are the only family of HDACs that have been found to deacetylate H4K16 
suggesting that their increased activity or expression could be a frequent event in 
cancer development [298]. 
 
The increased expression of class I HDACs is associated with cancer 
development. Conversely, the expression of class II HDACs is reduced in 
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tumours. Moreover, those that had higher expression of class II HDACs had a 
more favourable outcome [299]. 
 
Sirtuins SIRT1, -2, -3 and -7 have all be found to be upregulated in tumours 
[300]. SIRT1 is the most rigouously studied sirtuin in cancer and has found to be 
upregulated in breast, skin, colon and prostate cancers compared to 
untransformed tissues [258].  Regulators of SIRT1 expression have also been 
found to be lost or silenced in cancer development. The expression of 
hypermethylated in cancer 1 (HIC1) is lost in 60% of breast cancers, as well as 
other types of cancer such as brain, renal and colon. The loss of expression is 
the result of the methylation of a region of chromosome 17p13.3 [301]. HIC1 has 
been found to bind to the SIRT1 promoter and inhibit transcription, suggesting 
that its loss in tumourigenesis leads to the upregulation of SIRT1, promoting 
cancer development [302]. Deleted in breast cancer 1 (DBC1) is known to bind to 
the SIRT1 protein, inhibiting its catalytic activity and also disrupt its interaction 
with its substrates. DBC1 is located in chromosomal region that is deleted in 
human breast cancer (chromosome 8p21) [303] and whose expression is also 
lost in lung and colon cancer cell lines [304] suggesting that its loss leads to an 
increase in SIRT1 activity. This overexpression of SIRT1 leads to the 
deacetylation and suppression of down-stream targets, such as p53, and the 
decreased ability of inducing apoptosis in response to genotoxic stress [304]. A 
positive regulator of SIRT1 activity, active regulator of SIRT1 (AROS) has also 
been identified, whose expression positively correlates with SIRT1 in a range of 
cancer cell lines (kidney, colon, lung, bone and blood) and suppresses p53-
induced apoptosis in a SIRT1-dependent manner, suggesting that positive 
regulators of SIRT1 are upregulated in cancer [305]. Taking this further, the 
activity of SIRT1 is also regulated by its posttranslational status. Studies have 
shown that the sentrin-specific protease 1 (SENP1) desumoylates SIRT1 in 
response to genotoxic stress, which dramatically reduces its activity, resulting in 
the acetylation and activation of p53, resulting in the induction of apoptosis [306]. 
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This research suggests that proteins that regulate the sumoylation status of 
SIRT1 could also be important in cancer development. 
 
Recently, SIRT2, -5 and -7 were found to be elevated in pancreatic cancer [258]. 
SIRT7 was also shown to be upregulated in breast cancer, compared to normal 
tissue. Moreover, increased SIRT3 and SIRT7 expression was linked to lymph 
node-positive breast cancer, suggesting that they play a role in tumourigenesis 
and metastasis [307]. 
 
Further studies are required to assess the role of sirtuin expression and activity in 
cancer development. To have a full understanding of the dynamics of regulating 
the acetylation status of key modulators of cell fate, the expression and activity of 
HATs and HDACs have to be explored. Although sirtuin expression may not by 
statistically elevated in tumour samples, its activity could be increased or its 
cellular competitor could be lost or inhibited, making the understanding of sirtuin 
proteins roles in tumour biology infinitely more complex but ultimately more 
important. 
 
1.9.3 Targeting HDACs in cancer 
 
The study of HDACs has increased dramatically in recent years, mainly due to 
the discovery of their role in cancer but also due to the development of small 
molecules that can specifically target HDACs in vivo, influencing their activity.  
Although advances in HDAC inhibitors have been made, clinical development 
has been largely with class I and II proteins, the most notable compound being 
the small molecule inhibitor SAHA (Vorinostat), which was the first HDAC 
inhibitor to be approved by the FDA in 2006 for the treatment of cutaneous T-ell 
lymphoma (CTCL) [308]. No class III HDAC inhibitor, to date, has progressed 
from preclinical research into clinical trials for cancer treatment. What defines the 
interest in sirtuins is their intracellular targets, histone and non-histone proteins 
that are involved in a plethora of cellular processes, but also the fact that 
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established class I and II inhibitors like TSA do not effect sirtuin activity and 
newly developed sirtuin inhibitors appear to be selective for class III HDACs 
meaning sirtuin proteins provide a novel and selectable target in cancer [309].  
 
The investigatation into sirtuin inhibitors and their efficacy in different disease 
states is still in its infancy. To date, the compounds cambinol and tenovin-6 have 
been the most rigorously tested sirtuin inhibitors. Both compounds have been 
shown to target multiple sirtuin proteins, predominantly SIRT1 and SIRT2 (and 
possibly others) [310]. Cambinol is a dual sirtuin inhibitor, suppressing tumour 
growth in nude mice xenographed with burkitt lymphoma and human melanoma 
cells, respectively [311, 312]. Moreover, the antiproliferative function of cambinol 
was facilated by the acetylation of p53, promoting its activation and the 
acetylation of the B-cell lymphoma 6 protein (BCL6) oncoprotein, resulting in its 
inhibition [311]. Tenovin-6 was also shown to be a potent activator of p53 through 
the inhibition of SIRT1 and SIRT2, promoting the induction of apoptosis in tumour 
cell lines and reduced tumour growth in xenograft mice [312]. 
 
Other inhibitors such as sirtinol and EX527 have also been shown to successfully 
inhibit cancer cell growth. Sirtinol is known to induce senescent-like growth arrest 
in breast and lung cancer cell lines through inhibition of SIRT1 and SIRT2 [313]. 
Furthermore, sirtinol treatment increased the efficacy of cisplatin in prostate 
cancer cell lines [314]. EX527 is the most potent SIRT1 inhibitor identified, 
having an IC50 of 38nM [315] (although in our own study we found it to be 10-
fold less, it is still considered to be the most potent SIRT1 inhibitor identified 
[316]), although the effect EX527 monotreatment has on cell fate has not been 
fully elucidated as most publications only use it in combination with cytotoxic 
agents such as etoposide [315]. 
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THESIS AIMS AND OBJECTIVES 
 
The aim of this thesis was to investigate the importance of FOXO3a and sirtuins 
in breast cancer. As well as investigate whether they played important roles in 
the development of resistance, and more importantly, whether this interaction 
could be exploited therapeutically. 
 
Also, I aimed to elucidate the mechanism of action of known sirtuin inhibitors and 
whether it could be exploited to increase the efficacy of anticancer therapies, 
predominantely those that are known to indirectly effect the activation of 
FOXO3a. 
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CHAPTER 2 
 
MATERIALS AND METHODS 
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2.1 CELL CULTURE 
 
The human breast carcinoma cell lines MCF-7, MDA-MB-231, ZR-75-1, BT474 
and SkBr3 originated from the American Type Culture Collection and were 
acquired from Cancer Research UK, in which they were tested and 
authenticated. These procedures include cross-species checks, DNA 
authentication, and quarantine. Cell lines used in this thesis were in culture for <6 
months and were maintained in Dulbecco’s modified eagle medium 
(DMEM)(Sigma Aldrich, UK) containing 10% foetal calf serum (FCS) and 2 
mmol/L glutamine and 100 U/mL penicillin/streptomycin in a humidified incubator 
at 37°C  with an atmosphere of 10% CO2. 
 
The colon carcinoma cell line DL23, previously described [170], were grown in 
RPMI-1640 medium which was supplemented similarly as described above. 
 
The mouse embryonic fibroblasts (MEF) were derived from wildtype, p53-/- and 
FOXO-/- (FOXO1, FOXO3a and FOXO4) double knockout mice. Cells were 
cultured in DMEM and supplemented similarly as described above. 
 
MEF FOXO-/- were a kind gift from Professor Boudewijn Burgering, University 
Medical Centre, Utrecht. 
 
Cisplatin Resistant MCF-7 cells (CisR) and Lapatinib resistant SkBr3 cells (R5) 
were generated by myself and were cultured in the same conditions as the 
parental cell lines, apart from the exception that, when resistant, were 
supplemented with 1 µM/ml of cisplatin and 0.5 µM/ml of lapatinib, respectively. 
 
2.1.1 Cell line maintenance 
 
Cells were grown and split at approximately 80% confluency, twice a week (Cells 
were split at defined ratios MCF-7 1:5, SkBr3 1:5, DL23 1:7, ZR-75-1 1:5, MDA 
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231 1:6, BT474 1:5, NIH 3T3 WT 1:8, NIH 3T3 p53-/- 1:8 and MEF FOXO-/- 1:8). 
Media was aspirated and the cell monolayer was washed once in warm PBS and 
then detached by the addition of 1× trypsin-EDTA. After the cells were detached 
by the addition of trypsin, they were resuspended in the appropriate media and 
seeded into a new flask or into the appropriate cell culture plasticware. Cells 
were cultured for approximately 35 passages before discarding. 
 
2.1.2 Long-term maintenance of cells 
 
Cells of good health and a low passage number were detached from the 
monolayer with trypsin, as described above, and washed in media. They were 
then spun at 500× g for 5 minutes. The supernatant was discarded and the cell 
pellet was resuspended in FCS with 10% dimethyl sulphoxide (DMSO). 1 ml 
aliquots were transferred to cryotubes and slowly frozen in a Mr. Frosty (VWR 
International) at -80°C overnight before being transferred to storage in liquid 
nitrogen. 
 
For defrosting cells, cryotubes were defrosted rapidly in a waterbath (~37°C) and 
the defrosted solution was added to complete media and spun at 1000× g for 5 
minutes. The DMSO containing supernatant was removed and cell pellets were 
redissolved in fresh supplemented medium and placed in a 25cm2 culture flask to 
grow. 
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2.2 CHEMICALS  
 
Cisplatin (Onco-tain DBL, Leamington Spa) was maintained as a stock solution 
(3.3M) at room temperature and diluted in fresh media prior to treatment. 
Paclitaxel (Imperial College Healthcare, UK) was maintained as a stock solution. 
Lapatinib (LC laboratories, USA) was dissolved in DMSO and stored at -20°C at 
a concentration of 1mg/µl. Cycloheximide (Sigma-Aldrich, Dorset, UK) was 
dissolved in DMSO and stored at -20°C at a concentration of 10mg/µl. 
Nicotinamide (SigmaAldrich, UK) was dissolved in DMSO at concentration of 
10mM and stored at -20°C. SIRT inhibitors EX527 (6-Chloro-2,3,4,9-tetrahydro-
1Hcarbazole-1-carboxamide), Sirtinol (2-[(2-Hydroxynaphthalen-1-
ylmethylene)amino]-N-(1-phenethyl)-benzamide), and Salermide (N-{3-[(2-
hydroxynaphthalen-1-ylmethylene)-amino]-pheny-2-phenylpropionamide) were 
prepared according to reported procedures (synthesized by Sebastian Kroll and 
Paolo Di Fruscia), stock solutions of 10mM were dissolved in DMSO and stored 
at -20°C.  
 
2.3 IN VITRO SIRTUIN ACTIVITY ASSAY 
 
The Biomol hSIRT1/hSIRT2 activity assay (AK-555/ AK-556) was used to deduce 
the activity potential of SIRT inhibitors. These in vitro assays use only a few 
components and allow the study of inhibition or activation of protein activity.  
 
The assay was done essentially as described [317] and according to the 
manufacturer's instructions (Biomol International). All compounds were 
preincubated with the hSIRT1/hSIRT2 before commencing the reaction through 
the addition of the “Fluor de Lys” deacetylase substrate. Deacetylation of K382-
p53/K320-p53 was used as a marker of HDAC activity. All compounds were 
prepared fresh in DMSO to 10 mmol/L, 24 h before the assay was preformed. 
Fluorescence was read (excitatory, 360; emission, 460) using the Fluoroskan 
Ascent FL fluorometer (Thermo Fisher) using the Ascent software. The dose 
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concentrations were done in triplicate. The amounts of acetylation were derived 
from the levels of fluorescence (displayed in arbitrary fluorescence units). In 
addition, the percentages of inhibition were calculated from the arbitrary 
fluorescence unit of the treated assays and nontreated controls. 
 
2.4 THREE-DIMENSIONAL MODELLING 
 
To prepare the docking-related files including protein and inhibitors, the three 
dimensional structure of Human SIRT1 was modeled by the Protein Homology/ 
analogy Recognition Engine (Phyre; [318]). The modeled structure of SIRT1 is 
based on the structure of yeast Sir2 (PDB entry is 2HJH) already containing 
nicotinamide and Zn, with the original human SIRT1 amino acid sequence from 
residues 212 to 529. The threedimensional structure of SIRT2 used for docking 
was taken from the human Sirtuin C-pocket (PDB entry is 1J8F). The three 
inhibitor structures, Sirtinol, Salermide, and EX527, were generated by the 
Dundee PRODR G2 Server [319]. The docking studies were done using the site 
feature docking algorithm from the LibDock [320] software of the Discovery 
Studio package (version 2.1). The force field was applied to the SIRT1 and 
SIRT2 using the in-built CHARMm force field calculation. The binding region for 
the docking of SIRT2 is the same a previously described [321], which was a 10-Å 
sphere around the Gln167. The docking region used for SIRT1 was designed in a 
10-Åf sphere around the residue of Gln345, which is genetically conserved to the 
Gln167 Q7 of SIRT2. All the docking studies were carried out by default setting of 
the LibDock software and then the generated results of these docking studies 
were subjected to the “Score Ligand Poses” built-in function of the Discovery 
Studio to evaluate and rank the docking results. 
 
The best pose of each docking study was chosen based on the LigScore2 [322]. 
Furthermore, the best pose of each docking study was energy minimized with the 
protein structure by the “Ligand Minimization” function of the Discovery Studio. 
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All the structural presenting figures were created with the PyMOL program 
(DeLano Scientific). 
 
2.5 PROTEIN ANALYSIS 
 
2.5.1 Preparation of total protein lysates 
 
Whole cell extracts prepared by harvesting cells by using 1×trypin-EDTA, once 
detached medium was added to inactivate the trypsin and samples were spun 
500× g for 5 minutes. The supernatant was discarded and cell pellets were 
washed in PBS and spun for an additional 5 minutes (500× g). The supernatant 
was discarded and the cell pellet was frozen at -80ºC until lysis was performed. 
Frozen pellets were lysed in lysis buffer (0.1% Triton, 150 mmol/L NaCl, 50 
mmol/L Tris-HCl (pH 7.4), 10 mmol/L NaF, 1 mmol/L sodium orthovanadate, 30 
mmol/L Na β-glycerophosphate, and protease inhibitors ("Complete" protease 
inhibitor mixture, as instructed by the manufacturer, Roche Applied Science)) on 
ice for 10 min. Insoluble material was removed by centrifugation (13000rpm 4OC 
5 minutes). The supernatent was then transferred to a clean eppendorf tube and 
protein concentration was determined by Bio-Rad Dc protein assay.  
 
2.5.2 Determination of protein concentration 
 
Protein concentration was determined using the Bio-Rad Dc protein assay (Bio-
Rad Laboratories), as instructed by the manufacturer. 20µl of reagent S was 
added to 1 ml of reagent A. 100µl of this mixture were added to 2µl of protein 
solution. After 2 minutes, 800µl of reagent B was added to the mixture, the 
samples were shaken gently and then covered to protect them from direct 
sunlight. After 30 min incubation, absorbance was read at 750nm for each of the 
experimental samples as well as the non-protein containing control. Protein 
concentrations were determined by the equation absorbance x 25 = µg/µl.  
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2.5.3 Western blotting or Sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) 
 
Gels for elucidating protein expression were made using the acrylmide/bis stock 
solution. Twenty five percent ammonium persulphate (APS) and 
Tetramethylethylenediamine (TEMED) were used as polymerisation catalysts. 
SDS Gels consisted of a lower resolving gel and an upper stacking gel. The 
percentage of the resolving gel used depended on the size of the protein of 
interest. Lower percentage gels allowed better examination of proteins of higher 
molecular weight (mW) and vice versa (see table for the differing amount of 
constituents for each gel percentage). 
 
 Resolving gel Stacking gel 
 7% 10% 12% 14% 5% 
dH20-ml 5.02 4.02 3.35 2.68 3.67 
1.5M Tris pH 8.8 2.5 2.5 2.5 2.5   - 
1.5M Tris pH 6.8   -   -    -    - 0.42 
30%Acrylamide/ 
0.8% Bis mix 
(37.5:1) 
2.33 3.33 4.00 4.67 0.83 
10% SDS -µl 100 100 100 100 50 
25% APS -µl 40 40 40 40 20 
TEMED-µl 10 10 10 10 10 
Total-ml 10 10 10 10 5 
 
Table 2.1: SDS-PAGE percentages and their constituents 
 
To separate the proteins, 20µg of protein lysate was added to an equal volume of 
2× SDS loading buffer (4% (w/v) SDS, 62.5mM Tris-HXL (pH 6.8), % (v/v) 
glycerol, 0.01% (w/v) bromophenol blue) and boiled for 5 minutes at 100ºC. 
Samples were then spun at 1000rpm for 1 minute and the appropriate volume of 
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sample was loaded into the sacking wells. SDS-PAGE gels were run in running 
buffer (25mM Tris-Base, 250mM glycine, 0.1%(w/v) SDS) at 60V through the 
stacking gel and then 100V through the resolving gel. 
 
Once the proteins had been separated by SDS-PAGE, proteins were electro-
transferred on to Protlan nitrocellulose membranes (Schliecher and Schuell) 
using a wet tank blotting system (Bio-Rad Laboratories Trans-Blot Cell) in 
transfer buffer (25mM Tris, 190 mM glycine and 20% (v/v) ethanol) for 90 
minutes at 90V. PLEASE NOTE the tanks were packed in ice to ensure they did 
not overheat. 
 
 Membranes were then blocked in either 5% milk or 2.5% Bovine Serum albumin 
(BSA) in TBS plus 0.5% Tween (TBST) for 1 hour at room temperature and then 
incubated with a specific primary antibody (see table 2.2) for 16 hours at 4 
degrees (Table 2). Membranes were then washed every 15 minutes with 50mls 
TBST for one hour at room temperature. They were then treated with their 
respective horseradish peroxide conjugated secondary antibody (anti-rabbit or 
anti-mouse – see table 2.2) for one hour at room temperature. The membranes 
were then washed every 15 minutes with 50mls TBST for one hour at room 
temperature. The membrane was then developed using the enhanced 
chemiluminescence detection system (GE Healthcare, UK). 
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Antibody Product 
number 
Species Company 
EGFR 2232 rabbit Cell signalling technology 
p-EGFR (tyr1068) 2234 rabbit Cell signalling technology 
HER2/neu (C-18)   sc-284 rabbit Santa cruz 
P-HER2/ERB2 (y1248) 44-900 mouse Biosource 
HER3/ERB3 (c-17) sc-285 rabbit Santa cruz 
Total AKT 9272 rabbit Cell signalling technology 
Total AKT (5G3) 2966 mouse   
p-AKT(473) 9271 rabbit Cell signalling technology 
p-AKT (308) 9275 rabbit Cell signalling technology 
MAPK 4695 rabbit Cell signalling technology 
p-MAPK (tyr202/tyr204) 9101 rabbit Cell signalling technology 
FOXO1 (C29H4)  2880 rabbit Cell signalling technology 
FOXO3a H-144  
sc-11351 
rabbit Santa Cruz 
FOXO4   834 rabbit Gift - Prof. BM Burgering 
FOXM1 (k-19) (k-19) rabbit Santa cruz 
p53 Sc-98 mouse Santa cruz 
Gadd45alpha (c-20) Sc-792 rabbit  Santa cruz 
MDR1 (C219) 517310 mouse Calbiochem 
p27 (C-19) sc-528  rabbit  Santa cruz 
c/caspase-3 (Asp175) 9661 rabbit Cell signalling technology 
SIRT1 Ab32441 rabbit Abcam 
SIRT2  sc-20966 rabbit Santa cruz 
SIRT3 2627 rabbit Cell signaling 
SIRT4 s0948 rabbit Sigma Aldrich 
SIRT5 SA464 rabbit Biomol 
SIRT6 2950 rabbit Cell signaling 
SIRT7 Ab62748 rabbit  Abcam 
FLAG F1804 mouse Sigma Aldrich 
Beta-tubulin Sc-9104 rabbit Santa cruz 
Table 2.2: Antibodies used for western blotting 
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2.6 TOTAL RNA EXTRACTION 
 
Total RNA was isolated from mammalian cells using the RNeasy Kit (Qiagen, 
Crawley, UK). The protocol was performed in line with the manufacturers 
instructions. 
 
Frozen cell pellets were resuspended in 350µl of RLT buffer (containing 10% ß-
mercaptoethanol) and homogenised by pippetting with a 1000 µl pipette. 350 µl 
of 70% ethanol was added and the total mixture was added to the provided pin 
column and place in a 2ml collection tube and spun in a benchtop centrifuge for 
15s at 10,000rpm. The flow through was discarded and 700 µl of buffer RW1 was 
added to the column and was spun at 10,000rpm for 15s, the flow through was 
again discarded. Next, 500 µl of RPE buffer was added to the column and 
microcentrifuged for 15s, 10,000 rpm, the low through was discarded and the 
column was spun for an additional 2 minutes at 10,00 rpm to extract any waste 
from the column. The column was then transferred to a clean, steralize epindorf 
tube. 30 µl of RNase-free water was carefully added to the centre of the column 
and was spun for 1minute at 10,000 rpm to elute the extracted RNA. The purity 
and concentration of the RNA was then determined using Nanorop, which 
measures the spectrometric absorption at 260nm and 280nm.  RNA samples 
were then stored at -80ºC or immediately used to make cDNA, using first strand 
cDNA synthesis. 
 
2.6.1 First strand cDNA synthesis 
 
2 µg of total RNA was reverse transcribed into first strand cDNA using 
Superscript III first strand cDNA synthesis system (Invitrogen, Paisley, UK).  
One microlitre of random primers and 1 µl  of 10mM dNTPs mix (containing the 
four bases adenine, cytosine, guanine  and thymine) were added to 2 µg of total 
RNA to make a total volume of 14 µl (using sterile RNase free water). The 
sample was heated for 5 minutes at 65ºC and then placed immediately on ice for 
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1 minute. Four microlitres of 5× first strand buffer, 1µl of 0.1M DTT, 1 µl 
RNaseOUT and 1 µl of the reverse transcriptase Superscript III were then added 
to make a total volume of 20 µl. The mixture was spun for 15s at 500 rpm the 
placed on a thermocycler (GeneAmp PCR system 9700, Applied Biosystems) 
where they were incubated for 5 minutes at 25ºC for 5 minutes, then heated to 
50ºC for 50 minutes. The reaction was terminated by heating the mixture to 70ºC 
for 15 minutes. 
 
2.6.2 Real-time quantitative PCR (RT-qPCR) 
 
cDNA (synthesised as stated above) were used as template and gene 
expression was measured using RT-qPCR, which was performed using an ABI 
PRISM 7700 sequence detection system (Applied Biosystems), using the SYBR 
Green Mastermix (Applied Biosystems) according the the manufacturers 
instructions. Gene specific primers were designed using Primer Express 
Software (Applied Biosystems).  
 
Primers for FOXO3a (Human FOXO3a-sense TCTACGAGTGGATGGTGCGTT 
and FOXO3a-antisense CGACTATGCAGTGACAGGTTGTG) and L19 (Human 
L19-sense GCGGAAGGGTACAGCCAAT and L19-antisense 
GCAGCCGGCGCAAA) were optimised by previous members of the lab. 
 
Analysis of gene expression was performed using the relative standard curve 
method, where 2µg of cDNA from each sample was mixed and diluted into serial 
dilutions (1/4, 1/16, 1/64 and 1/256). As a control the established housekeeping 
gene L19 was used to normalise gene expression between samples. 
 
The reaction mix contained 2µl of sample and 23µl of SYBR Green master mix, 
primers and water were added to a final volume of 25µl. The TAQMAN 7700 real-
time PCR machine was used to measure gene expression. All measurements 
were performed in triplicate. 
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2.7 TRANSFECTION OF PLASMID DNA 
 
Cells were seeded into 10cm3 dishes to confluency of approximately 60%. 
Plasmid DNA was transfected using Fugene. The ratio 3:1 (ul of fugene: µg of 
DNA) was used, as recommended by the manufacturer. 
 
To begin, 975 µl of optimem (sterile DMEM containing no supplements can also 
be used) was pipetted into a plastic bijou. 6 µl of fugene were then carefully 
added and the mixture was shaken slightly and left at RT for 5 minutes. After 
which 2 µg of plasmid DNA was added, gently mixed and left at room 
temperature for 20 minutes. The mixture was then pippetted dropwise into the 
10cm3 dish while gently being shaken, ensure the mixture dispersed eveny. 
Overexpression of desired proteins were confirmed 24 h after transfection, after 
cell harvesting and western blot analysis. 
 
2.8 RNA INTERFERANCE (RNAi) 
 
RNA interference was used to specifically repress the expression of a chosen 
gene or genes. 
 
In this study, all SMARTpool siRNAs used were purchased from Dharmacon, 
RNA technologies. The SMARTpool siRNAs used were: FOXO3a (L-00307-00), 
siSIRT1 (L-003540-00), siSIRT2 (L-004826-00). 
 
Oligofectamine (Invitrogen LT) was used as the transfection reagent. 200,000 
cells per well of a 6-well plate, were plated 24h prior to transfection. For each 
well, 70µl of Optimem, was mixed with 5µl oligofectamine and incubated at room 
temperature for 10min. This solution was then mixed with 250µl Optimem and 
7.5µl (50nM final concentration) siRNA oligos specific for each gene. After 25min 
incubation, 160µl OPTIMEM was added to each mixture, reaching a final volume 
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of 500µl, which was then added to the wells that have been previously washed 
with warmed PBS. The plates were then incubated for 4 h at 37ºC, after which 2 
ml of DMEM, containing 10%FCS, was added to each well and the plates were 
incubated for a further 24 h.  
 
Cells were then treated with cytotoxic agents and cell cycle analysis was 
performed. Also protein expression was confirmed using western blot. 
 
As control, cells were also treated with just 1× universal buffer (used as the 
siRNA vector) containing no siRNA. This ensured that any effect the transfection 
procedure had on the cells would be detected. Also cells were transfected with a 
non-specific siRNA (D-001210-01-05, Dharmacon), which does not target any 
known proteins, ensuring that any non-targeting effects of siRNA delivery and 
interaction with cellular machinery would be measured.  
 
2.9 CELL CYCLE ANALYSIS 
 
The cell cycle was analysed using flow cytometry. The media was removed and 
the cells were washed with 1ml PBS (the media and wash was retained). Cells 
were then scraped in cold PBS on ice and then spun at 4000rpm (4oC) for 10 
minutes (using a Sorvall Legend RT). The supernatant was discarded and the 
pellet was resuspended and washed in 500µl PBS and spun at 4000rpm (4oC) 
for 10 minutes and then resuspended and fixed in 5ml of 90% ethanol at 4oC for 
16 hours. Cells were then spun at 4000rpm (4oC) for 10 minutes. The 
supernatant was discarded and the cells were washed in 1ml PBS and then spun 
at 4000rpm (4oC) for 10 minutes. The supernatant was discarded and then the 
cells were stained using 500µl propidium iodide (50µmol/L) for 1 hour and then 
analysed using a FACS canto and FACSDiva software (BD Biosciences). 
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2.10 SULFORHODAMINE B (SRB) ASSAY 
 
The SRB assay is used as a measurement of cell proliferation/viability, the dye 
binds to and stains the protein content of the cell. Because the binding of the 
SRB is stoichiometric, the amount of dye extracted from the stained cells is 
directly proportional to cell mass and is representative of cell number [323]. 
Approximately 3000 cells were seeded in each well of the 96-well plates. After 
culture, 100µL of trichloroacetic acid (TCA) was added to each well and 
incubated for 1 h at 4°C. The plates were then washed with deionized water 
three times before incubation at room temperature for one hour with 0.4% 
sulforhodamine B in 1% acetic acid. The plates were then washed with 500 µL 
1% aceitc acid or until unbound SRB was washed away. The plates were then 
left to air-dry overight and then stored. To measure the plate, 100 µL Tris (10 
mmol/L) was then added to each well to solubilize the bound sulforhodamine B 
dye and placed on a rotator for 30 minutes to evenly distribute the dye. The 
plates were then read at 492 nm using the Sunrise plate reader (Tecan Group 
Ltd). 
 
2.11 CASPASE-GLO 3/7 ASSAY 
 
Caspase assays were done using the Caspase-Glo 3/7 assay kit (Promega) 
according to the manufacturer's protocol.  
 
Cells were culture as described previously in 96-well CulturPlates (6005680, 
PerkinElmer, UK). After cells were treated with the appropriate regimes of 
cytotoxic compounds, 50µl of the 100µl medium/compound mix was removed 
from each of the wells. 50µl of caspase-glo assay was added to each well; plates 
were covered with foil and were gently mixed for 30 minutes at RT. 
Luminescence was read by the PHERAstar Plus (BMG Labtech). Experiments 
were performed in triplicate.  
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CHAPTER 3 
 
SIRT INHIBITORS INDUCE CELL DEATH AND p53 
ACETYLATION THROUGH TARGETING BOTH 
SIRT1 AND SIRT2 
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3.1 INTRODUCTION 
 
The development and progression of cancer involves both epigenetic and genetic 
changes leading to the alteration of gene expression and thus cell phenotype. It 
is well established that alteration in the epigenome of the cell through promoter 
hypermethylation and histone deacetylation is a common facet of tumorigenesis. 
Indeed, previous studies have reported that the promoters of tumour suppressor 
genes, such as p16INK4A and p15INK4B, frequently demonstrate increases in DNA 
methylation and/or histone deacetylation, thereby leading to gene silencing [324]. 
However, emerging evidence also suggests that the role of acetylation as a 
protein post-translational modification, independent of histone modification, may 
also play a critical role in cell fate and thus tumorigenesis. For example, the 
activities of the tumour suppressors’ p53 and FOXO3a are both in part regulated 
by their acetylation status.  The degree of acetylation is largely mediated by a 
balance between histone acetyl transferase (HATs) and histone deacteylase 
(HDAC) activity, in a substrate specific manner.  
 
Sirtuins (also called SIRTs) are NAD+-dependent class III HDACs that share 
extensive homologies with the yeast histone deacetylase Silent Information 
Regulator 2 (Sir2) [325]. In yeast [233], nematode worms [234] and fruit flies 
[326] SIRT/Sir2 activity has been shown to be crucial for lifespan extension in 
response to metabolic and other environmental stresses [327-330]. In mammals, 
seven Sir2 homologues (Sirtuin 1-7 or SIRT1-7) have been identified, which 
possess primarily histone deacetylase (SIRT1, -2, -3, -5) or mono-
ribosyltransferase activity (SIRT4 and SIRT6) [225, 226], which target histone 
and various non-histone proteins in distinct subcellular locations.  
 
The mammalian SIRT1 is the direct homologue of the yeast Sir2 and has a wide 
range of substrates and cellular functions. SIRT1 can induce chromatin silencing 
through deacetylation of histones H1, H3 and H4 [331], and can modulate cell 
survival by regulating the transcriptional activities of p53 [332], NFκB [333], 
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FOXO proteins [223, 265] and p300 [334]. In contrast to SIRT1, SIRT2 is 
predominantly a cytoplasmic protein and has been shown to be able to 
deacetylate a number of cytoplasmic substrates, including α-tubulin [243, 335]. 
 
Both SIRT1 and SIRT2 may have a role in the development of cancer. For 
example, SIRT1 can activate stress defence and DNA-repair mechanisms, thus 
allowing the preservation of the genomic integrity [237]. Conversely, it has also 
been demonstrated that SIRT1 overexpression can enhance tumour growth, and 
promote cell survival in response to stress and drug resistance. Nevertheless, 
SIRT1 has been shown to be up-regulated in a spectrum of cancers, including 
lymphomas, leukaemia and soft-tissue sarcomas, prostate cancer, lung and 
colon carcinomas [336-338]. Overexpression of SIRT2 can significantly prolong 
the mitotic (M) phase and delay mitotic exit. In consequence, it has been 
proposed that SIRT2 might function as a mitotic checkpoint protein in G2/M to 
prevent the induction of chromosomal instability, particularly in response to 
microtubule inhibitor (MTI) mediated mitotic stress [244]. Consistently, tumours 
with high levels of SIRT2 are refractory to chemotherapy, especially microtubule 
poisons [339].  
 
The dual role of SIRTs in modulating the acetylation of tumour suppressor 
proteins and chromatin renders them attractive therapeutic targets for anti-cancer 
drug development [237]. However, despite the development of a number of 
effective SIRT inhibitors, little is known regarding the specific mechanisms of 
action and cellular targets of these proteins. In the present study, we have used 
breast cancer cells as a model system, and profiled the in vitro and in vivo 
activity of several recently developed potent SIRT inhibitors. Moreover, we have 
identified the tumour suppressor p53 as the critical target of the SIRT-inhibitor-
induced cell death in breast cancer cells.  
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3.2 RESULTS 
 
3.2.1 Sirtinol and Salermide induce cell death while EX527 triggers G1 
arrest 
 
To gain insights into the anti-cancer potential of the three novel synthetic SIRT 
inhibitors EX527 [340], Sirtinol [309] and Salermide  [321] (Figure 3.1), we first 
investigated the effects of these SIRT inhibitors on the proliferation of the breast 
carcinoma cell line MCF-7. The natural SIRT inhibitor nicotinamide was also 
included as a reference compound. SRB results showed that concentrations of 
25µM and over of either Sirtinol or Salermide could significantly inhibit MCF-7 cell 
proliferation (>80% of inhibition), whereas only >100µM of EX527 could 
effectively repress MCF-7 cell proliferation (Figure 3.2). Even at 100µM, 
nicotinamide failed to elicit any substantial inhibitory effect on MCF-7 cells 
(Figure 3.2).  To confirm these proliferative results, we next examined the effects 
of these SIRT inhibitors on cell cycle progression and treated cycling MCF-7 cells 
with 50µM of each of the four SIRT inhibitors for 0, 24 and 48 h. Flow analysis 
results showed that both Sirtinol and Salermide effectively induced cell death, 
while EX527 treatment caused an increase in G1 cell population, with no 
detectable cell death (Figure 3.3A). These cell proliferation data were supported 
by morphological examination using light microscope demonstrating that only 
Sirtinol and Salermide could induce extensive cell death at 50µM (Figure 3.3B). 
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Figure 3.1 Sirtuin Inhibitors. The molecular structure of the sirtuin inhibitors, 
Nicotamide, EX527, Sirtinol and Salermide. 
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Figure 3.2 Effects of SIRT inhibitors on MCF-7 cell proliferation. MCF-7 cells 
were treated with 0-100µM of nictotinamide, EX527, Sirtinol or Salermide for 0, 
24, 48 and 72 h. Cell proliferation was determined by sulforhodamine B assay. 
Results shown are mean ± SD of three independent experiments. 
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Figure 3.3 Effects of SIRT inhibitors on MCF-7 the cell cycle and 
mophology A) MCF-7 cells were either untreated or treatmented with 50 µM of 
nicotinamide, EX527, Salermide or Sirtinol for 0, 24 and 48 h and flow cytometric 
analysis of DNA content was performed after propidium iodide staining. 
Percentage of cells in each phase of the cell cycle (sub-G1, G1, S, and G2/M) is 
indicated. Representative data from three independent experiments are shown. 
B) Representative phase-contrast microscopy images of MCF-7 cells untreated 
or after treatment with 50 µM of nicotinamide, EX527, Salermide or Sirtinol 
(magnification 100X). 
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3.2.2 G1 arrest exhibited by EX527 is reversible 
 
To examine whether the cytotoxic effects of sirtinol and salermide were 
reversible, MCF7 cells were treated with 50 µM of nicotinamide, EX527, 
Salermide or Sirtinol for 0, 24, 48 and 72 hours. At 24 hours cells were also 
washed and culture in inhibitor-free medium for 24 and 48 hours. The effect on 
proliferation was assessed using SRB (Figure 3.4).  
 
The removal of sirtinol and salermide had no effect on the viability of the MCF7 
cells, compared to the cells that had been continually exposed to the sirtuin 
inhibitors, suggesting that short treatment of sirtinol and salermide resulted in 
non-reversible apoptosis and cell death (Figure 3.4). Interestingly, the cytostatic 
effects of EX527 were reversible; cells washed at 24 hours were able to continue 
proliferating in inhibitor-free medium similar to the rate of proliferation of the 
untreated controls (Figure 3.4). Moreover, the effect on proliferation of cells 
continually treated with EX527 compared to washed cells was statistically 
significant (p<0.001). These results strengthen the findings that sirtinol and 
salermide are more cytotoxic that EX527, and that the cytostatic function of 
EX527 is reversible. 
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Figure 3.4 The cytostatic effect of EX527 is reversible. MCF-7 cells were 
treated with 50µM of nictotinamide, EX527, Sirtinol or Salermide for 0, 24, 48 and 
72 h.. Cells were also treated for 24 h with each compound and then washed 
with PBS, and cultures in inhibitor-free media. Cell proliferation was determined 
by sulforhodamine B assay. Results shown are mean ± SD of three independent 
experiments. 
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3.2.3 SIRT inhibitors display potent in vitro SIRT1/2 inhibitory activities 
 
To unravel the molecular basis for the difference in cytotoxicity between these 
SIRT inhibitors, we examined the in vitro inhibitory potential of these SIRT 
inhibitors on SIRT1 and SIRT2 using an in vitro HDAC activity fluorescent assay. 
The percent values of SIRT activity at different doses (0-100 µM) of inhibitors 
were first determined against human recombinant SIRT1 and SIRT2 using a 
synthetic p53 derived peptide as a substrate, and from these data the IC50 
values for the SIRT inhibitors were established (Figure 3.5). The in vitro assay 
revealed that Sirtinol displayed a higher degree of inhibitory activity towards 
SIRT1 than SIRT2, with IC50 of 37.6 and 103.4 µM, respectively. Salermide also 
exhibited comparable SIRT1 and SIRT2 inhibitory activity (IC
50
=76.2 and 45.0 
µM, respectively). EX527 showed the higher SIRT1 inhibitory activity (IC
50
=0.38 
µM) and SIRT2 inhibitory activity (IC
50
=32.6 µM) compared to Sirtinol and 
Salermide, while nicotinamide had relatively low potency against SIRT1 with an 
IC50 of 85.1 but potently inhibited SIRT2 (IC
50
=1.16 µM). These in vitro SIRT1/2 
inhibition results are generally in consensus with the previously published data 
on the efficacy of some of these SIRT inhibitors on SIRT1 and -2 [309, 315, 340]. 
However, these in vitro data could not completely explain for the failure of EX527 
to induce cell death, as EX527 has higher SIRT2 inhibitory activity than Sirtinol, 
and higher SIRT1 inhibitory activity compared to Sirtinol and Salermide, yet does 
not induce cell death. 
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Figure 3.5 In vitro SIRT1 and SIRT2 inhibition assays. Recombinant human 
SIRT1 and SIRT2 were treated with various concentrations of Sirtinol, Salermide, 
EX 527 and nicotinamide as indicated and their relative inhibitory potential 
(against DMSO as controls) was analysed and displayed as % of SIRT activity. 
Results shown are mean ± SD of three independent experiments. 
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3.2.4 Modelling of SIRT1/2 docking predicts Sirtinol and Salermide binding 
efficiently to SIRT1/2, and of EX527 to SIRT1 alone 
 
Next, we analysed the inhibitory functions of these SIRT inhibitors using 
computational docking studies (Modelling was performed by Chun-Yuan Chen, 
Hong Kong University). Preliminary, computational docking studies were carried 
out on Sirtinol, Salermide and EX527 using both Gold and LibDock in an effort to 
rationalize the observed SIRT1/SIRT2 selectivity differences. For these studies, 
the crystal structure of hSIRT2 (PBD code: 1J8F) was used along with a hSIRT1 
model, and the inhibitors docked into the C-pocket (Figure 3.6A). The hSIRT1 
model was obtained from the Phyre website (structure 2HJH) and based on the 
homologous yeast protein Sir2 (Figure 3.6A). In terms of SIRT1 binding, both 
Sirtinol and Salermide show significant hydrogen bonding interactions with Gln 
345 and His 363 (Figure 3.6B). EX527 also displays hydrogen bonding to Gln 
345, with additional π- π interactions with His 363 and Phe 273. In terms of 
SIRT2 binding, Sirtinol and Salermide show comparable hydrogen bonding 
interactions with Gln 167 (Figure 3.6B). Sirtinol also displays π- π interactions 
with His 187 and Phe 119, whereas Salermide has a hydrogen bond with His 187 
and no interaction with Phe 119. For EX527, we did not find any significant 
interactions with SIRT2, the closest interaction identified being a van der waals 
force between EX527 and Ala 85. On the basis of these results, it is plausible 
that the residues Phe 273, Phe 297, Gln 345, and His 363 of SIRT1 and residues 
Phe 96, Phe 119, Gln 167, and His 187 of SIRT2 may play critical roles in 
inhibitor binding. Our docking studies suggest that both Sirtinol and Salermide 
can form key interactions with these residues in the requisite binding pocket, 
whereas EX-527 only forms strong interactions with SIRT1. In conclusion, the 
computational modelling and docking studies suggest that that both Sirtinol and 
Salermide have high degrees of selectivity for SIRT1/2, while EX527 has a high 
specificity for SIRT1 but not SIRT2. 
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The present computational study is in general consistent with the in vitro HDAC 
assay in that both Sirtinol and Salermide target SIRT1 and SIRT2, while EX527 
has a high specificity for SIRT1. However, whilst EX527 demonstrated strong in 
vitro inhibitory activity towards SIRT2, the docking assay suggested little affinity 
between EX527 and SIRT2. Taken together, these findings suggest that Sirtinol 
and Salermide have a high affinity for SIRT1 and SIRT2, while EX527 is selective 
for SIRT1 but not SIRT2. These findings also suggested that both SIRT1 and 
SIRT2 have to be inhibited in order to induce cell death in vivo as they target 
SIRT1 and SIRT2, while EX527 induced cell cycle arrest at G1 because it targets 
only SIRT1. 
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Figure 3.6 The three-dimensional structures of SIRT1 and SIRT2. A) The 
crystal structure of hSIRT2 (PBD code: 1J8F) was used along with a hSIRT1 
model, and the inhibitors docked into the C-pocket. The hSIRT1 model was 
obtained from the Phyre website (structure 2HJH) and based on the homologous 
yeast protein Sir2. B) Structures of the complexes of inhibitors with SIRT1 and 
SIRT2 modelled by docking the inhibitors onto the C-pocket of SIRT1 and SIRT2 
structure after minimization (Modelling was performed by Chun-Yuan Chen, 
Hong Kong University). 
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3.2.5 Sirtinol and Salermide but not EX527 can induce p53 acetylation in 
vivo 
 
To investigate further the distinct effects of the SIRT inhibitors on cell fate, we 
performed Western blot analysis on MCF-7 cells treated with 50 µM for 0, 24 and 
48 h, to study their effects on the acetylation status of the SIRT1/2 target p53 
(Figure 3.7A). Interestingly, Sirtinol and Salermide but not EX527 could induce 
p53 acetylation at lysine 382, which has been shown to correlate with p53 
activation. Consistently, the p53 acetylation was also accompanied by an 
induction of p53 stability. The control nicotinamide was ineffective in inducing p53 
acetylation at the concentrations studied. To examine the effects of the 
compounds on SIRT2 activity, we investigated the expression levels of 
acetylated tubulin, which has been shown to be a specific SIRT2 target [243]. 
The results demonstrated that only Sirtinol and Salermide but not EX527 and 
nicotinamide could induce tubulin acetylation. We next treated MCF-7 cells for 24 
h with a range of concentrations of SIRT inhibitors and harvested the cells for 
Western blot analysis (Figure 3.8B). Similar to earlier data, the results showed 
that at concentrations of > 50 µM, Sirtinol and Salermide, but not EX527 and 
nicotinamide, are able to induce p53 acetylation and that only Sirtinol and 
Salermide but not EX527 and nicotinamide can induce tubulin acetylation. 
Notably, there was also a general decrease in protein levels in MCF-7 cells after 
treatment with 100 µM Salermide and was likely to be a result of protein 
degradation due to cell death after drug treatment. The failure of EX527 to induce 
p53 and tubulin acetylation was not because of its lack of SIRT-inhibitory activity 
as it could effectively cause global protein acetylation as revealed by the acetyl-
Lysine antibody. Together these results suggest that while both Sirtinol and 
Salermide target SIRT1 and -2, EX527 only inhibits SIRT1 and not SIRT2 
effectively and that p53 acetylation requires inhibition of both SIRT1 and -2.  
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Figure 3.7 Effects of SIRT inhibitors on p53, tubulin, and global lysine 
acetylation. A) MCF-7 cells were treated with 50 µM of SIRT inhibitors for 0, 24 
and 48 h of nicotinamide, Salermidem Sirtinol or EX527. The expression of 
SIRT1, SIRT2, acetylated-lysine, acetylated-p53, p53, acetylated-tubulin and 
tubulin was analysed by western blotting. B) MCF-7 cells were treated with 
increasing concentrations (0-100µM) and western blot analysis was performed to 
determine the protein expression levels of SIRT1, SIRT2, acetylated-p53, p53, 
and tubulin. 
 114 
3.2.6 The cytotoxic function of sirtinol and salermide is dependent on the 
presence of functional p53 
 
To examine the role of p53 in mediating the cytotoxic and cytostatic effects of the 
SIRT inhibitors, we treated breast carcinoma cell lines [341], MCF-7 (wild-type 
p53), MDA-MB-231(mutant p53), BT474 (mutant p53), and ZR-75-1 (very low 
p53 expression) with 50 µM of SIRT inhibitors for 0, 24 and 48 h. Cell cycle 
analysis results showed that both Sirtinol and Salermide effectively induced cell 
death in MCF-7 cells, but the ability of Sirtinol and Salermide to induce cell death 
is compromised in other breast cancer cell lines without functional p53 (Figure 
3.8). Notably, EX527 treatment caused a substantial increase in G1 cell 
population with little cell death in all breast carcinoma cell lines, with the 
exception of BT-474. To further confirm these results, we also studied the effects 
of the SIRT inhibitors on the cell cycle status of mouse embryo fibroblasts 
(MEFs) derived from wild-type and p53-deficient mice (Figure 3.9). Consistent 
with the breast carcinoma cell line data, the flow cytometric results indicated that 
while EX527 treatment caused a substantial increase in G1 population with little 
cell death in both the wild-type and p53-/- MEFs, Sirtinol and Salermide only 
induced cell death efficiently in wild-type but not p53-/- MEFs (Figure 3.9A).  We 
next examined the expression of acetylated-lysine, acetylated-p53, acetylated-
tubulin in the wild-type and p53-/- MEFs following SIRT inhibitor treatment (Figure 
3.9B). The western blot results showed that Sirtinol and Salermide, but not 
EX527 , are able to induce p53 acetylation in the wild-type MEFs, and that 
Sirtinol and Salermide but not EX527 can induce tubulin acetylation in both the 
wild-type and p53-/- MEFs. Western blotting using the acetyl-Lysine antibody 
again revealed that EX527 is more effective than Sirtinol and Salermide in 
inducing the acetylation of some proteins and some of these EX527 targets might 
account for its ability to induce G1 arrest. Cleaved caspase-3 was used as a 
marker of apoptosis, and the western blot results showed loss of p53 decreases 
the cleavage and activation of caspase-3, reiterating our findings from the cell 
cycle analysis (Figure 3.9B). Together these results suggest that functional p53 
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is required for the cytotoxic function of Sirtinol and Salermide but is dispensable 
for the cytostatic effects of EX527.   
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Figure 3.8 The effect of SIRT inhibitors on the cell cycle and dependence 
on functional p53 A) MCF-7, MDA-MB-231, BT474, and ZR-75-1 breast 
carcinoma cells were treated with 50 µM of SIRT inhibitors for 0, 24 and 48 h of 
Sirtinol, EX527 and Salermide. Flow cytometric analysis of DNA content was 
performed after propidium iodide staining. Percentage of cells in each phase of 
the cell cycle (sub-G1, G1, S, and G2/M) is indicated. Representative data from 
three independent experiments are shown. 
 
 117 
 
Figure 3.9 Effects of SIRT inhibitors on cell cycle status and p53, tubulin, 
and global lysine acetylation. A) wild-type (WT) and p53-/- MEFs were treated 
with 50 µM of SIRT inhibitors for 0, 24 and 48 h of Sirtinol, EX527 and Salermide. 
Flow cytometric analysis of DNA content was performed after propidium iodide 
staining. Percentage of cells in each phase of the cell cycle (sub-G1, G1, S, and 
G2/M) is indicated. Representative data from three independent experiments are 
shown. B) The expression of cleaved (active) caspase-3, acetylated-lysine, 
acetylated-p53, p53, acetylated-tubulin and tubulin was analysed by western 
blotting in the SIRT inhibitor-treated wild-type (WT) and p53-/- MEFs.   
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3.2.7 EX 527 protects MCF-7 cells from paclitaxel treatment 
 
To access whether combination of sirtuin inhibitors could increase the 
proapoptotic potency of an established cytotoxic agent, 50µM of sirtinol, 
salermide and EX527 were treated alone or in combination with 10nM of 
paclitaxel for 0-72 hours, cell proliferation was assessed using SRB assay 
(Figure 3.10A). Treatment of paclitaxel resulted in a decrease in cell viability, 
suggesting that the cells were undergoing apoptosis. As previously observed 
Sirtinol treatment was the most cytoxic of the sirtuin inhibitors but no combination 
of paclitaxel with sirtinol or salermide resulted in a marked decrease in cell 
viability compared with paclitaxel treatment alone. Interestingly EX527 treatment 
was able to protect cells from paclitaxel treatment. To assess this further, MCF-7 
cells were treated with sub-lethal concentrations of paclitaxel (0-2.5nM) alone or 
in combination with Sirtinol, EX-527 and Salermide for 72 hours, cell viability 
being determined using SRB (Figure 3.10B).  
 
A decrease in cell viability was observed as you increased the concentration of 
paclitaxel (287.8% ± 10.2, 219.1% ± 25, 64.3% ± 2.9 and 68.8% ± 9.3 for 0, 0.1, 
1 and 2.5nM paclitaxel treatment respectively) (Figure 3.10B). The treatment of 
Sirtinol and Salermide (50µM) alone resulted in reducing cell viability below 
100% meaning cell cycle arrest and apoptosis had occurred. Sirtinol and 
Salermide were able to reduce cell viability without paclitaxel. Interestingly, 
cotreatment of EX527 with paclitaxel at all concentrations protected MCF-7s from 
paclitaxel treatment. This effect was especially marked at 1nM treatment of 
paclitaxel with EX527, where single treatment with paclitaxel reduced the cellular 
population to 64.3% (SD ± 2.9), single treatment of EX527 had no effect (277% 
±16.1 compared to 287.8% ± 10.2 of the vector treated control) whereas 
combination with EX 527 resulted in 226.4% (SD ±21.7), a marked protection in 
cell viability.  
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This highlights that therapeutically, some sirtuin inhibitors could actually 
decrease the efficacy of established chemotherapeutic drugs when used in 
combination, the converse to what would be expected. 
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Figure 3.10 EX527 protects against paclitaxel treatment. A) MCF-7 cells were 
treated with 10nM of Paclitaxel, 50µM of SIRT inhibitors alone or in combination 
for 0, 24, 48 and 72 h. B) MCF-7 cells were treated with 0, 0.1, 1 and 2.5nM of 
Paclitaxel alone or in combination with 50µM of SIRT inhibitors. Cell proliferation 
was determined by sulforhodamine B assay. Results shown are mean ± SD of 
three independent experiments.  
 121 
3.2.8 Silencing of both SIRT1 and SIRT2 is required for inducing MCF-7 cell 
death 
 
Our earlier results suggested that induction of cell death by SIRT inhibitors in 
vivo requires the inactivation of both SIRT1 and SIRT2. To examine this 
conjecture, MCF-7 cells were transfected with either control siRNA or siRNA 
against SIRT1, SIRT2 or SIRT1 and SIRT2. The transfected cells were then 
incubated with or without 10nM of the chemotherapeutic drug paclitaxel for 24 h 
before subjected to cell cycle and Western blot analyses. The cell cycle analysis 
showed that siRNA-mediated knockdown of endogenous SIRT1 or SIRT2 
individually had no discernable effect on the cell cycle status of MCF-7 cells, but 
silencing of endogenous SIRT1 and SIRT2 simultaneously induced a noticeable 
G2/M phase cell cycle arrest as well as cell death (Figure 3.11A). Interestingly, 
treatment of MCF-7 with 10nM paclitaxel also elicited a cell death and cell cycle 
arrest profile similar to that induced by SIRT1/2 knockdown. In addition, we 
discovered that silencing of SIRT2 alone actually abolished the paclitaxel-
induced G2/M cell cycle arrest and cell death. The Western blot analysis 
confirmed successful SIRT1 and/or SIRT2 knockdown and showed that the 
SIRT1/2 knockdown-induced G2/M arrest and cell death was associated with an 
increase in p53 acetylation (Figure 3.11B).  
 
Intriguingly, paclitaxel treatment also resulted in a similar increase in p53 
acetylation, and this p53 hyperacetylation was again accompanied by cells 
undergoing G2/M arrest and cell death. In addition, we discovered that silencing 
of SIRT2 alone by specific siRNA suppressed paclitaxel-induced cell cycle arrest 
and cell death as well as p53 acetylation. Together these results suggest that 
paclitaxel mediates the G2/M arrest-associated cell death through inducing the 
acetylation and activation of p53.  
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Figure 3.11 Effects of SIRT1/2 silencing and paclitaxel on cell cycle 
progression and p53 acetylation. MCF-7 cells were either untransfected 
(Mock), transfected with non-specific (NS) siRNA (100 nM) or siRNA smart pool 
against SIRT1 (100 nM) , SIRT2 (100 nM), or SIRT1 plus SIRT2 (100 nM) for 24 
h and then incubated for another 24 h in the absence or presence of 10nM 
paclitaxel.  A) Flow cytometric analysis of DNA content was performed after 
propidium iodide staining. Percentage of cells in each phase of the cell cycle 
(sub-G1, G1, S, and G2/M) is indicated. Representative data from three 
independent experiments are shown. B) The expression levels of SIRT1, SIRT2, 
acetylated-p53, p53, and tubulin were determined by Western blotting. 
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3.3 DISCUSSION 
 
In this study, we have for the first time compared the potencies, mechanisms of 
action, and cellular targets of the three recently developed SIRT inhibitors, 
Sirtinol, Salermide and EX527. From cell proliferation and cell cycle assays, it 
was found that while Sirtinol and Salermide can effectively induce cell death, 
EX527 does not trigger cell death, but a cell cycle arrest. The in vitro SIRT 
inhibitory assay shows that all three compounds potently inhibited SIRT1, with 
EX527 at least two orders of magnitude more potent than Sirtinol and Salermide. 
This finding is supported by computational docking studies demonstrating that all 
three inhibitors bind SIRT1 with high affinity. However, despite the in vitro SIRT 
inhibitory assay showing high degrees of inhibitory activity against SIRT2 for all 
three compounds, only Sirtinol and Salermide exhibit high affinity for SIRT2 in the 
structural studies. It is important to note that the structural studies do have their 
own limitations - providing a qualitative examination of SIRT2 inhibition using 
sirtuin small molecule inhibitiors - but the results are supported by the in vivo 
finding that EX527 failed to cause the re-acetylation of tubulin, a critical cellular 
target of SIRT2 [342]. This finding is also consistent with our in vivo results 
indicating that inactivation of both SIRT1 and SIRT2 is required for induction of 
cell death and p53 acetylation and that EX527 neither triggers cell death nor p53 
acetylation in MCF-7 cells. The structural-in vitro activity discrepancy could be 
due to the fact that in the in vitro SIRT2 inhibitory assay the recombinant human 
SIRT2 is the single predominant Sirtuin species existing at high concentrations 
and the specificity might be lost as a result. Alternatively, EX527 could have an 
altered selectivity towards the recombinant SIRT2 protein under in vitro 
experimental conditions. Moreover, the in vitro assays used a short synthetic p53 
peptide instead of the full-length wild-type protein. These observations showed 
that the in vitro SIRT assays are not always consistent with findings in vivo, 
which may be based upon cell cycle analysis, analysis of global acetylation 
profiles, SIRT isoform-specific target acetylation, and docking studies. 
Nevertheless, this also highlights the fact that the in vitro SIRT assay data has to 
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be interpreted with caution and should not be use alone in studying SIRT or 
inhibitor activity. It is important to note however, that while the structural and 
computational docking studies provide a qualitative appreciation of possible 
sources of inhibitor selectivity, further detailed biological study is required (for 
example, site-selective mutations) to verify these results in vivo. For example, 
while the results provide qualitative comparisons with a recent report by Lara et 
al [321], the precise binding modes of the inhibitors differ. Moreover, 
computational studies by Huhtiniemi et al [343] suggest that the conformational 
freedom of the ‘flexible loop’ region of the C-pocket may play a crucial role in 
substrate binding, something that is not taken into account using static docking 
techniques. Pacholec et al have recently employed novel NMR techniques to 
elucidate sirtuin-targeted compounds in vivo to great success, suggesting that 
the discrepancies that we have observed between structural modeling and in 
vitro assays experiments could be investigated further using such techniques 
[344].  
 
It is notable that in this study we examined the cellular potency and targets of the 
SIRT inhibitors using the MCF-7 breast carcinoma cell line because they have 
substantial levels of SIRT1 and SIRT2 as well as a functional p53. In mammalian 
cells, the transcription factor p53 functions as a tumor suppressor and has been 
shown to be a target of acetylation as well as SIRT1 and SIRT2. Acetylation of 
functional p53 leads to its activation and is usually triggered in response to 
oncogenic as well as environmental stress signals, including oxidative stress and 
chemotherapeutic drug treatments [345]. Once activated, p53 triggers the 
apoptotic programme to induce cell death. In cell based in vivo studies, both 
Sirtinol and Salermide but not EX527 can efficiently induce p53 acetylation and 
stabilization, and this was associated with the induction of cell death in MCF-7 
cells. Moreover, further studies using breast carcinoma cell lines with different 
p53 status and wild-type and p53-deficient MEFs showed that Sirtinol and 
Salermide are ineffective in inducing apoptosis of cell lines that lacked p53 
expression. These findings suggest that the tumour suppressor p53 is integral to 
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the cytotoxic activity of the SIRT inhibitors Sirtinol and Salermide, and the failure 
of EX527 to trigger cell death is because of its inability to cause the acetylation 
and activation of endogenous p53. Lain et al. [312] also reported that they found 
no acetylation of p53 in response to EX527 monotreatment, although the data 
was not shown in the publication. A cooperative role for SIRT1 and SIRT2 to 
regulate stress-induced cell death pathways in a p53-independent manner has 
also been described [339]. It is also likely that SIRT inhibitors, like Sirtinol and 
Salermide, also target SIRTs other than SIRT1 and -2. Nevertheless, SIRT1 and 
-2 will probably have a more prominent role in controlling cell growth and survival 
as they exist in the same intracellular compartments (ie. nucleus and cytoplasm) 
as most of the cell cycle and death regulators [229]. The reason why Sirtinol and 
Salerimide are ineffective in causing global lysine acetylation is unclear. 
However, since these global lysine acetylation patterns are associated with 
treatment with the very potent SIRT1 inhibitor EX527, it could be that these 
acetylated patterns might represent proteins preferentially targeted by SIRT1 
and/or other HDACs. 
 
Data from SIRT inhibitor experiments also suggest that both SIRT1 and SIRT2 
have to be inactivated in order to induce cell death in vivo, at least in SIRT1 and 
SIRT2 positive cells. This is confirmed by the siRNA-silencing experiments 
showing that not one but both SIRT1 and SIRT2 have to be deleted to cause cell 
death. This observation is consistent with a recent study demonstrating that 
despite the interaction of SIRT1 with p53, deletion of SIRT1 in MEFs fails to 
induce p53 acetylation and activate the apoptotic function of p53 [346]. Notably, 
cell cycle profiles of MCF-7 cells are different in response to treatment with EX-
527 compared to SIRT-1 siRNA, and this might suggest that additional 
mechanisms of induction of cell cycle arrest by EX-527, which could be mediated 
by inhibiting other histone deacetylases (HDACs). Intriguingly, treatment with the 
chemotherapeutic drug paclitaxel also induces a G2/M-arrest associated cell 
death indistinguishable from that triggered by silencing of SIRT1 and SIRT2. The 
fact that this was also accompanied by p53 acetylation suggest that SIRT 
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inhibitors, such as Sirtinol and Salermide, and paclitaxel function through 
common pathways and mediate their cytotoxic effects through targeting p53 and 
acetylation. Unexpectedly, silencing of SIRT2 is sufficient to repress the cytotoxic 
effects of paclitaxel and abolish p53 hyperacetylation. Similarly, SIRT1 knock-
down could also prevent paclitaxel from causing the reacetylation of tubulin. The 
molecular mechanisms responsible are unknown, and might involve 
compensatory mechanisms between different SIRT proteins.  It is also likely that 
SIRT2 silencing will cause cell cycle arrest and chromatin condensation as 
revealed by sirt2-deficient mouse studies [244]. As a consequence, SIRT2 
silencing alone may lessen the potency of chemotherapeutic drugs, such as 
paclitaxel, which preferentially target proliferating cells.  Examining whether the 
differing sirtuin inhibitors could complement paclitaxel treatment, MCF7 cells 
were treated the sirtuin inhibitors alone and in combination with paclitaxel. There 
was no perceived additive or synergistic effect of paclitaxel with sirtinol or 
salermide, reiterating that their have already reached the maximum potency with 
which they can induce apoptosis. EX527 treatment did reduce the potency of 
paclitaxel treatment both when treated with increasing concentrations and over a 
time course, protecting cells from apoptosis, most likely due to the potent arrest 
at G1. Moreover, the potent G1 arrest observed with EX527 treatment is 
overcome when the compound is withdrawn, allowing cells to proliferate 
normally. Unlike sirtinol and salermide treatment, whose effect on the cellular 
phenotype cannot be reversed. These findings add caution to using any sirtiun 
inhibitor in combination with established chemotherapeutic regimes, without 
investigating their exact effect on the cellular phenotype. Compunds that are not 
fully illucidated could have undesirable effects.  
 
In summary, we have used a combination of in vitro SIRT inhibition assay, 
structural studies and in vivo cell based systems to investigate the substrate 
specificity and efficacy of three novel SIRT inhibitors, Sirtinol, Salermide and 
EX527. Together the results also provide evidence to show that the cytotoxic 
effect of SIRT inhibitors is mediated predominantly through the inactivation of 
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both SIRT1 and -2 and the subsequent acetylation of the tumour suppressor p53. 
These data also suggest that a redundancy of functions may exist between 
SIRT1 and SIRT2, and that SIRT1 and SIRT2 cooperate to deacetylate the 
tumour suppressor protein p53 to attenuate cell death. 
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3.4 FUTURE WORK 
 
To elucidate further the cytotoxic functions of sirtinol and salermide, it would be 
interesting to make resistant cell lines to these compounds to observe the exact 
mechanism that regulate sirtuin mediated apoptosis. They are still able to initiate 
apoptosis in a p53 independent manner, albeit less efficiently. Understanding 
these mechanisms will increase the potency of sirtuin inhibitors and possibly their 
clinical relevance. 
 
Due to the fact that EX527 treatment results in the acetylation of a different 
subset of genes to other sirtuin inhibitors, investigating further the exact genes 
that are acetylated with EX527 treatment could represent a new pool of genes 
that are only deacetylaed by SIRT1. Because SIRT1 is found to be upregulated 
in many cancers, these posttranslational targets could be important in tumour 
progression and could be impart responsible for SIRT1s role in tumourigenesis. 
 
The cell cycle profile observed with SIRT1 and SIRT2 knockdown displays a 
marked increase in the G2-M population, as well as an increase in sub G1 cells. 
This is different to the cell cycle profile of sirtinol and salermide treated cells 
containing WT p53 where a marked increase in sub G1 cells is observed, 
meaning that although SIRT1 and SIRT2 inhibition results in the induction of 
apoptosis, sirtinol and salermide are executing their cytotoxic actions by 
additional mechanism, possibly by inhibiting other sirtuin family members. The 
development of SIRT1-/- and SIRT2-/- knockout MEFs would allow for the study 
of the addition functions of sirtinol and salermide. 
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CHAPTER 4 
 
RESISTANCE TO LAPATINIB THROUGH LOSS OF 
FOXO3a IN SKBR3 CELLS 
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4.1 INTRODUCTION 
  
The human epidermal growth factor (HER) family consists of four members, 
EGFR, HER2, HER3 and HER4. They are type I transmembrane growth factor 
receptor tyrosine kinases, EGFR and HER2 being the most well defined 
members [347]. HER2 (neu), the oncogenic tyrosine kinase is overexpressed in 
25% of breast cancer cases; unfortunately these tumours are more prevalent in 
premenopausal women and ultimately lead to a poorer clinical outcome. This 
makes HER2 a promising therapeutic target [14]. The study of 5,232 breast 
cancer cases showed 48% to be EGFR positive [99]. Although EGFR expression 
does not inversely correlate with patient survival, like HER2 overexpression, 
recent publications are starting to unravel its importance, suggesting that its 
subcellular localisation is important in breast cancer, showing nuclear 
accumulation of EGFR is inversely correlated with patient survival [102].  
 
Lapatinib (also known as GW572016 and Tykerb) is an orally administered 
potent small molecule inhibitor that functions as a dual inhibitor, binding 
reversibly to EGFR and HER2 tyrosine kinases, inducing growth arrest or tumour 
cell apoptosis in EGFR dependent or HER2-depedent tumour cell lines or 
xenographs [290, 348]. It is currently the most clinically developed dual tyrosine 
kinase inhibitor (TKI) and was found to increase progression-free survival in 
patients with advanced HER2-postive tumours when given in combination with 
the antimetabolite chemotherapy drug capecitabine (Xeloda) compared with 
capecitabine alone, in patients who had already failed previous treatment 
regimes with anthracyclines, taxanes and trastuzumab [349].  
 
Although Lapatinib shows promise, some patients develop resistance and 
eventually relapse [350, 351]. Unfortunately, these mechanisms of resistance are 
poorly understood. Elucidating the mechanisms of acquired resistance to TKIs 
will provide essential information that will lead to advances in novel therapeutic 
strategies and in turn, lead to increased clinical efficacy. 
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We and others have shown previously the importance of FOXO3a in eliciting the 
proapoptotic potency of TKI therapy [291-293]. FOXO3a a member of the 
forkhead family of transcription factors and is negatively regulated by the 
PI3K/AKT signaling cascade [126]. HER2 overexpression in cancer leads to the 
up-regulation of PI3K activity and phosphorylation of AKT. Upon activation, AKT 
enters the nucleus where it phosphorylates FOXO3a, causing its nuclear export 
and subsequent inhibition of transcriptional activity [352, 353]. FOXO3a is known 
to regulate a plethora of target genes important for cell cycle regulation (e.g., 
p27Kip1, p130(RB2), cyclin D), apoptosis (e.g., Bim, Fas-ligand and TRAIL) and 
oxidative stress (e.g., mnSOD and Catalase) [84, 151, 156, 165, 170, 171, 173, 
176], so inhibiting its transcriptional activity results in growth, survival and 
development of cancer cells. 
 
It has been shown recently that low expression of FOXO3a in ovarian cancer 
[354] and the nuclear exclusion of FOXO3a in Acute Myeloid Leukemia is linked 
with a poorer clinical outcome [355]. In this study we report the loss of FOXO3a 
expression in the in vitro derived lapatinib resistant cell lines from SkBr3 breast 
cancer cells. Moreover, loss of FOXO in NIH 3T3 mouse embryonice fibroblasts 
confers resistance to lapatinib and FOXO knock out cells can be resensitised to 
lapatinib by reinstating FOXO3a expression, suggesting modulation of FOXO3a 
expression with combined therapy could circumvent lapatinib resistance and 
improve clinical outcome. 
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4.2 RESULTS 
 
4.2.1 Generation and characterisation of Lapatinib resistant cells 
 
SkBr3 breast cancer cell lines were continually exposed to increasing 
concentrations of lapatinib in vitro for two months, after which resistance 
developed and cells were actively proliferating in the presence of lapatinib. 
Resistant cells (termed SkBr3 R5) were then maintained in 0.5µM of lapatinib. 
SRB assay was used to confirm resistance, WT and R5 cells were treated with 
increasing concentrations of lapatinib for 72 hours, the IC50 for WT and R5 cells 
were 0.42 and 1.23µM respectively (Figure 4.1A). R5 cells tolerated 
concentrations ~3 times higher than that of the parental cell lines. Cell cycle 
analysis was also performed; WT and R5 cells were treated with 1µM of lapatinib 
for 24 hours (Figure 4.1B). WT cells treated will lapatinib resulted in a reduction 
of cells in the G1 phase of the cell cycle (66.9 to 53.9%) and an increase in sub 
G1 (7.2 to 30.2%) indicating that they were undergoing apoptosis. Conversely a 
reduction in cells in the G1 phase of the cell cycle was not observed in R5 cells 
treated with lapatinib (65.8 to 67.2%). Although there was an increase in the sub 
G1 population, this was not as marked as observed in the parental cell lines. 
Together these results confirm that SkBr3 R5 cells are more resistant to lapatinib 
compared to their parental cell line. 
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Figure 4.1 SkBr3 R5 cells are resistant to lapatinib compared with parental 
cell lines.  A Resistant R5 and parental SkBr3 cells (WT) were treated with 0-
10µM of lapatinib for 72 h. Cell viability was determined by SRB assay. Points, 
mean of three independent experiments; bars, SD. B Resistant R5 and WT cells 
were treated with DMSO or 1µM of Lapatinib for 24 h, flow cytometric analysis of 
DNA content was done after propidium iodide staining. Percentage of cells in 
each phase of the cell cycle (sub-G 1, G1, S, and G2-M) is indicated. 
Representative data from three independent experiments are shown 
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We and others have previously shown FOXO3a to be important in eliciting the 
proapoptotic potency of EGRF/HER2 targeted therapies [291-293]. To examine 
the effect of the development of resistance on FOXO3a and other proteins 
important in PI3K signaling, protein expression was elucidated using western blot 
(Figure 4.2A). The protein expression of the EGFR family members, EGFR, 
HER2 and HER3 did not change between WT and R5 cells, although an increase 
in EGFR phosphorylation is observed. In keeping with this, a slight increase in 
the phosphorylation of AKT (308 & 473) was also observed, as well as a marked 
decrease in P-ERK (202/204). Strikingly, there was a significant reduction in the 
protein expression of FOXO3a (as well as P-FOXO3a Thr32). We have shown 
previously that there is an inverse correlation between the expression of 
FOXO3a and the pro-proliferative transcription factor FOXM1 [98]. This 
observation is reiterated in the R5 cells, where there is an increase in expression 
of FOXM1. We also checked the expression of MDR1, which we have previously 
shown to be important in the FOXO3a-dependent development of 
chemoresistance in leukemic cells [356]. In this setting, there was no change in 
the expression of MDR1. 
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Figure 4.2 Characterisation of the R5 cells and their parental cell line 
SkBr3. Lapatinib resistant SkBr3 cells were made by exposing WT cells to 
increasing concentrations of lapatinib over a period of 2 months. Resistant cells 
were defined as those able to actively proliferate in lapatinib-suplemented 
medium. Expression of proteins involved in PI3K signalling and their relative 
phosphorylation levels (A) and the HDAC class III Sirtuins (B) were determined 
in WT and R5 cells by western blot of total cell lysates (Normally cycling cells 
were harvested ~70%) 
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4.2.2 Loss of FOXO3a confers resistance to lapatinib 
 
To confirm the importance of FOXO3a in lapatinib mediated apoptosis in SkBr3 
cells, the endogenous pool was reduced using targeted siRNA specific for 
FOXO3a and cell viability and cell cycle analysis were performed. Successful 
knockdown was confirmed using western blot (Figure 4.3A). After 24 hours 
treatment with 0-1µM lapatinib, an increase in cell viability was observed in the 
siFOXO3a cells compared with the mock and non-specific treated control (Figure 
4.3C). This is most evident at 1µM treatment where the cell viability increases 
from 39.1 and 32.9 to 52.4% for the mock (p<0.01), non-specific control (p<0.05) 
and siFOXO3a treated cells, respectively. Cell cycle analysis reaffirmed this 
observation, showing a reduction in sub G1 population of lapatinib treated cells, 
compared to the controls (32.4, 38.3 to 26% for the mock, non-specific and 
siFOXO3a, respectively)(Figure 4.3B).  
 
Due to the fact that obtaining 100% knockdown is difficult to achieve via transient 
transfection, FOXO negative (FOXO-/-) and wild type MEFs were used to 
examine the conjecture further (Figure 4.4A). Both FOXO-/- and WT MEFs were 
treated with increasing concentrations of lapatinib for 72 hours (Figure 4.4B), cell 
viability was observed using SRB. FOXO-/- MEFs were ~5 times more resistant 
to lapatinib than their parental counterparts (37.24 to 6.47µM, respectively). 
When treated with 0-10µM of lapatinib for 24 h (Figure 4.4C), viability in WT 
MEFs reduced from 100% to 74.4%, indicating cytotoxicity, whereas treatment 
on FOXO-/- cells resulted in an increase in cell viability from 100% to 114.1%, 
suggesting the cells were actively proliferating. Statistical analysis (two-way 
ANOVA Bonferonni post-test) revealed a significant protection against lapatinib 
treatment in the FOXO-/- at concentrations of 5 and 10µM (p<0.01). 
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Figure 4.3 FOXO3a targeted knockdown protects SkBr3 cells from lapatinib 
treatment SkBr3 cells were treated with mock, non/specific and FOXO3a 
targeted siRNA for 24 h and then treated for another 24h with 1µM of lapatinib. 
Successful knockdown was confirmed by western blot of total cell lysates (A) and 
flow cytometric analysis of DNA content was performed after propidium iodide 
staining (B). Percentage of cells in each phase of the cell cycle (sub-G 1, G1, S, 
and G2-M) is indicated. Representative data from three independent experiments 
are shown. SRB assay was also performed (C). Mock, non-specific and 
siFOXO3a treated cells were seeded into a 96 well plate and 24 h later treated 
with 0-1µM for a further 24h. Statistical analysis was performed using two way 
ANOVA Bonferonni post-test (* = p<0.05, ** = p<0.01 *** = p<0.001). 
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Figure 4.4 Loss of FOXO reduces the potency of Lapatinib. NIH 3T3 cells 
WT and FOXO null MEFs (A) were treated for 72 h with 0-100µM of Lapatinib (B) 
and for 24 h with 0-10µM (C) Cell proliferation was determined by SRB assay. 
Results shown are mean ± SD of three independent experiments. IC50s were 
also calculated for WT and FOXO-/- cells (6.47 & 37.24µM respectively). 
Statistical analysis was performed using two way ANOVA Bonferonni post-test (* 
= p<0.05, ** = p<0.01 *** = p<0.001). Part A performed by Miss Stephanie Guest
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4.2.3 Overexpressing FOXO3a in FOXO-/- MEFs resensitises cells to 
lapatinib treatment. 
 
To assess the ability of FOXO3a to resensitize FOXO-/- MEFs to lapatinib, 
FOXO3a was overexpressed and treated with 5µM of lapatinib and DMSO vector 
control for 24 hours (previously shown to have no negative effect on viability at 
24h treatment). Overexpression was confirmed by western blot (Figure 4.5A) and 
cell cycle analysis was also performed (Figure 4.5B). Treatment of the FOXO-/- 
MEFs with lapatinib resulted in the dephosphorylation of EGFR showing that 
lapatinib does effected EGFR activity but there was little effect on the cell cycle 
compared with the vector control and no marked increase in the percentage of 
sub G1 cells (4 to 5.9%, DMSO, lapatinib treatment, respectively) (Figure 4.5B). 
Reinstating FOXO3a expression causes a reduction of cells in the G1 phase and 
an increase of the sub G1 population, indicating that the cells are undergoing 
apoptosis. Treatment with lapatinib resulted in the dephosphorylation of EGFR 
and a further increase in the sub G1 population from 18.1 to 26% respectively 
(Figure 4.5B). It is unsurprising that the sole addition of FOXO3a can induce 
apoptotis, as one of the marked effects of lapatinib treatment is the increased 
stabilisation and cellular expression of FOXO3a. This overexpression is merely 
mimicking one of the mechanisms of action of lapatinib.  
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Figure 4.5 Reinstating FOXO3a results in sensitivity to lapatinib NIH 3T3 
FOXO-/- were transfected with FOXO3a or backbone vector and were treated 
with 5µM of lapatinib or DMSO control for 24 h. Protein expression was 
determined using western blot of total cell lysates (A) and flow cytometric 
analysis of DNA content was done after propidium iodide staining (B) Percentage 
of cells in each phase of the cell cycle (sub-G 1, G1, S, and G2-M) is indicated. 
Representative data from three independent experiments are shown. 
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4.3 DISCUSSION 
 
We and others have shown previously the importance of FOXO3a in eliciting the 
proapoptotic potential of EGRF/HER2 targeted therapies [291-293]. To take this 
line of study further and examine the role of FOXO3a in acquired resistance to 
TKIs we developed the lapatinib resistant cell line SkBr3 R5. Confirming 
resistance, R5 cells were shown to tolerate ~3 times higher concentrations of 
lapatinib compared to the parental cell lines using the SRB growth assay. The 
effect of lapatinib treatment on WT and R5 cells was also shown to have a 
differing effect on the cell cycle. WT cells displayed a reduction of cells in the G1 
phase of the cell cycle and an increase in the sub G1 population. R5 cells did not 
show a reduction of cells in G1 but a slight increase, and the induction of 
apoptosis was markedly decreased compared to WT cells treated with lapatinib 
(14.9%compared with 30.2% respectively). 
 
The resistant cells displayed increased phosphorylation of EGFR and preferential 
activation of the PI3K signaling cascade and a decrease in ERK activation. This 
highlights the important of PI3K signaling in tumour development and resistance. 
On further inspection R5 cells were shown to have a marked decrease in 
expression of FOXO3a. 
 
To confirm this conjecture, WT cells were transfected with FOXO3a targeted 
siRNA. The knockdown of FOXO3a conferred resistance to lapatinib and 
provided statistically significant protection from lapatinib (p<0.05). To examine 
the effect of complete loss of FOXO3a and its other family members FOXO1 and 
FOXO4, FOXO-/- derived NIH 3T3 MEFs (and WT) were treated with an 
increasing concentration of lapatinib for 24 and 72 hours. Treatment of lapatinib 
for 24 hours resulted in a decrease in cell viability in the WT but not the FOXO-/- 
cells. The FOXO-/- negative cells were also shown to be ~5 times more resistant 
to lapatinib treatment (72h). This suggests that there is some redundancy among 
FOXO proteins in the R5 cells, i.e. FOXO1 and 4 can partially compensate, albeit 
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less efficiently, for the loss of FOXO3a in the R5 cells. This has been previously 
reported in FOXO deficient (CRE-mediated disruption) mice [357].  
 
With this study we show for the first time, from in vitro derived lapatinib resistant 
cell lines (SkBr3 R5), that loss of FOXO3a occurs during the development of 
resistance to lapatinib. Mechanisms of resistance to lapatinib have previously 
been reported [291, 358], but this has always been in the ER-positive breast 
cancer cell line BT-474 and did not show any effect on or loss of FOXO3a. 
Although interestingly, their study does support our findings, due to the fact that 
in the resistant BT474 cell line (rBT474), lapatinib treatment was still found to 
cause the dephosphorylation of HER2, HER3, AKT and MAPK, suggesting a loss 
of function of proteins further down the signaling cascade, for example FOXO3a, 
resulting in an inability to elicit the proapoptotic response [291]. Moreover, 
because this lack of efficacy could be a result of low levels or loss of FOXO3a - 
the cytoplasmic localisation of FOXO3a is associated with poor survival in 
patients [359] - compounds that stabilise FOXO3a, increase its expression and/or 
causes its derepression could be used to resensitise lapatinib-resistant tumours, 
maximising its proapoptotic potency and efficacy.  
 
Recently it was shown that FOXO3a expression is lost in human lung 
adenocarcinoma (LAC) (~60%) and that this was predominantly though gene 
deletion, highlighting the role of FOXO3a as a tumour suppressor, promoting 
carcinogen-induced apoptosis, inhibiting carcinogenesis [285, 360]. 
 
To summarise, FOXO3a is known to be responsible for the cytotoxic function of a 
range of chemotoxic agent such as Paclitaxel, Imatinib and Trastazumab [102, 
182, 183, 361], This strengthens its importance as a marker for responsiveness 
to targeted therapies, since overexpression of HER2 does not necessarily 
correlate to a positive clinical outcome. Also, FOXO3a status could prove to be 
an important diagnostic factor in other groups of patients such as ER+/HER- 
negative, who could benefit from combination therapy with lapatinib [362]. 
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4.4 FUTURE WORK 
 
To show further that FOXO3a is important in the efficacy of lapatinib and that 
loss of FOXO3a is a clinically relevant mechanism of resistance, patient samples 
that have been treated with lapatinib could be investigated to examine FOXO3a 
expression and whether it correlated with reduction in tumour size. Current trials, 
such as the neo-ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment 
Optimisation) study, which assesses the ability of paclitaxel in combination with 
lapatinib, trastuzumab or both, to reduce tumour size before surgery would 
provide a unique opportunity to investigate the role of FOXO3a in lapatinib 
cytotoxicity prior to the treatment of established chemotherapeutic agents such 
as FEC (5FU, epirubicin and cyclophosphamide) [363]. Although the patients 
have been treated with lapatinib and paclitaxel, we have shown previously that 
FOXO3a is also important in eliciting the proapoptotic potency of paclitaxel [183, 
364]. Investigating clinical samples would strengthen the importance of FOXO3a 
expression in eliciting the cytotoxic action of many chemotherapeutic agents. 
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CHAPTER 5 
 
THE ROLE OF SIRT1 IN CISPLATIN RESISTANCE 
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5.1 INTRODUCTION 
 
Cisplatin (cis-diamminedichloro-platinum), a platinum-based chemotherapeutic 
agent has been an established and important treatment for many cancers, 
including ovarian, bladder, testicular and non-small lung cancer, as a single 
agent and in combination with other anticancer agents, reducing tumour burden 
and increasing life expectancy of patients [365, 366]. 
 
Although cisplatin is not used as a first-line therapy in breast cancer, recent 
studies have shown that at least in a subset of patients termed, ‘triple negative’ – 
lacking the expression of estrogen, progesterone and HER2 receptors – who 
account for 15% of all breast cancer cases [367], showed response to 
neoadjuvant cisplatin treatment. 22% of patients achieved pathological complete 
response and 64% of patients had a clinical complete or partial response [368]. 
In another study, patients displayed a reduction in the risk of progression by 
47%, when treated in combination with cisplatin and gemcitabine, compared with 
non-triple negative metastatic breast cancer patients [369]. These studies 
highlight the possible use of cisplatin as a viable therapy for some breast cancer 
patients. 
 
Platinum-based compounds mediate their cytotoxicity by forming platinum 
intrastrand and interstrand DNA adducts activating nuclear excision repair and 
homologous recombination pathways [370]. The inability to activate appropriate 
DNA repair mechanisms lead to the accumulation of DNA strand breaks, and 
ultimately the induction of apoptosis and cell death [371]. 
 
Resistance to cisplatin is a major clinical obstacle, after an initial favorable 
response the majority of patients relapse with cisplatin-resistant disease [372]. 
Several pathways and mechanisms have been associated with the acquisition of 
cisplatin resistance, including increased cell proliferation, an increase in drug-
efflux pumps, increased response to DNA damage repair, and evasion of pro-
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apoptotic pathways [365, 372]. Several targets have been implicated in the 
development of resistance in breast cancer cell lines, including amphiregulin 
[373], Dicer [374], cyclin D1 and BCL2 [375]. However, a better understanding of 
the molecular mechanisms that cause chemotherapeutic resistance are needed 
so that the benefit of platinum-based treatments to patients can be prolonged, as 
well as increasing their efficacy with possible combinatorial therapies. 
 
Recently it has been shown that the PI3K/PKB/FOXO pathway is important in the 
cellular response to cisplatin treatment in ovarian cancer cells [376] and 
mediates its cytotoxicity in colon carcinoma cells [377]. The histone deacetylase 
SIRT1 has also been shown to be important in the development of cisplatin 
resistance in prostate cancer cell lines [314], epidermiod adenocarcinoma and 
hepatoma cell lines [378, 379]. Moreover, SIRT1 knock down was shown to 
sensitize the p53-deficient chicken cell lines, DT40 to cisplatin treatment [339]. 
 
In this study we evaluate the effect cisplatin resistance has on proteins involved 
in the PI3K/PKB/FOXO pathway and also the HDAC class III proteins, termed 
sirtuins. Using MCF-7 derived cisplatin resistant (termed CisR) and parental cell 
lines we found that SIRT1 was upregulated, and that this upregulation protected 
CisR cells from cisplatin treatment. Also, SIRT1 suppressed the activation of 
FOXO3a. These findings highlight the role of SIRT1 in the development of 
chemoresistance but more importantly the effect the upregulation of SIRT1 has 
on suppressing the proapoptotic potency of chemotoxic agents that indirectly 
active FOXO3a. 
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5.2 RESULTS 
 
5.2.1 Development and characterisation of cisplatin resistant cells 
 
The breast cancer cell line MCF-7 was continually exposed to increasing 
concentrations of cisplatin in vitro for two months, after which, resistance 
developed and cells were actively proliferating in the presence of cisplatin. 
Resistant cells (CisR) were then maintained in 1µM of cisplatin. The growth 
assay SRB was used to confirm resistance. MCF-7 wildtype (WT) and CisR cells 
were treated with increasing concentration of cisplatin (0-1µM) for 72 hours 
(Figure 5.1). MCF7 WT cells showed a dose-dependent decrease in cell viability, 
whereas little effect on proliferation was observed in the cisR cells. At 1 µM 
treatment cell viability was 38.5% (SD±5.2) and 81.6% (SD±5.1) for WT and cisR 
cells respectively, and this difference in viability was shown to be statistically 
significant (p<0.001) (Figure 5.1). To confirm cisplatin resistance using another 
method, MCF-7 WT and CisR cells were treated with 1µM of cisplatin for 0-48 
hours and cell cycle analysis was performed (Figure 5.1). WT cells displayed an 
increase in G2-M population at 24 h treatment compared to the zero hour control 
(46.4% compared with 26.9%). At 48h post treatment there was a decrease in 
G2-M cells and G1 population but an increase in the sub G1 cells, indicating cells 
they were undergoing apoptotis. Whereas CisR cells displayed no significant 
change in cell cycle distribution when treated with cisplatin, showing that they are 
indeed resistant to cisplatin treatment (Figure 5.1).  
 
It has been shown recently that FOXO3a is important in modulating the 
cytotoxicity of cisplatin in colon carcinoma cells [377], to examine whether there 
were any changes in protein expression between WT and CisR cells we checked 
the expression of FOXO3a and proteins important in its regulation (Figure 5.2). 
We found that FOXO3a expression had decreased in the CisR cells compared 
with WT parental cell lines. There was also an increase in phosphorylation of 
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AKT (473) which has been shown to be important in regulating the activity of 
FOXO3a and a possible mechanism of resistance [380].  
 
Due to the decreased expression of FOXO3a we characterized the expression of 
the class III HDAC proteins, termed sirtuins (Figure 5.2). SIRT1, SIRT2 and 
SIRT3 have previously been shown to interact with and regulate the subcellular 
localisation and activity of FOXO3a [223, 269, 270]. Profiling all seven sirtuins, 
there were changes in expression. SIRTs 6 and 7 appeared to be down-
regulated although not markedly. The most striking change was a ~3 fold 
increase in the protein expression of SIRT1 (Figure 5.2), which is known to effect 
the activation of downstream targets by FOXO3a, inhibiting its ability to activate 
genes involved in the pro-apoptotic response, instead activating a subset of 
genes involved in stress resistance [223]. 
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Figure 5.1 CisR cells are resistant to cisplatin compared with the parental 
cell line, MCF7 MCF7 WT and cisR cells were treated with increasing 
concentrations of cisplatin for 72 hours. Proliferation was determinded by 
sulforhodamine B assay. Results are in triplicate. Mean ± S.D. MCF7 cells were 
treated with cisplatin (1µM) for 0, 24 and 48 hours. Cells were fixed in ethanol 
and the DNA content was analyzed after propidium iodide staining by flow 
cytometry 
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Figure 5.2 Characterisation of CisR cells compared with their parental cells 
MCF-7 Expression of proteins involved in PI3K signaling and their relative 
phosphorylation levels (A) and the HDAC class III Sirtuins (B) were determined 
in WT and CisR cells by western blot of total cell lysates (Normally cycling cells 
were harvested ~70%) 
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5.2.2 FOXO3a is not activated in CisR cells 
 
To assess the effect of cisplatin treatment on FOXO3a expression we treated WT 
and CisR cells for 0-48h with 1µM of cisplatin (Figure 5.3). Cisplatin treatment in 
WT cells showed an increase in the cellular expression of FOXO3a and an 
increase in expression of the canonical downstream target, p27. In CisR cells, 
cisplatin treatment resulted in an increase of SIRT1 at 24h but no effect on 
FOXO3a or p27, suggesting that SIRT1 upregulation is suppressing the 
activation of FOXO3a (Figure 5.3). 
 
To expand this conjecture further, WT and CisR cells were transfected with mock 
control, control siRNA or siRNA against SIRT1 (Figure 5.4). The transfected cells 
were then incubated with or without 1 µM of cisplatin for 24 hour before the cells 
were subjected to cell cycle and Western blot analyses. The cell cycle analysis 
showed that the siRNA-mediated knockdown of endogenous SIRT1 in both 
untreated WT and CisR cells had no discernable effect on the cell cycle. 
Strikingly, treatment of cisplatin when SIRT1 expression was reduced in CisR 
cells displayed a marked increase in the sub G1 population compared with mock 
and non-specific siRNA treated controls (37.2% compared to 9.9% 10.1% 
respectively)(Figure 5.4). WT cells treated with cisplatin showed an increase in 
the sub G1 population compared to the untreated control (14% compared to 
2.1%), this population was markedly increased when SIRT1 expression had been 
reduced, from 14.3% and 13.3% to 26.9% (mock, non-specific and siRNA SIRT1 
respectively)(Figure 5.4). This data highlights the role of SIRT1 in mediating the 
cytotoxicity of cisplatin in WT MCF-7 cells, showing that its expression negatively 
affects the efficacy of cisplatin. Also it suggests the SIRT1 overexpression plays 
a major role in development of resistance to DNA damaging-inducing agents, 
such as cisplatin. 
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Figure 5.3  Cisplatin treatment activates FOXO3a in WT but not CisR cells 
WT and CisR cells were treated with 1µM of cisplatin for 0-48 h. Protein 
expression was determined using western blot of total cell lysates. 
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5.2.3 SIRT1 can protect cells from cisplatin treatment 
 
To examine whether the sole overexpression of SIRT1 can protect cells from 
cisplatin treatment MCF-7 cells were transfected with empty expression vector or 
expression vector encoding FLAG tagged SIRT1 for 24 h, then reseeded into a 
96 well plate for 24 h and treated with increasing concentrations of cisplatin (0-
21µM) for a further 24 h, proliferation was determined using the growth assay 
SRB and overexpression was confirmed using western blot (Figure 5.5). 
 
SIRT1 overexpression protected MCF-7 cells from cisplatin treatment at all 
concentrations tested showing no statistical effect on cell viability 
(p<0.001)(Figure 5.5). This protection being most prominent at 21µM cisplatin 
treatment where the empty expression vector control had 48.1% viability 
compared with the SIRT1 transfected cells that had 90.5% cell viability (p<0.001). 
This demonstrates that the sole overexpression of SIRT1 can protect cells from 
cistplatin treatment and that SIRT1 plays a vital role in the development of 
cisplatin resistance, protecting cells from the cisplatin induced activation of 
apoptosis, favouring a prosurvival outcome. 
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Figure 5.4 Knocking down SIRT1 sensitizes WT and cisR cells to cisplatin 
treatment MCF7 WT and cisR cells were transfected with mock, control siRNA 
pool or SIRT1 targeted siRNA for 24 h and then treated with DMSO or cisplatin 
(1µM) for 48 hours. Sufficient knock-down was confirmed using western blot of 
total cell lysates. For cell cycle analysis cells were fixed in ethanol and the DNA 
content was analyzed after propidium iodide staining. 
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Figure 5.5 SIRT1 overexpression protects MCF-7s from cisplatin MCF-7 
cells were transfected with FLAG and FLAG-SIRT1 for 24h then treated with 
increasing concentrations of cisplatin (0-21µM) for a further 24 hours. 
Overexpression was confirmed using western blot of total cell lysates. 
Proliferation was determined by sulforhodamine B assay. Results are in triplicate. 
Mean ± S.D 
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5.3 DISCUSSION 
 
The role of the PI3K signalling pathway and its components are known to be 
important in a range of cellular processes and has been shown to be important in 
many human malignancies. Changes in the regulation of these components are 
known to be important in tumour development, for example, the overexpression 
of HER2 leads to the activation of the PI3K and its downstream effectors, 
resulting in increased cell cycle progression, proliferation and survival [381]. In 
ovarian cancer, dysregulation of the PI3K cascade through increased activity of 
AKT leads to the development of resistance to cisplatin treatment [382]. 
 
In this study, we show for the first time that SIRT1 is upregulated in derived 
cisplatin resistant breast cancer cell lines and that the specific upregulation of 
SIRT1 protects resistant cells from cisplatin induced apoptosis possibly by 
suppressing the activation of FOXO3a. 
 
We and others show that the activation of FOXO3a in cisplatin-resistant cells is 
incomplete [377]. The lack of activation of FOXO3a in the cisplatin resistant cells 
suggests that this suppression of activity is due to the upregulation of SIRT1. 
SIRT1 overexpression in cisplatin sensitive cells was sufficient to protect MCF7 
cells from cisplatin treatment. 
 
An earlier passage of the CisR cells were used by Kwok et al [383] and were 
found to have increased expression of the DNA damage repair genes XRCC1 
and  BRCA2. We have previously shown that FOXO3a represses the expression 
of pro-survival transcription factor FOXM1 in response to the tyrosine kinase 
inhibitor gefitinib [98]. A likely mechanism of resistance could be the suppression 
of FOXO3a activity by SIRT1 allows FOXM1 to upregulate DNA damage repair 
genes, allowing continued proliferation and evasion of apoptosis. 
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Moreover, SIRT1 -/- DT40 chicken cells, which are deficient of p53, displayed 
increased sensitivity to cisplatin, highlighting that SIRT1s role in chemoresistance 
is possibly independent of its interaction and regulation of p53, and must be due 
to other cell cycle regulatory genes such as FOXO3a to regulate its cytotoxicity 
[339]. 
 
The silencing of SIRT1 expression was sufficient to resensitise resistant cells to 
cisplatin treatment, as well as increasing the cytotoxicity of cisplatin in WT cells. 
Interestingly there is a ~4 fold increase in phosphorylated AKT on residue 473 
whereas the phosphorylation of 308 was unchanged. It is interesting to note that 
the fold change observed in P-AKT (473) expression is similar to the fold change 
in SIRT1 expression. It has previously been shown that deregulation of P-AKT 
(473) leads to a deficient phosphorylation of specific downstream targets. 
Genetic ablation of sin1 abolished phosphorylation of AKT on serine 473 and 
disrupted its interaction with rictor-mTOR, but phosphorylation of AKT on 
threonine 308 was maintained. AKT was unable to phosphorylate FOXO3a 
(Thr32) but was still able to interact and phosphorylate other targets, such as 
TSC2 and GSK3 [384]. Guertin et al reiterated these findings, showing that loss 
of mTORC2 function, through loss of mLST8 and rictor in mouse embryonic 
fibroblasts differentially affected the phosphorylation status of AKT downstream 
targets, showing that AKT could no longer phosphorylate FOXO3a but was still 
able to phosphorylate other proteins targets [83]. Expanding these findings, it is 
logical to presume that the contrary exists where increased phosphorylation of 
AKT (473) preferentially represses the activity of FOXO3a. Further research is 
needed to understand whether SIRT1 overexpression and the development of 
resistance suppresses FOXO3a activity by directly regulating the post-
translational status of FOXO3a, or indirectly via regulating the activity of other 
proteins in the PI3K signalling cascade, or both. 
 
Irrespective of the mechanism of SIRT1s regulation of FOXO3a these findings 
have implications on treatment regimes for patients who are being treated with 
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cisplatin or who have developed resistance to cisplatin treatment. Combining 
cisplatin with sirtuin targeted therapy should circumvent resistance and increase 
the efficacy of cisplatin treatment, as well as allowing the lowering of the 
concentration of cisplatin used, reducing toxicity, side-effects, increasing patient 
quality of life. 
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5.4 FUTURE WORK 
 
Because cisplatin is used in triple-negative tumours, a specific subset of breast 
cancer patients, to confirm the important of SIRT1 in the development of cisplatin 
resistance additional cisplatin resistant cell lines such as MDA-MB-231, BT20 
and Cal51, which are model cell lines that are negative for ER, PR and HER2, 
should also be made to strengthen the findings of MCF CisR cells and show that 
it is not a cell line specific finding. Investigating SIRT1 expression in these cell 
lines would produce data that would be more clinically significant, especially if 
specific SIRT1 inhibitors could be used to resensitise them to cisplatin treatment. 
Also it would be interesting to examine whether SIRT1 is upregulated in 
therapies that are known to elicit their cytotoxic effect through indirectly activating 
FOXO3a, such as paclitaxel [183, 364].  
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CHAPTER 6 
 
SIRTINOL TREATMENT ENHANCES THE PRO-
APOPTOTIC POTENCY OF LAPATINIB IN A 
FOXO3a-DEPENDENT MECHANISM 
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6.1 INTRODUCTION 
 
Lapatinib, also known as GW572016 and Tykerb, is an orally administered potent 
small molecule inhibitor that functions as a dual inhibitor, binding reversibly to 
EGFR and HER2 tyrosine kinases, inducing growth arrest or tumour cell 
apoptosis in EGFR dependent or HER2-dependent tumour cell lines or 
xenographs [290, 348]. We and others have shown previously that the tyrosine 
kinase inhibitors (TKIs) Lapatinib and Gefitinib (a specific EGFR inhibitor), 
modulates their anti-proliferative potency through the transcription factor, 
FOXO3a, highlighting its crucial role in maintaining the pro-apoptotic efficacy of 
these targeted therapies [291-293] . FOXO3a is a member of the FOXO 
subfamily of forkhead transcription factors, which contains three other members, 
FOXO1, FOXO4 and FOXO6 in humans, and regulate a plethora of gene 
involved in many cellular including cell cycle regulation (e.g., p27Kip1, 
p130(RB2), cyclin D), apoptosis (e.g., Bim, Fas-ligand and TRAIL) and oxidative 
stress (e.g., mnSOD and Catalase) [84, 126, 151, 156, 165, 170, 171, 173, 176]. 
 
Histone deacetylases (HDACs) and histone acetytransferases (HATs), namely 
the class III HDACs termed sirtuins, control the aceytylation status of histones 
and non-histone proteins. The regulation of the posttranslational status of non-
histone targets such as p53 has been shown to affect its activity, DNA-binding 
affinity and stability [212, 385-387]. There are seven mammalian sirtuins (SIRT1-
7) and unlike the other classes of HDACs are dependent on the coenzyme NAD+ 
[388]. All sirtuins contain a catalytic domain of ~275 amino acids [300].  SIRT1 
being the most studied due to its homology to the yeast deacetylase Sir2 [223]. 
Sir2 is evolutionary conserved and is known to regulate longevity and aging in 
lower organisms, such as, Caenorhabditis elegans [389]. 
 
The development of HDAC inhibitors (HDACi) as viable therapeutic regimes has 
mainly focused on inhibitors of class I and II HDACs [390], SAHA (Vorinostat)  
being the first HDACi approved by the Food and drugs administration (FDA) for 
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the treatment of cutaneous T-cell lymphoma (CTCL). Since many other 
compounds have undergone or are undergoing clinical development [308, 391], 
but none to date have targeted the sirtuins, although mouse models have been 
used to show compounds that target sirtuins, such as the tenovins, namely 
tenovin-6, reduce tumour growth [312].  Sirtinol, a sirtuin inhibitor, was found to 
have an antiproliferative effect, through inhibition of SIRT1 and SIRT2 in breast 
cancer cells [313]. We have shown previously that the antiproliferative effect of 
sirtinol was less efficient in p53 null mouse embroyonic fibroblast (MEFs) and cell 
lines containing mutant p53 [316]. 
 
Recent clinical trials have shown that lapatinib is effective at treating patients 
overexpressing HER2, and more interestingly lapatinib in combination with 
capecitabine has been shown to prolong progression-free survival in patients that 
were previously receiving trastazumab [349, 392], An emerging problem with 
TKIs is the development of resistance. Understanding the molecular mechanisms 
of how this resistance arises would provide knowledge on whether patients would 
initially be receptive to targeted therapy and the likely success of combinatorial 
treatment. 
 
Here, we demonstrate the importance of FOXO3a in the proapoptotic potency of 
lapatinib, and sirtinol treatment causes the stability and cellular accumulation of 
FOXO3a. In combination, lapatinib and sirtinol display synergism at inducing 
apoptosis, this synergy being dependent on the presence of FOXO, due to its 
stabilization by sirtinol treatment and its activation by lapatinib. 
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6.2 RESULTS 
 
6.2.1 The antiproliferative function of sirtuin inhibitors is dependent on the 
presence of FOXO proteins 
 
We have previously shown that the proapoptotic potency of the sirtuin inhibitors 
sirtinol and salermide are dependent on the presence of functional p53 [316]. 
Because there are similarities between the regulation of p53 and FOXO, we took 
NIH 3T3 mouse embryonic fibroblasts (MEFs) wild-type (WT), p53 null (p53-/-) 
and FOXO null (FOXO-/- lacking FOXO1, FOXO3a and FOXO4), and treated 
them with 0-100µM of EX527, sirtinol and salermide for 72 hours and assessed 
their effect using the proliferation assay SRB. The antiproliferative effect of 
EX527 was impaired by the lack of FOXO, suggesting that it elicits its cytostatic 
action through the FOXO family members (p<0.001) (Figure 6.1). Moreover, it is 
logical to suggest that the unknown acetylated protein seen with EX527 
treatment (Figure 3.7) could be involved in directly or indirectly (via the PI3K 
cascase) regulating FOXO activity. Although this would need to be investigated 
further. 
 
Interestingly, we also found that between 10-40µM of sirtinol treatment the loss of 
FOXO proteins significantly decreased its efficacy (p<0.001), suggesting that at 
lower concentrations, the cytotoxic mechanism of sirtinol is modulated through 
FOXO proteins (Figure 6.1).  Moreover, the presence of FOXO proteins was 
more important than the presence of p53 at influencing cell viability when treated 
with the three sirtuin targeted compounds (Figure 6.1). 
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Figure 6.1 The antiproliferative effects of Sirtinol and EX527 are dependent 
on the presence of FOXO A NIH 3T3 cells WT, p53 null and FOXO null mouse 
embryonic fibroblasts were treated for 72 hours with 0-100µM of Sirtinol, EX527 
and Salermide. Cell proliferation was determined by sulforhodamine B assay. 
Protein expression was confirmed using western blot analysis of total cell lysates. 
Results shown are mean ± SD of three independent experiments. Statistical 
analysis was performed using one way ANOVA (* = p<0.05, ** = p<0.01 *** = 
p<0.001).  
 165 
6.2.2 Sirtinol treatment stabilizes FOXO3a, increasing its cellular 
expression 
 
Because sirtinol is the most cytotoxic sirtuin inhibitor that we tested, we decided 
to access the effect of sirtinol treatment on FOXO3a protein expression. To 
distinguish that the effects on FOXO3a and the cell phenotype by sirtinol 
treatment was independent of the presence of p53, SkBr3 cells – which contain 
mutant p53 - were taken and treated with 0-100µM of sirtinol for 24h; protein 
expression was analysed using western blot (Figure 6.2A). Sirtinol treatment 
resulted in the increased cellular expression of FOXO3a compared with the 
DMSO treated control. Interestingly sirtinol treatment had no effect on the 
phosphorylation of AKT (308) suggesting that sirtinol treatment was not affecting 
the canonical PI3K signalling cascade upstream of FOXO3a (Figure 6.2A) but by 
another mechanism of regulation, possibly via changes in mTORC2 activity or 
mdm2-dependent ubiquitination and degradation [193, 393]. 
 
To assess the impact of sirtinol treatment in a setting containing WT p53, MCF-7 
cells were treated with 25µM of sirtinol for 0-8h (Figure 6.2B). Treatment resulted 
in the increase in cellular expression of FOXO3a. MCF-7s were treated with 
25µM of sirtinol for 24 h and there was no statistically significant increase in 
FOXO3a mRNA expression (Figure 6.2C), suggesting that sirtinol treatment 
causes the stabilization of FOXO3a, similar to its effect on p53, but that this 
effect was p53-independent as it was abserved in both p53 WT and mutant cell 
lines. 
 
To confirm the conjecture whether the effect on FOXO3a was posttranslational, 
MCF7 cells were taken and WT FOXO3a-FLAG and 294D FOXO3a-FLAG (294D 
being a phosphorylation mimic that is ubiquinated and degraded) were 
overexpressed for twenty four hours and then treated with CHX for 0-8h with or 
without sirtinol (Figure 6.3). The degradation of FOXO3a when treated with 
DMSO was similar to what was previously reported [193], its cellular expression 
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reduced 50% after 8 hours of cyclohexamide treatment (Figure 6.2A). The 
treatment of 25µM of sirtinol caused the stabilization of WT FOXO3a when 
treated with cyclohexamide, the cellular abundance of FOXO3a being the same 
as 0 hour untreated cells (Figure 6.2B). But sirtinol was unable to stabilize the 
phosphorylation mimic 294D FOXO3a (Figure 6.2C), its degradation rate being 
similar to FOXO3a WT. This suggests that sirtuin inhibition caused by sirtinol 
treatment results in the acetylation and stabilization of FOXO3a and that this 
acetylation dysregulates the phosphorylation of FOXO3a on serine 294 and its 
subsequent ubiquitination and degradation. There is an evolutionary conserved 
lysine residue at 290, suggesting that acetylation here, sterically hinders 
phosphorylation of FOXO3a, but this needs to be investigated further through 
site-specific mutations of FOXO3a – unacetylatable and acetylation mimics – to 
confirm the exact lysine residues responsible for modulating FOXO3a protein 
expression. 
 
To confirm the stabilization only occurred with sirtinol treatment, EX527 was also 
tested and was unable to protect WT FOXO3a from degradation (Figure 6.3D), 
suggesting that more than one sirtuin needs to be inhibited to cause the 
stabilization of FOXO3a. 
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Figure 6.2 Sirtinol treatment stabilizes FOXO3a A SkBr3 cells were treated 
with 0-100µM sirtinol for 24 h. Protein expression was analysed using western 
blot. B MCF-7 cells were treated with 25µM of Sirtinol for 0-8h; protein 
expression was determined using western blot. C MCF-7 cells were treated with 
25µM sirtinol for 24 h. Cells were collected and total RNA was isolated. FOXO3a 
mRNA levels were analyzed by real-time quantitative PCR normalized with L19 
mRNA levels. Experiments were done in triplicate. Mean ± SD 
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Figure 6.3 Sirtinol treatment stabilizes FOXO3a A MCF-7 cells were 
transfected with WT FOXO3a-FLAG and treated with cyclohexamide for 0-8h 
alone or in combination (B) with 25µM of sirtinol, protein expression was 
determined using western blot C MCF-7 cells were transfected with FOXO3a-
FLAG 294D mutant and treated with cyclohexamide and sirtinol for 0-8h, protein 
expression was determined using western blot D MCF-7 cells were transfected 
with WT FOXO3a-FLAG for 24h and then treated with cyclohexamide and 50 µM 
EX527 for 0-8h. Protein expression was analyses using western blot. Protein 
expression was analysed using imageJ. 
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Increasing the protein level of FOXO3a is important in the cytotoxic function of 
sirtinol, to see if activating FOXO3a can increase this cytotoxcity. WT, A3 (a 
constitutively active/nuclear localised FOXO3a, previously described [182]) and 
294D were over-expressed and treated with and without sirtinol (Figure 6.4). 
Successful uniform over-expression was confirmed using western blot and 
assessment of the effect on the cell cycle was observed using flow cytometry. 
Overexpression of FOXO3a did result in an increase in the sub G1 population 
from 2.1 to 9.4, 13.8 and 7.2% (Untransfected, WT, A3 and 294D respectively), 
showing that the A3 unphosphorylated mutant is the most pro-apoptotic form of 
FOXO3a, mostly likely due to its nuclear localisation (Figure 6.4). Sirtinol 
treatment resulted in an increase in the sub G1 population of the untransfected 
cells from 2.1 to 15.4%, similar to what was previously observed (Figure 3.3A). 
Overexpression of WT FOXO3a and sirtinol treatment increased this apoptotic 
population to 22.8% but strikingly, overexpression of the A3 mutant and sirtinol 
treatment caused a marked increase to 39.6%. The 294D mutant with sirtinol 
treatment induced a sub G1 population of 18.6%, suggesting that the increase 
potency of FOXO3a is due to its stabilization and activation (Figure 6.4).  
 
To confirm these observations, the colon carcinoma cell line DL23, expressing a 
constitutively active FOXO3a where the three AKT phosphorylation sites have 
been mutated to alanines, is fused to the ligand-binding domain of the estrogen 
receptor (FOXO3a:ER) protein that is activated and translocated to the nucleus 
upon tamoxifen treatment [170], was taken and treated for 0-24 hours with 
tamoxifen, sirtinol and in combination (Figure 6.5A). Western blot analysis 
confirms that tamoxifen activates FOXO3a (a change in the migration of FOXO3a 
in the gel), Sirtinol treatment stabilizes the FOXO3a:ER construct,  and 
combination treatment results in the stabilization and activation of FOXO3a:ER 
(Figure 6.5A). The effects on FOXO3a are posttranslational, as no differential 
effect on FOXO3a mRNA is observed with any of the treatments performed 
(Figure 6.5B). To assess the effect of combination treatment on cell proliferation 
DL23 cells were treated with tamoxifen, sirtinol and in combination for 24 hours, 
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cell viability was observed using the growth assay SRB. Combination treatment 
was shown to be more cytotoxic than treatment of tamoxifen and sirtinol alone, 
cell viability being 14.9, 47.9 and 37.6% respectively (24 h, p<0.001) (Figure 
6.5D). This enhance cytotoxicity was also observed when examining the effect of 
combination treatment on proliferation (Figure 6.5C). These results suggests that 
sirtinol treatment could increase the proapoptotic potency of targeted therapies 
that indirectly activate FOXO3a [337]. The regulation of the FOXO3a 
downstream targets mnSOD, p27 and Bim were examined using western blot. 
No synergistic upregulation of of mnSOD or p27 was observed and no change in 
Bim expression was seen with any of the treatments (data not shown), 
suggesting that FOXO3a must be eliciting this increase in pro-apoptotic potency 
through its other downstream targets (supplemental figure 8.1). 
 171 
 
Figure 6.4 Sirtinol treatment combines with overexpression of FOXO3a to 
induce apoptosis  MCF7 cells were transfected with FOXO3a (WT/A3/294D) for 
24h and treated with 50µM of sirtinol for a further 24h. Protein expression was 
elucidated using western blot analysis. Cell cycle analysis of the same samples 
was performed after propidium iodide staining.  
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6.2.3 Increasing cellular expression of FOXO3a increases the proapoptotic 
potency of Lapatinib  
 
Previously we and others have shown FOXO3a to be important in the 
proapoptotic potency of the tyrosine kinase inhibitors gefitinib and lapatinib [291-
293]. Also Lapatinib indirectly activates FOXO3a while not activating other cell 
mechanisms such as JNK, meaning it is an optimal model for looking at the role 
of active FOXO3a in cancer treatment [293]. To confirm this SkBr3 cells were 
treated with 0-10 µM of Lapatinb for 24 hours, protein expression was examined 
using western blot (Figure 6.6). Lapatinib treatment resulted in a dose-dependent 
decrease in the AKT phosphorylation. Interestingly, dephosphorylation and 
activation of FOXO3a was observed even at the lowest concentration, 0.1 µM 
(Figure 6.6). Moreover, a dose-dependent increase in the cellular expression of 
FOXO3a was observed, suggesting that one of the mechanisms of action of 
lapatinib is to increase the cellular expression of FOXO3a to increase its 
cytotoxicity (Figure 6.6). To access whether sirtinol treatment could complement 
lapatinib treatment by increasing the expression of FOXO3a, SkBr3 cells were 
treated with 1µM lapatinib and 50 µM of sirtinol and in combination for 0, 8, 16 
and 24 hours. Protein expression was confirmed by western blot (Figure 6.7).  
 
Lapatinib treatment caused the dephosphorylation of EGFR, HER2 and AKT, and 
subsequently FOXO3a, resulting in its activation (Figure 6.7). Sirtinol treatment 
stabilized FOXO3a expression but did not result in a change of AKT 
phoshorylation even though treatment did result in the dephosphorylation of 
EGFR and HER2 (albeit much slower when compared with lapatinib treatment) 
(Figure 6.7). Combination treatment resulted in the stabilization of FOXO3a and 
its activation. Mimicking the observation seen with the FOXO3a:ER inducible 
system. This increase in activated FOXO3a resulted in the cleavage of 
proapoptotic marker caspase-3 more readily when compared to single treatments 
of lapatinib and sirtinol, suggesting the cells are more readily undergoing 
apoptosis (Figure 6.7). To confirm this increase in activity the caspase 3-7 
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activity Glo-assay (Figure 6.8) was treated with 1µM lapatinib and 50 µM of 
sirtinol and in combination for 0, 2, 4, 6 and 8 hours. Combination of lapatinb and 
sirtinol treatment caused a 4-fold increase in cleaved caspase-3 before any 
increase is observed with single treatment of each compound, reiterating that 
these cells are undergoing apoptosis more readily and that combinatorial 
treatment is more cytotoxic than single treatment. Cell viability was also 
performed to confirm that the effects seen were not due to large differences in 
the cell populations (Figure 6.8). Of course, fewer cells are present in the 
combination treated cells after 8 hours but this is because they are detaching 
from the 96-well plate and undergoing apoptosis. In the SRB growth assay, dead 
or dying cells are lost in the steps of the assay; meaning only viable cells are 
stained and recorded. This is not the case for the caspase-3/7 assay where all 
cells are retained. 
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Figure 6.5 Combining FOXO3a activation with sirtinol treatment results in a 
marked effect on proliferation A DL23 cells expressing a FOXO3a:ER fusion 
protein we treated with 200nM Tamoxifen, 25µM sirtinol and in combination for 0-
48h. Protein expression was determined using western blot. B Cells were 
collected and total RNA was isolated. FOXO3a mRNA levels were analyzed by 
real-time quantitative PCR normalized with L19 mRNA levels. Experiments were 
done in triplicate. Mean ± SD. C Cell proliferation was determined by SRB assay. 
D DL23 cells were treated with 200nM tamoxifen, 25µM sirtinol and in 
combination for 24h, cell proliferation was determinded using SRB assay. 
Results shown are mean ± SD of three independent experiments. Statistical 
analysis was performed using one way ANOVA (* = p<0.05, ** = p<0.01 *** = 
p<0.001). 
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Figure 6.6 Lapatinib activates FOXO3a and increases its expression in a 
dose-dependent manner SkBr3 cells were treated with 0-10µM of lapatinib for 
24 h. Protein expression of total cell lysates was determined using western blot.  
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Figure 6.7 Lapatinib and sirtinol treatment synergise SkBr3 cells were 
treated with 1µM of Lapatinib, 50µM Sirtinol and in combination for 0-24h. Protein 
expression was determined using western blot. 
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Figure 6.8 Lapatinib and sirtinol treatment synergise to activate caspase 3 
Cleaved caspase 3/7  activity assay was performed in SkBr3 cells were treated 
for 0-8h with 1µM of Lapatinib, 50µM Sirtinol and in combination . Results of two 
independent experiments in triplicate. Mean ± SD. The proliferation assay SRB 
was also performed to confirm cell population  
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6.2.4 Lapatinib treatment synergises with sirtinol treatment 
 
To confirm the effects on cell viability, cell cycle analysis was performed. SkBr3 
cells were treated with an increasing concentration of sirtinol (0-50 µM) alone and 
in combination with 1 µM Lapatinib treatment (Figure 6.9). Cell cycle analysis 
confirms that combinatorial treatment of lapatinib with sirtinol resulted in a 
marked increase in the induction of apoptosis compared with single treatment. 
Cells treated with lapatinib had a sub G1 population of 13.8% compared with the 
DMSO treated control (5.9%), 50 µM of sirtinol treatment caused a sub G1 
population of 10.3%, but when treated in combination this apoptotic population 
rose in a dose-dependent manner to 31.7% (Figure 6.9). To assess whether this 
complementation was synergistic, the growth assay SRB was performed. SkBr3 
cells were treated for 24 hours with an increasing concentration of lapatinib (0-10 
µM) and sirtinol (0-50 µM) and in combination (Figure 6.10A). IC50s were also 
calculated for lapatinib and sirtinol over a larger concentration range (18.10 µM 
and 69.91 µM respectively)(Figure 6.10B). From these data, we calculated the 
degree of synergy using the combination index (CI) algorithm of Chou and 
Talalay [394]. In general, CI values less than one indicate synergy and above 
one indicate antagonism. The CI algorithm has been used previously to calculate 
the degree of synergy between other drug combinations of chemotherapeutic 
agents [395-398]. Sirtinol was found to synergise with lapatinib, and this was 
most efficacious at the lower concentrations of lapatinib treatment, the 
combination index being 0.42, 0.57 and 0.76 for 1, 5 and 10 µM of lapatinib, 
respectively (Figure 6.10C). It was also noted that EX527 cotreatment with 
lapatinib was not synergistic (Figure 6.11) but antagonistic to the proapoptotic 
potency of lapatinib. This results bears similarity to the experiment where EX527 
was treated in combination with paclitaxel (Figure 3.10), where it protected MCF-
7s from paclitaxel treatment. Highlighting the fact that dual inhibitors, like sirtinol, 
that inhibit more than one sirtuin family member are likely to provide benefit in 
combination.  
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Figure 6.9 Sirtinol synergises with Lapatinib SkBr3 cells were treated with 
increasing concentrations of Sirtinol alone or in combination with lapatinib (1µM) 
for 24 hours. Cell cycle analysis was performed after propidium iodide staining.  
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Figure 6.10 Sirtinol synergises with Lapatinib  A SkBr3 cells were treated with 
0-10µM Lapatinb alone or in combination with 0-50µM of Sirtinol for 24 h. 
Statistical analysis was performed using one way ANOVA (* = p<0.05, ** = 
p<0.01 *** = p<0.001). B SkBr3 cells were treated with 0-100 µM of lapatinib and 
0-500 µM of sirtinol for 24 h.  Cell proliferation was determined by 
sulforhodamine B assay. Results shown are mean ± SD of three independent 
experiments. IC50s were calculated using graphpad (lapatinib = 18.10 µM, 
sirtinol = 69.91) C combination index analysis of lapatinib and sirtinol  treatment. 
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Figure 6.11 EX527 does not synergise with Lapatinib  A SkBr3 cells were 
treated with increasing concentrations of EX527 alone or in combination with 
lapatinib (1µM) for 24 hours. Cell cycle analysis was performed after propidium 
iodide staining. B SkBr3 cells were treated with 0-10µM Lapatinb alone or in 
combination with 0-50µM of EX527 for 24 h. Cell proliferation was determined by 
sulforhodamine B assay. Results shown are mean ± SD of three independent 
experiments. 
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To assess whether this synergism was dependent on the presence of FOXO 
family members, NIH 3T3 WT and FOXO-/- were treated with DMSO, Lapatinib 
(10 µM), sirtinol (40 µM) and in combination for 72 hours, and cell viability was 
accessed using SRB (Figure 6.12A). Lapatinib treatment resulted in a decrease 
in cell viability from 100% (DMSO control) to 84.7%, sirtinol treatment resulted in 
a decrease of viability to 84.4%, but combination resulted in a statistically 
significant (p<0.001) decrease of cell viability to 46.2%, when compared to single 
treatments and the DMSO controls. In the FOXO-/- no statistically significant 
effect on cell viability was observed under any treatment, highlighting the role of 
FOXO proteins in the efficacy of lapatinib and sirtinol treatments and the efficacy 
of combination treatment (Figure 6.12A). 
 
Interestingly, when NIH 3T3 wildtype cells were treated with 0-10 µM of lapatinib 
alone or in combination with 0-100 µM of sirtinol, there was an additive effect 
seen at lower concentrations of sirtinol 0-40 µM but not at higher concentrations. 
(Figure 6.12B) This correlates with the concentrations of sirtinol treatment that 
are dependent on the presence of FOXO proteins to elicit its cytotoxic effect 
(Figure 6.1), reiterating the importance of FOXO3a in the synergism between 
lapatinib and sirtinol. Above 50 µM of sirtinol treatment, other proteins such as 
p53 are activated (see figure from chapter 1) and become the main factor in 
controlling cell fate. Because of this fact I was unable to distinguish the 
synergistic effect of combination treatment in NIH 3T3 cells. But it is interesting to 
note that NIH 3T3 cells do not overexpress EGFR or HER2, the cellular targets of 
lapatinib, meaning sirtinol could increase its efficacy in patients who do not 
display HER2 overexpression or EGFR hyperactivation, meaning combining 
lapatinib with sirtuin inhibitors could display benefit in a wider subset of patients. 
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Figure 6.12 Loss of FOXO reduces the potency of Lapatinib A NIH 3T3 cells 
WT and FOXO null MEFs were treated for 72 hours with 1µM Lapatinib, 30µM of 
Sirtinol and in combination. B NIH 3T3 WT cells were treated for 72 h with 0-10 
µM of lapatinib and 0-100µM of sirtinol and in combination. Cell proliferation was 
determined by sulforhodamine B assay. Results shown are mean ± SD of three 
independent experiments. Statistical analysis was performed using one way 
ANOVA (* = p<0.05, ** = p<0.01 *** = p<0.001). 
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6.3 DISCUSSION 
 
We and others have shown previously the transcription factor FOXO3a to be 
important in the proapoptotic potency of the tyrosine kinase inhibitors gefitinib 
and lapatinib [291-293] We have also shown that sirtinol elicits its induction of 
apoptosis in a p53 dependent manner [316]. Here we show that the cytotoxic 
effect of sirtinol, at low concentrations, is dependent on the presence of FOXO 
family members. Examining this further the effect of sirtinol treatment on 
FOXO3a was found to cause its stabilization, which was independent of mRNA 
expression, meaning sirtinol treatment resulted in the acetylation of FOXO3a and 
its subsequent stabilization. 
 
We then addressed whether the stabilizing effect of sirtinol treatment could 
complement FOXO3a activation. Overexpression of the constitutively active 
(non-phosphorylatable) FOXO3a caused a marked increase in sub G1 cells, 
compared to WT FOXO3a and the 294D mutant (phospho-mimic), which could 
not be stabilized. This observation suggests that the FOXO3a 294D mutant did 
not cause an increase in apoptotic cells when treated with sirtinol because it 
could not be stabilized, meaning the proapoptotic function of sirtinol was due to 
the stabilization and activation of FOXO3a. 
 
The efficacy of targeted therapies such as lapatinib, Gefitinib and Herceptin [102, 
291-293] are directly associated with the expression of FOXO3a. To address the 
hypothesis of whether sirtinol cotreatment could increase the proapoptotic 
potency of lapatinib, we took the ER negative, HER2 overexpressing cell lines 
SkBr3 and treated them with single treatment of laptinib (1µM 0-24 h) sirtinol 
(50µM 0-24 h) and in combination. Lapatinib treatment resulted in the 
dephosphorylation of EGFR, HER2 and AKT, leading to the dephosphorylation 
and subsequent activation of FOXO3a. Sirtinol treatment increases the cellular 
expression of FOXO3a (2.3 times higher than the control), this was independent 
of FOXO3a desphosphorylation of Thr32, suggesting the stabilization of FOXO3a 
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is independent of PI3K signalling cascade. Sirtinol treatment did lead to the 
dephosphorylation of EGFR and HER2, albeit, much slower than is observed 
with lapatinib treatment. Others have shown that SAHA treatment results in 
destabilization of EGFR mRNA resulting in loss of expression [399], we did not 
observe a decrease in protein expression but it does suggest that sirtinol and 
possibly other class III inhibitors have multiple cytotoxic mechanisms, like class I 
and II HDAC inhibitors. 
 
Statistical analysis showed that sirtinol synergised with lapatinib treatment and 
that this synergy was more potent with lower concentrations of lapatinib. This 
reiterates the hypothesis that the cellular availability of the intracellular effector, 
FOXO3a is the factor limiting efficacy of lapatinib treatment, meaning 
combination treatment with sirtuin inhibitors, namely sirtinol, would reduce the 
amount of lapatinib needed, increasing efficacy but reducing toxicity. Also 
performing a dose-titration of lapatinib treatment in SkBr3 cells (0-10 µM for 24 
h), shows a dose dependent increase in FOXO3a expression, but 
dephosphorylation of FOXO3a (Thr32) was observed at 0.1 µM of lapatinib 
treatment suggesting sirtinol treatment is mimicking one of the mechanisms of 
action of lapatinib, meaning less is needed when treated in combination with 
sirtinol. Moreover, SkBr3 cells contain mutant p53, highlighting the fact that the 
proapoptotic potency achieved with combinatorial treatment of lapatinib and 
sirtinol is not a result of p53 induced apoptosis. Also the concentrations used are 
below that which are seen to induce the acetylation of p53 [316], and the effect of 
sirtinol at these concentrations are dependent on the presence of FOXO family 
members. We also tested the ability of EX527 to synergise with lapatinib 
treatment, conversely it was antagonistic of lapatinib treatment, suggesting that a 
dual inhibitor like sirtinol elicits its effect by stabilising its downstream targets 
(p53 and FOXO3a), something EX527 is unable to do because it is inefficient at 
inhibiting multiple sirtuin proteins. 
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Previous publications have highlighted that the acetylation of FOXO1 alters its 
DNA-binding affinity and sensitises it to phosphorylation [400]. These 
publications only assessed lysine residues within the DNA binding domain, not 
regions associated with stability or degradation (294, 388 and 425). This study 
also used a pan sirtuin inhibitor nicotinamide which does not specifically target 
sirtuins but all NAD dependent proteins within the cell. Moreover, they only 
observed an increase in FOXO1 acetylation when cells were treated in 
combination with TSA, the HDAC class I and II inhibitor. Others have also shown 
that forkhead proteins, namely foxP3, can be stabilized with a combination of 
HDAC inhibitors [401], we have show for the first time using a single sirtuin 
inhibitor, sirtinol, can cause the stabilisation of FOXO3a.  
 
Sirtinol treatment also causes the stabilization of p300 (supplemental figure 8.2), 
which could explain for the increased proapoptotic potency of sirtinol. SIRT2 is 
known to regulate the autoacetylation of p300 [402], inhibiting more sirtuins 
results in its own autoactivation and increased interaction with targets such as 
p53 and FOXO3a, eliciting a proapoptotic response. The HDAC class II inhibitor, 
Tricostatin A, has been shown previously to increase the interaction of p300 with 
p53 [403]. 
 
This study supports the use of HDAC class III inhibitors as a viable therapy in 
HER2 overexpressing tumours. p53 mutations are associated with poor clinical 
outcome and are the most frequent cellular event in carcinogenesis [404]. Sirtuin 
inhibitors function dependently and independent of p53 mutations. In patients 
that have mutant p53, sirtinol can be used to increase the efficacy of FOXO3a 
targeting therapy, as well as in WT p53 containing tumours, having its own 
cytotoxic effects. 
 
In this study we show that combining sirtinol with lapatinib, increases its pro-
apoptotic potency and that this increase in potency is due to the stabilization and 
activation of FOXO3a. Recently the interest in developing compounds that effect 
 187 
the translocation of FOXO3a from the cytoplasm to the nucleus and the 
subsequent antiproliferative effect in cancer cell lines has been highlighted [289]. 
But these inhibitors would encounter the same issues as already approved 
therapies. The deregulation of the PI3K pathway traps FOXO3a in the cytoplasm, 
but resistant cells (Figure 4.2) have been associated with an increase in 
phosphyated FOXO3a and reduced total FOXO3a. Sirtuin inhibition with sirtinol 
treatment increases the cellular pool of FOXO3a, independent of AKT 
phosphorylation, increasing the efficacy therapeutic compounds that indirectly 
activate FOXO3a. Developing compounds that have a similar effect on FOXO3a 
would be a more worthy line of research. 
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6.4 FUTURE WORK 
 
Investigating the exact mechanism of action sirtinol treatment has on FOXO3a, 
by cloning FOXO3a acetylatable and non-acetylatable mutants (mutating lysine 
residues to alanines and glutamine). With these tools we would be able to mimic 
the proapoptotic effect sirtinol treatment has on FOXO3a and investigate which 
downstream targets are eliciting the activation of apoptosis and cell death. 
 
During the undertaking of the thesis we also investigated the subset of genes 
that were eliciting the proapoptotic role of FOXO3a but were unable to identify 
the downstream target(s) responsible. To investigate this further, CHIP-seq could 
be used to identify the genes that FOXO3a is binding to under differing treatment 
regimes. Not only would it identify the genes involved but also the promoter 
regions to which FOXO3a is binding to. 
 
Developing compounds that target both EGFR/HER2 and sirtuins and evaluating 
its efficacy compared to established targeted therapies, e.g. lapatinib, gefitinib 
and herceptin. Moreover, evaluating its efficacy in different cell lines (different 
disease types, lung, breast, ovarian and prostate) and all cell lines that are 
resistant to established chemotherapeutic regimes such as tamoxifen and 
aromatase inhibitors. 
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CHAPTER 7 
 
FINAL DISCUSSION 
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7.1 Targeting HDACs in cancer 
 
The study of HDACs has increased exponentially over the last decade, mainly 
due to the discovery of their role in cancer progression, metastasis and the 
development of resistance, but also due to the development of small molecules 
that can specifically target HDACs in vivo influencing their activity.  
 
The most well defined HDAC inhibitor (HDACi) to date is the class I and II small 
molecule inhibitor SAHA (Vorinostat), which was the first to be approved by the 
FDA in 2006 for the treatment of cutaneous T-cell lymphoma (CTCL) [308]. Since 
the approval of SAHA many HDAC inhibitors have entered clinical development, 
the most recent success being Romidepsin (Istodax) which was also approved 
by the FDA for the treatment of CTCL in 2009 [405]. Although clinical trials of 
many compounds are ongoing, currently no HDAC inhibitor has been approved 
for the treatment of solid tumours i.e. breast cancer, and no class III HDAC 
inhibitor has progressed from preclinical research into clinical trials for cancer 
treatment. The compounds cambinol and tenovin-6 have been the most 
rigorously tested sirtuin inhibitors to date, both suppressing tumour growth in 
nude mice xenographed with burkitt lymphoma and human melanoma cells, 
respectively [311, 312]. Although more recently a milestone has been reached of 
testing a sirtuin inhibitor in a clinical setting, the potent SIRT1 inhibitor EX527 
(SEN0014196) entered into a phase I clinical trial for the treatment of 
huntington’s disease early in 2010. Although this study is testing sirtuin inhibition 
in a different disease state, it will provide valuable information about the 
tolerability and toxicity of sirtuin inhibitors in healthy adults, answering concerns 
on issues such as cardiac toxicity, which has been an issue with HDAC class I 
and II inhibitors [308], and could yet prove to be a bump in the road for sirtuin 
inhibitors as a cancer treatment due to the fact that SIRT1,-3 and -7 appear to 
have cardio-protective roles in blocking stress-induced cardiac hypotrophy and 
possibly other stress-related diseases [406]. If proved successful, targeting class 
III HDACs could provide a selective advantage over other family members 
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because class III inhibitors like sirtinol do not affect the class I and II HDACs, and 
the established class I and II inhibitors, like TSA, do not affect Sirtiuns [309].  
 
Most if not all previous publications have elucidated the molecular targets of 
sirtuin inhibitors using combinations of high concentrations of inhibitors, for 
example, nicotinamide and TSA, or in combination with cytotoxic agents like 
etoposide [315]. Although these are valid studies and bring valuable information 
about possible combinatorial therapies that could be used, they skirt around the 
molecular biology of how to specifically target and produce a therapeutic benefit 
from this interesting family of proteins. 
 
An aim of this thesis was to elucidate the mechanism of action of known sirtuin 
inhibitors. With this study I believe it has become apparent that pan sirtuin 
inhibitors, like nicotinamide, that target all sirtuins and any NAD+ dependent 
protein in the cell, only work at high concentrations (in the miliolar range) and do 
not appear to display any benefit. Specifically targeting two or more sirtuins is a 
better but a discernibly more challenging scenario. One, having to decipher the 
exact combination of sirtuins to target, and two, whether using a single inhibitor 
that can specifically target the desired sirtuins and not other family members is 
achievable, or combining specific single inhibitors of each protein is a better and 
more worthwhile approach. Here it has been shown that inhibition of SIRT1 and 
SIRT2 in combination results in the induction of apoptosis, but the cell cycle 
profile is not the same as observed with sirtinol treatment, indicating that their 
inhibition does lead to the induction of apoptosis but that other family members 
should also be inhibited for sirtuin targeted therapies to elicit a more cytotoxic 
effect and a potent induction of apoptosis in cancer cells. 
 
I believe we have shown successfully that the sole targeting of SIRT1 would not 
provide benefit or increased efficacy of known chemotherapeutic compounds, in 
the contrary, it would reduce their proapoptotic potencies and possibly lead to the 
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development of mechanisms of resistance. This conundrum could be responsible 
for the current misunderstanding of the role of sirtuins in cancer cell biology. 
 
Most sirtuin literature is dominated by the question whether SIRT1 is an 
oncogene or tumour suppressor [407-409]. SIRT1 has been shown to be 
upregulated in caloric restriction, extending lifespan and reducing the risk of 
cancer development [236, 238, 410, 411]. But conceptually, if you consider 
cancer, as an entity in itself, a logical step in its development would be to 
upregulate SIRT1 (and other sirtuins) to protect itself from DNA damage from 
genotoxic agents, regulate metabolism and oxidative stress, in an environment 
that is constantly combating the cancer. SIRT1 may suppress tumour formation 
but when a tumour has already developed, increased SIRT1 expression may 
help it to survive. Recently Boily et al [412] showed that sirT1 null mice were not 
prone to cancer formation compared to WT mice, at odds with Wang et al who 
showed that SIRT1 was responsible for chromosomal stability and that SIRT1+/- 
p53+/- mice were more cancer prone than SIRT1 +/+ p53+/- mice. [413] It is 
interesting to note that resveratrol was championed as a possible antitumour 
compound through its action of increasing SIRT1 activity in BRCA1-associated 
breast cancer [414], but Boily et al showed that the antitumour function of 
resveratrol was in part independent of the presence of SIRT1 [412]. Moreover, 
recent publications have shown that resveratrol and its derivatives are not direct 
activators of SIRT1 [330, 344, 415, 416]. This finding buoys our own suspicions 
of the in vitro assays not being the best determinants of compound specificity 
and ability to influence sirtuin protein activity in vivo [316]. They should be used 
in combination with a range of techniques to make sure they concur with in vitro 
and in vivo data. These findings do not detract from the fact that resveratrol does 
exhibit antitumour activity and has displayed benefit [300], but the involvement 
and importance of SIRT1 and other sirtuins in eliciting its antitumour effect needs 
to be more clearly defined.  
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Misunderstandings or misconceptions of the underlying molecular biology of 
sirtuins and their roles in various processes have produced effectively two sides 
of thought, under the banners of tumour suppressor and oncogene, respectively. 
I believe further research is needed to clarify the roles of sirtuins in cancer cell 
biology but increasingly evidence is pointing towards their roles in tumour 
development.  
 
It is important to remember that SIRT2, SIRT3 and SIRT7 have also been shown 
to be upregulated in tumours [300, 307], and that compounds that inhibit more 
than one sirtuin, like sirtinol, cambinol and tenovin-6 appear to be more 
efficacious than single inhibitors like EX527. We confirmed within our own study 
with siRNA targeting SIRT1, SIRT2 and in combination, that both need to be 
inhibited to induce apoptosis, suggesting that there is a certain amount of 
compensation that can occur when only one sirtuin has been targeted. Both 
SIRT1 and SIRT2 are known to regulate the activity of p53 [274, 417] and it is 
easy to imagine a scenario where SIRT1s inhibition results in an increase in 
SIRT2 activity or interaction with p53, deacetylating p53, albeit less efficiently 
than SIRT1, but sufficient enough to cause a different outcome in cell fate, for 
example cell cycle arrest rather than apoptosis. It is possible mechanisms like 
this that make understanding the role of sirtuins in cancer cell biology difficult. 
The overexpression of one specific sirtuin may be sufficient to protect cancer 
cells from chemotoxic agents but the inhibition of two or more is required to 
sensitize cells to cytotoxic compounds. Moreover, the regulation of non-histone 
proteins that are integral to cell cycle regulation and proliferation, like p53 and 
FOXO are key cellular targets of sirtuins and their inhibition with HDAC inhibitors 
results in their stabilization and activation. Interestingly, tenovins were initially 
identified using a cell-based screen analyzing p53 activation [312, 316]. Also, 
within our own study inhibition of SIRT1 with EX527 causes the acetylation of a 
different subset of genes and does not influence the acetylation of p53 on lysine 
382, a marker for p53 activation and induction of apoptosis [418]. Moreover, the 
cytostatic action of EX527 is not dependent upon the presence of wildtype, 
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mutated or the expression of p53, but is dependent on the presence of FOXO 
proteins, supporting the importance of the forkhead transcription factors in 
eliciting the function of sirtuin targeted compounds, be it cytostatic or cytotoxic.  
 
7.2 Sirtuins and chemotherapeutic resistance 
 
I have shown that SIRT1 is important in the development of resistance to 
cisplatin and that SIRT1 overexpression suppresses the activation of FOXO3a. 
SIRT1 has been shown to be upregulated in prostate cancer, suppressing the 
activation of FOXO1. Treatment with SIRT1 targeted siRNA, sirtinol and 
nicotinamide resulted in the reactivation of FOXO1 and induction of a growth 
arrest [419].  
 
Sharma et al strengthen the knowledge of how cancer cells can develop 
resistance that do not involve genetic alterations i.e. mutations, but a small 
percentage of the cell population become ‘drug tolerant persisters’ due to 
changes in chromatin structure [420, 421]. Prolonged exposure to cytotoxic 
agents, such as cisplatin and the targeted therapy gefitinib, led to the 
development of permanently resistant cells. Also, their results showed that a 
decrease in histone acetylation on lysine 16 (H4K16) was involved in the 
development of resistance. H4K16 is known to be one of the main intracellular 
targets regulated by SIRT1 [246, 422] and loss of H4K16 acetylation was shown 
by Fraga et al to be a ‘hallmark of cancer development’ and suggested SIRT1 to 
be the primary culprit for histone acetylation dysregulation in cancer [296]. 
Moreover, these resistant cells could be resensitised to chemotoxic agents by 
combining them with HDAC inhibitors. Extrapolating this to our findings, SIRT1 
could be the first step in the development of resistance and increasing migratory 
potential and metastasis, strengthening the importance of developing HDAC 
targeted therapies. 
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7.3 Combination therapy 
 
It is becoming apparent that combinatorial treatment with targeted therapies can 
increase their efficacy. Combined treatment of trastuzumab (Herceptin) and 
lapatinib has been shown to increase patient free survival in HER2 
overexpressing women with metastatic breast cancer, compared to lapatinib 
treatment alone, despite having disease progression on trastuzumab treatment 
previously [423]. Lapatinib has also been found to increase progression-free 
survival in patients with advanced HER2-postive tumours when given in 
combination with the antimetabolite chemotherapy drug capecitabine (Xeloda) 
compared with capecitabine alone, in patients who had already failed previous 
treatment regimes with anthracyclines, taxanes and trastuzumab [349]. 
 
We and others have shown the importance of FOXO3a in eliciting the 
proapoptotic potency of the targeted therapies, such as lapatinib and gefitinib 
[291-293]. Within this study we forward this knowledge and understanding by 
showing that loss of the FOXO family members is sufficient to confer resistance 
to lapatinib and that the cellular expression of FOXO3a is decreased in lapatinib 
resistant SkBr3 cell lines. More importantly, reinstating FOXO3a expression in 
FOXO-/- MEFs was sufficient to resensitise them to lapatinib treatment, 
strengthening the importance of FOXO3a in mediating the response to lapatinib 
and the therapeutic importance of compounds that can increase the cellular 
expression of FOXO3a, like sirtinol. 
 
It is becoming more apparent that the non-histone targets of sirtuins play an 
important role in the regulation of cell cycle progression, offering something 
different to class I and II HDACs. I believe the future of combinatorial therapy lies 
within the grasp of sirtuins. The development of compounds like CUDC-101 
which combine recent advancements in targeted therapies, with potent HDAC 
class I and II inhibitors, in my opinion, pave the way for the development of novel 
therapies [424]. CUDC-101 is effectively a receptor tyrosine kinase inhibitor 
 196 
fused to a HDAC class I and II inhibitor which displays potent inhibition of EGFR, 
HER2 and HDAC (2.4, 15.7 and 4.4nM, respectively) and is more toxic in cancer 
cell lines that monotreatment of erlotinib, vorinostat, lapatinib and in combination 
[424]. Cai et al. have proven it is possible to combine HDAC inhibitors and 
targeted therapies and still maintain their specific potencies. More recently, 
CUDC-101 has been shown to inhibit proliferation in 54 human cancer cell lines 
(Breast, Pancreatic, Liver, CTCL, Ovarian and more) and be more effective in 
reducing tumour size in a range of tumour types in xenograph models, when 
compared with vorinostat, erlotinib and lapatinib treatment [425]. Because of the 
non-histone targets of sirtuins, namely FOXO3a, and the dependence of sirtuin 
inhibitors like sirtinol on FOXO3a to elicit its cytotoxic activity. A similarly 
designed compound with a sirtuin inhibitor instead of a class I and II inhibitor 
would hypothetically be able to deliver even more therapeutic benefit that CUDC-
101, if sirtuin inhibitors can be shown not to be indirectly toxic to animal models 
and humans. Sirtinol treatment alone results in the stabilization of both FOXO3a 
and p53, increasing their cellular expressions causing the activation of 
proapoptotic pathways [316]. Sirtinol also synergises with lapatinib treatment in a 
FOXO3a dependent mechanism to cause a marked increase in the induction of 
apoptosis in SkBr3 cells. Interestingly, one of the mechanisms of action of 
lapatinib is to cause a dose-dependent increase in FOXO3a expression, yet only 
the lowest concencentration of lapatinib (0.1µM) is required to inhibit the PI3K 
signaling cascade and activate FOXO3a. Essentially I believe lapatinib and 
sirtinol synergise because sirtinol treatment mimics one of the mechanisms of 
action of lapatinib i.e. stabilizing FOXO3a. This means less lapatinib is needed in 
combination treatment compared to lapatinib treatment alone, possibly reducing 
adverse off-target side-effects. To confirm whether sirtinol and lapatinib could be 
combined as one structure, synergy would have to be assessed using 
isobologram analysis, where synergy is calculated using set molar ratios, for 
example L1:S1, L1:S10 etc (L = lapatinib and S- sirtinol). 
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Conceptually, it is interesting to consider the recent research that has shown 
EGFR/HER2 targeted therapies resensitise both HER2 overexpressing and 
HER2 negative tumours to endocrine therapy [11, 426]. Xia et al showed quite 
eloquently that lapatinib treatment resulted in an increase in ER activity which 
was due to the activation of FOXO3a [291]. In this setting, lapatinib treatment is 
shifting HER2 overexpressing tumours back to dependence on ER signaling and 
ER mediated proliferation, promoting tumour survival, and that this shift can be 
exploited therapeutically using endocrine therapy. But essentially what is 
occurring is that FOXO3a is not efficiently activating proapoptotic mechanisms 
inducing apoptosis and cell death, but targets genes that promote survival. 
SIRT1 has been shown to mediate forkhead activity by deacetylating FOXO3a 
resulting in the activation of genes involved in destressing and survival, such as 
mnSOD and catalase [223, 265], and we have shown that SIRT1 is upregulated 
during the development of resistance to cisplatin. In HER2 overexpressing 
tumours, SIRT1 expression is protecting cancer cells from the cytotoxic effects of 
lapatinib by limiting the repertoire of genes that FOXO3a can activate. Inhibiting 
sirtuins with chemical inhibitors would not only have their own cytotoxic function 
but reduce the ability of tumours to upregulate prosurvival mechanism by re-
enabling FOXO3a to activate transcriptional targets involved with a proapoptotic 
response, increasing the efficacy of targeted therapies. Moreover, exploiting 
these mechanisms of resistance with endocrine therapy is only viable when 
tumours shift their dependency back to ER driven proliferation. Recently Turner 
et al have shown that the fibroblast growth factor receptor 1 (FGFR1) is amplified 
in ~10% breast cancer cases and is associated with poorer prognosis and 
resistance to endocrine therapy [13, 427]. If tumours revert to or develop FGFR1-
dependent signaling after lapatinib treatment, then the combination of endocrine 
agents will not have an increased cytotoxic effect, allowing tumours to persist. 
This possible scenario reiterates that increasing the efficacy of targeted therapies 
by modulating FOXO3a expression and activity with HDAC inhibitors could prove 
to be a more successful endeavor, reducing the likelihood of the development of 
resistance, killing tumours outright. 
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I believe that the research undertaken in this thesis does shed light on how 
breast cancer cells develop resistance and the importance sirtuins and FOXO 
family members play in this dynamic process. Furthermore, I believed we have 
shown that this can be exploited therapeutically with small molecule inhibitors. 
Further study is required to explore these research themes, but I believe that it is 
a step – albeit a small one – in improving cancer therapies, leading to the 
ultimate goal of successfully, responsibly and sustainably improving lives. 
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Supplemental Figure 8.1: FOXO3a activation and sirtinol treatment in 
combination do not increase the expression of p27, mnSOD or Bim DL23 
cells expressing a FOXO3a:ER fusion protein we treated with 200nM Tamoxifen, 
25µM sirtinol and in combination for 0-24h. Protein expression was determined 
using western blot. 
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Supplemental Figure 8.2 Sirtinol treatment stabilizes p300 MCF-7 cells were 
treated for 0-8h with CHX and in combination with 25µM sirtinol or the DMSO 
vector control. Protein expression was examined using western blot. 
 
 202 
REFERENCES 
 
1. Parkin, D.M., et al., Global cancer statistics, 2002. CA Cancer J Clin, 
2005. 55(2): p. 74-108. 
2. Ferlay, J., D.M. Parkin, and E. Steliarova-Foucher, Estimates of cancer 
incidence and mortality in Europe in 2008. Eur J Cancer, 2010. 46(4): p. 
765-81. 
3. Wiseman, M., The second World Cancer Research Fund/American 
Institute for Cancer Research expert report. Food, nutrition, physical 
activity, and the prevention of cancer: a global perspective. Proc Nutr Soc, 
2008. 67(3): p. 253-6. 
4. Lynch, H.T., et al., Hereditary breast cancer: part I. Diagnosing hereditary 
breast cancer syndromes. Breast J, 2008. 14(1): p. 3-13. 
5. Miki, Y., et al., A strong candidate for the breast and ovarian cancer 
susceptibility gene BRCA1. Science, 1994. 266(5182): p. 66-71. 
6. Wooster, R., et al., Identification of the breast cancer susceptibility gene 
BRCA2. Nature, 1995. 378(6559): p. 789-92. 
7. Scully, R. and D.M. Livingston, In search of the tumour-suppressor 
functions of BRCA1 and BRCA2. Nature, 2000. 408(6811): p. 429-32. 
8. Hayashi, S.I., et al., The expression and function of estrogen receptor 
alpha and beta in human breast cancer and its clinical application. Endocr 
Relat Cancer, 2003. 10(2): p. 193-202. 
9. Ali, S. and R.C. Coombes, Endocrine-responsive breast cancer and 
strategies for combating resistance. Nat Rev Cancer, 2002. 2(2): p. 101-
12. 
10. Osborne, C.K. and R. Schiff, Estrogen-receptor biology: continuing 
progress and therapeutic implications. J Clin Oncol, 2005. 23(8): p. 1616-
22. 
11. Leary, A.F., et al., Lapatinib restores hormone sensitivity with differential 
effects on estrogen receptor signaling in cell models of human epidermal 
 203 
growth factor receptor 2-negative breast cancer with acquired endocrine 
resistance. Clin Cancer Res, 2010. 16(5): p. 1486-97. 
12. Hanahan, D. and R.A. Weinberg, The hallmarks of cancer. Cell, 2000. 
100(1): p. 57-70. 
13. Turner, N., et al., FGFR1 amplification drives endocrine therapy resistance 
and is a therapeutic target in breast cancer. Cancer Res, 2010. 70(5): p. 
2085-94. 
14. Slamon, D.J., et al., Human breast cancer: correlation of relapse and 
survival with amplification of the HER-2/neu oncogene. Science, 1987. 
235(4785): p. 177-82. 
15. Lane, D.P., Cancer. p53, guardian of the genome. Nature, 1992. 
358(6381): p. 15-6. 
16. Efeyan, A. and M. Serrano, p53: guardian of the genome and policeman 
of the oncogenes. Cell Cycle, 2007. 6(9): p. 1006-10. 
17. Soussi, T., et al., Locus-specific mutation databases: pitfalls and good 
practice based on the p53 experience. Nat Rev Cancer, 2006. 6(1): p. 83-
90. 
18. Moll, U.M., et al., Transcription-independent pro-apoptotic functions of 
p53. Curr Opin Cell Biol, 2005. 17(6): p. 631-6. 
19. Carter, S. and K.H. Vousden, Modifications of p53: competing for the 
lysines. Curr Opin Genet Dev, 2009. 19(1): p. 18-24. 
20. Abbas, T. and A. Dutta, p21 in cancer: intricate networks and multiple 
activities. Nat Rev Cancer, 2009. 9(6): p. 400-14. 
21. Kortlever, R.M., P.J. Higgins, and R. Bernards, Plasminogen activator 
inhibitor-1 is a critical downstream target of p53 in the induction of 
replicative senescence. Nat Cell Biol, 2006. 8(8): p. 877-84. 
22. Crighton, D., et al., DRAM, a p53-induced modulator of autophagy, is 
critical for apoptosis. Cell, 2006. 126(1): p. 121-34. 
23. Rouault, J.P., et al., Identification of BTG2, an antiproliferative p53-
dependent component of the DNA damage cellular response pathway. Nat 
Genet, 1996. 14(4): p. 482-6. 
 204 
24. Villunger, A., et al., p53- and drug-induced apoptotic responses mediated 
by BH3-only proteins puma and noxa. Science, 2003. 302(5647): p. 1036-
8. 
25. Sax, J.K., et al., BID regulation by p53 contributes to chemosensitivity. Nat 
Cell Biol, 2002. 4(11): p. 842-9. 
26. Lee, S.B., et al., Destabilization of CHK2 by a missense mutation 
associated with Li-Fraumeni Syndrome. Cancer Res, 2001. 61(22): p. 
8062-7. 
27. Danovi, D., et al., Amplification of Mdmx (or Mdm4) directly contributes to 
tumor formation by inhibiting p53 tumor suppressor activity. Mol Cell Biol, 
2004. 24(13): p. 5835-43. 
28. Vousden, K.H., Activation of the p53 tumor suppressor protein. Biochim 
Biophys Acta, 2002. 1602(1): p. 47-59. 
29. Vassilev, L.T., MDM2 inhibitors for cancer therapy. Trends Mol Med, 2007. 
13(1): p. 23-31. 
30. Batchelor, E., A. Loewer, and G. Lahav, The ups and downs of p53: 
understanding protein dynamics in single cells. Nat Rev Cancer, 2009. 
9(5): p. 371-7. 
31. Momand, J., et al., The MDM2 gene amplification database. Nucleic Acids 
Res, 1998. 26(15): p. 3453-9. 
32. Klein, C. and L.T. Vassilev, Targeting the p53-MDM2 interaction to treat 
cancer. Br J Cancer, 2004. 91(8): p. 1415-9. 
33. Tovar, C., et al., Small-molecule MDM2 antagonists reveal aberrant p53 
signaling in cancer: implications for therapy. Proc Natl Acad Sci U S A, 
2006. 103(6): p. 1888-93. 
34. Vousden, K.H. and X. Lu, Live or let die: the cell's response to p53. Nat 
Rev Cancer, 2002. 2(8): p. 594-604. 
35. Brown, C.J., et al., Awakening guardian angels: drugging the p53 
pathway. Nat Rev Cancer, 2009. 9(12): p. 862-73. 
36. Tang, Y., et al., Acetylation is indispensable for p53 activation. Cell, 2008. 
133(4): p. 612-26. 
 205 
37. Malumbres, M. and M. Barbacid, Cell cycle, CDKs and cancer: a changing 
paradigm. Nat Rev Cancer, 2009. 9(3): p. 153-66. 
38. Park, M.T. and S.J. Lee, Cell cycle and cancer. J Biochem Mol Biol, 2003. 
36(1): p. 60-5. 
39. Collins, K., T. Jacks, and N.P. Pavletich, The cell cycle and cancer. Proc 
Natl Acad Sci U S A, 1997. 94(7): p. 2776-8. 
40. Vermeulen, K., D.R. Van Bockstaele, and Z.N. Berneman, The cell cycle: 
a review of regulation, deregulation and therapeutic targets in cancer. Cell 
Prolif, 2003. 36(3): p. 131-49. 
41. Satyanarayana, C.R., et al., Influence of the genetic polymorphisms in the 
5' flanking and exonic regions of CYP2C19 on proguanil oxidation. Drug 
Metab Pharmacokinet, 2009. 24(6): p. 537-48. 
42. Malumbres, M. and M. Barbacid, Mammalian cyclin-dependent kinases. 
Trends Biochem Sci, 2005. 30(11): p. 630-41. 
43. Sherr, C.J. and J.M. Roberts, CDK inhibitors: positive and negative 
regulators of G1-phase progression. Genes Dev, 1999. 13(12): p. 1501-
12. 
44. Giacinti, C. and A. Giordano, RB and cell cycle progression. Oncogene, 
2006. 25(38): p. 5220-7. 
45. Malumbres, M. and M. Barbacid, Cell cycle kinases in cancer. Curr Opin 
Genet Dev, 2007. 17(1): p. 60-5. 
46. Besson, A., S.F. Dowdy, and J.M. Roberts, CDK inhibitors: cell cycle 
regulators and beyond. Dev Cell, 2008. 14(2): p. 159-69. 
47. Lukas, J., C. Lukas, and J. Bartek, Mammalian cell cycle checkpoints: 
signalling pathways and their organization in space and time. DNA Repair 
(Amst), 2004. 3(8-9): p. 997-1007. 
48. Maddika, S., et al., Cell survival, cell death and cell cycle pathways are 
interconnected: implications for cancer therapy. Drug Resist Updat, 2007. 
10(1-2): p. 13-29. 
49. Elmore, S., Apoptosis: a review of programmed cell death. Toxicol Pathol, 
2007. 35(4): p. 495-516. 
 206 
50. Meier, P., A. Finch, and G. Evan, Apoptosis in development. Nature, 2000. 
407(6805): p. 796-801. 
51. Cotter, T.G., Apoptosis and cancer: the genesis of a research field. Nat 
Rev Cancer, 2009. 9(7): p. 501-7. 
52. Cohen, G.M., Caspases: the executioners of apoptosis. Biochem J, 1997. 
326 ( Pt 1): p. 1-16. 
53. Igney, F.H. and P.H. Krammer, Death and anti-death: tumour resistance to 
apoptosis. Nat Rev Cancer, 2002. 2(4): p. 277-88. 
54. Kischkel, F.C., et al., Cytotoxicity-dependent APO-1 (Fas/CD95)-
associated proteins form a death-inducing signaling complex (DISC) with 
the receptor. EMBO J, 1995. 14(22): p. 5579-88. 
55. Gross, A., J.M. McDonnell, and S.J. Korsmeyer, BCL-2 family members 
and the mitochondria in apoptosis. Genes Dev, 1999. 13(15): p. 1899-911. 
56. Wei, M.C., et al., Proapoptotic BAX and BAK: a requisite gateway to 
mitochondrial dysfunction and death. Science, 2001. 292(5517): p. 727-
30. 
57. Brunelle, J.K. and A. Letai, Control of mitochondrial apoptosis by the Bcl-2 
family. J Cell Sci, 2009. 122(Pt 4): p. 437-41. 
58. Porter, A.G. and R.U. Janicke, Emerging roles of caspase-3 in apoptosis. 
Cell Death Differ, 1999. 6(2): p. 99-104. 
59. Walsh, J.G., et al., Executioner caspase-3 and caspase-7 are functionally 
distinct proteases. Proc Natl Acad Sci U S A, 2008. 105(35): p. 12815-9. 
60. Matalova, E., et al., Molar tooth development in caspase-3 deficient mice. 
Int J Dev Biol, 2006. 50(5): p. 491-7. 
61. Janicke, R.U., et al., Caspase-3 is required for DNA fragmentation and 
morphological changes associated with apoptosis. J Biol Chem, 1998. 
273(16): p. 9357-60. 
62. Enari, M., et al., A caspase-activated DNase that degrades DNA during 
apoptosis, and its inhibitor ICAD. Nature, 1998. 391(6662): p. 43-50. 
 207 
63. Zhang, J., et al., Resistance to DNA fragmentation and chromatin 
condensation in mice lacking the DNA fragmentation factor 45. Proc Natl 
Acad Sci U S A, 1998. 95(21): p. 12480-5. 
64. Ura, S., et al., Caspase cleavage of MST1 promotes nuclear translocation 
and chromatin condensation. Proc Natl Acad Sci U S A, 2001. 98(18): p. 
10148-53. 
65. Taylor, R.C., S.P. Cullen, and S.J. Martin, Apoptosis: controlled demolition 
at the cellular level. Nat Rev Mol Cell Biol, 2008. 9(3): p. 231-41. 
66. Jaattela, M., Multiple cell death pathways as regulators of tumour initiation 
and progression. Oncogene, 2004. 23(16): p. 2746-56. 
67. Rodriguez-Viciana, P., et al., Phosphatidylinositol-3-OH kinase as a direct 
target of Ras. Nature, 1994. 370(6490): p. 527-32. 
68. Schubbert, S., K. Shannon, and G. Bollag, Hyperactive Ras in 
developmental disorders and cancer. Nat Rev Cancer, 2007. 7(4): p. 295-
308. 
69. Tidyman, W.E. and K.A. Rauen, The RASopathies: developmental 
syndromes of Ras/MAPK pathway dysregulation. Curr Opin Genet Dev, 
2009. 19(3): p. 230-6. 
70. Shaw, R.J. and L.C. Cantley, Ras, PI(3)K and mTOR signalling controls 
tumour cell growth. Nature, 2006. 441(7092): p. 424-30. 
71. Engelman, J.A., J. Luo, and L.C. Cantley, The evolution of 
phosphatidylinositol 3-kinases as regulators of growth and metabolism. 
Nat Rev Genet, 2006. 7(8): p. 606-19. 
72. Djordjevic, S. and P.C. Driscoll, Structural insight into substrate specificity 
and regulatory mechanisms of phosphoinositide 3-kinases. Trends 
Biochem Sci, 2002. 27(8): p. 426-32. 
73. Vivanco, I. and C.L. Sawyers, The phosphatidylinositol 3-Kinase AKT 
pathway in human cancer. Nat Rev Cancer, 2002. 2(7): p. 489-501. 
74. Maiese, K., Z.Z. Chong, and Y.C. Shang, OutFOXOing disease and 
disability: the therapeutic potential of targeting FoxO proteins. Trends Mol 
Med, 2008. 14(5): p. 219-27. 
 208 
75. Toker, A. and A.C. Newton, Cellular signaling: pivoting around PDK-1. 
Cell, 2000. 103(2): p. 185-8. 
76. Fu, Z., et al., Plk1-dependent phosphorylation of FoxM1 regulates a 
transcriptional programme required for mitotic progression. Nat Cell Biol, 
2008. 10(9): p. 1076-82. 
77. Engelman, J.A., Targeting PI3K signalling in cancer: opportunities, 
challenges and limitations. Nat Rev Cancer, 2009. 9(8): p. 550-62. 
78. Jacinto, E., et al., SIN1/MIP1 maintains rictor-mTOR complex integrity and 
regulates Akt phosphorylation and substrate specificity. Cell, 2006. 127(1): 
p. 125-37. 
79. Mora, A., et al., PDK1, the master regulator of AGC kinase signal 
transduction. Semin Cell Dev Biol, 2004. 15(2): p. 161-70. 
80. Parker, P.J. and S.J. Parkinson, AGC protein kinase phosphorylation and 
protein kinase C. Biochem Soc Trans, 2001. 29(Pt 6): p. 860-3. 
81. Alessi, D.R., et al., Mechanism of activation of protein kinase B by insulin 
and IGF-1. EMBO J, 1996. 15(23): p. 6541-51. 
82. Scheid, M.P., P.A. Marignani, and J.R. Woodgett, Multiple 
phosphoinositide 3-kinase-dependent steps in activation of protein kinase 
B. Mol Cell Biol, 2002. 22(17): p. 6247-60. 
83. Guertin, D.A., et al., Ablation in mice of the mTORC components raptor, 
rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-
FOXO and PKCalpha, but not S6K1. Dev Cell, 2006. 11(6): p. 859-71. 
84. Brunet, A., et al., Akt promotes cell survival by phosphorylating and 
inhibiting a Forkhead transcription factor. Cell, 1999. 96(6): p. 857-68. 
85. Toker, A. and M. Yoeli-Lerner, Akt signaling and cancer: surviving but not 
moving on. Cancer Res, 2006. 66(8): p. 3963-6. 
86. Kumar, C.C. and V. Madison, AKT crystal structure and AKT-specific 
inhibitors. Oncogene, 2005. 24(50): p. 7493-501. 
87. Franke, T.F., PI3K/Akt: getting it right matters. Oncogene, 2008. 27(50): p. 
6473-88. 
 209 
88. Datta, S.R., et al., Akt phosphorylation of BAD couples survival signals to 
the cell-intrinsic death machinery. Cell, 1997. 91(2): p. 231-41. 
89. Mayo, L.D. and D.B. Donner, A phosphatidylinositol 3-kinase/Akt pathway 
promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc 
Natl Acad Sci U S A, 2001. 98(20): p. 11598-603. 
90. Alessi, D.R., et al., Molecular basis for the substrate specificity of protein 
kinase B; comparison with MAPKAP kinase-1 and p70 S6 kinase. FEBS 
Lett, 1996. 399(3): p. 333-8. 
91. Manning, B.D. and L.C. Cantley, AKT/PKB signaling: navigating 
downstream. Cell, 2007. 129(7): p. 1261-74. 
92. Liu, Q., et al., SHIP is a negative regulator of growth factor receptor-
mediated PKB/Akt activation and myeloid cell survival. Genes Dev, 1999. 
13(7): p. 786-91. 
93. Wisniewski, D., et al., A novel SH2-containing phosphatidylinositol 3,4,5-
trisphosphate 5-phosphatase (SHIP2) is constitutively tyrosine 
phosphorylated and associated with src homologous and collagen gene 
(SHC) in chronic myelogenous leukemia progenitor cells. Blood, 1999. 
93(8): p. 2707-20. 
94. Olayioye, M.A., et al., The ErbB signaling network: receptor 
heterodimerization in development and cancer. EMBO J, 2000. 19(13): p. 
3159-67. 
95. Wheeler, D.L., E.F. Dunn, and P.M. Harari, Understanding resistance to 
EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin 
Oncol, 2010. 
96. Hynes, N.E. and H.A. Lane, ERBB receptors and cancer: the complexity 
of targeted inhibitors. Nat Rev Cancer, 2005. 5(5): p. 341-54. 
97. Ciardiello, F., Epidermal growth factor receptor inhibitors in cancer 
treatment. Future Oncol, 2005. 1(2): p. 221-34. 
98. McGovern, U.B., et al., Gefitinib (Iressa) represses FOXM1 expression via 
FOXO3a in breast cancer. Mol Cancer Ther, 2009. 8(3): p. 582-91. 
 210 
99. Klijn, J.G., et al., The clinical significance of epidermal growth factor 
receptor (EGF-R) in human breast cancer: a review on 5232 patients. 
Endocr Rev, 1992. 13(1): p. 3-17. 
100. Sordella, R., et al., Gefitinib-sensitizing EGFR mutations in lung cancer 
activate anti-apoptotic pathways. Science, 2004. 305(5687): p. 1163-7. 
101. Kosaka, T., et al., Mutations of the epidermal growth factor receptor gene 
in lung cancer: biological and clinical implications. Cancer Res, 2004. 
64(24): p. 8919-23. 
102. Real, P.J., et al., Blockade of epidermal growth factor receptors 
chemosensitizes breast cancer cells through up-regulation of Bnip3L. 
Cancer Res, 2005. 65(18): p. 8151-7. 
103. Muller, W.J., et al., Single-step induction of mammary adenocarcinoma in 
transgenic mice bearing the activated c-neu oncogene. Cell, 1988. 54(1): 
p. 105-15. 
104. Finkle, D., et al., HER2-targeted therapy reduces incidence and 
progression of midlife mammary tumors in female murine mammary tumor 
virus huHER2-transgenic mice. Clin Cancer Res, 2004. 10(7): p. 2499-
511. 
105. Ursini-Siegel, J., et al., Insights from transgenic mouse models of ERBB2-
induced breast cancer. Nat Rev Cancer, 2007. 7(5): p. 389-97. 
106. Baselga, J. and S.M. Swain, Novel anticancer targets: revisiting ERBB2 
and discovering ERBB3. Nat Rev Cancer, 2009. 9(7): p. 463-75. 
107. Ellis, M.J., et al., Estrogen-independent proliferation is present in 
estrogen-receptor HER2-positive primary breast cancer after neoadjuvant 
letrozole. J Clin Oncol, 2006. 24(19): p. 3019-25. 
108. De Laurentiis, M., et al., A meta-analysis on the interaction between HER-
2 expression and response to endocrine treatment in advanced breast 
cancer. Clin Cancer Res, 2005. 11(13): p. 4741-8. 
109. Ramjaun, A.R. and J. Downward, Ras and phosphoinositide 3-kinase: 
partners in development and tumorigenesis. Cell Cycle, 2007. 6(23): p. 
2902-5. 
 211 
110. Konstantinopoulos, P.A., M.V. Karamouzis, and A.G. Papavassiliou, Post-
translational modifications and regulation of the RAS superfamily of 
GTPases as anticancer targets. Nat Rev Drug Discov, 2007. 6(7): p. 541-
55. 
111. Bachman, K.E., et al., The PIK3CA gene is mutated with high frequency in 
human breast cancers. Cancer Biol Ther, 2004. 3(8): p. 772-5. 
112. Zhao, L. and P.K. Vogt, Class I PI3K in oncogenic cellular transformation. 
Oncogene, 2008. 27(41): p. 5486-96. 
113. Miron, A., et al., PIK3CA mutations in in situ and invasive breast 
carcinomas. Cancer Res, 2010. 70(14): p. 5674-8. 
114. Luo, J., B.D. Manning, and L.C. Cantley, Targeting the PI3K-Akt pathway 
in human cancer: rationale and promise. Cancer Cell, 2003. 4(4): p. 257-
62. 
115. Li, J., et al., PTEN, a putative protein tyrosine phosphatase gene mutated 
in human brain, breast, and prostate cancer. Science, 1997. 275(5308): p. 
1943-7. 
116. Hao, Z.M., et al., Design of a ribozyme targeting human telomerase 
reverse transcriptase and cloning of it's gene. World J Gastroenterol, 
2003. 9(1): p. 104-7. 
117. Riegert-Johnson, D.L., et al., Cancer and Lhermitte-Duclos disease are 
common in Cowden syndrome patients. Hered Cancer Clin Pract, 2010. 
8(1): p. 6. 
118. Schrager, C.A., et al., Clinical and pathological features of breast disease 
in Cowden's syndrome: an underrecognized syndrome with an increased 
risk of breast cancer. Hum Pathol, 1998. 29(1): p. 47-53. 
119. Simpson, L. and R. Parsons, PTEN: life as a tumor suppressor. Exp Cell 
Res, 2001. 264(1): p. 29-41. 
120. Depowski, P.L., S.I. Rosenthal, and J.S. Ross, Loss of expression of the 
PTEN gene protein product is associated with poor outcome in breast 
cancer. Mod Pathol, 2001. 14(7): p. 672-6. 
 212 
121. Carpten, J.D., et al., A transforming mutation in the pleckstrin homology 
domain of AKT1 in cancer. Nature, 2007. 448(7152): p. 439-44. 
122. Maroulakou, I.G., et al., Akt1 ablation inhibits, whereas Akt2 ablation 
accelerates, the development of mammary adenocarcinomas in mouse 
mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T 
transgenic mice. Cancer Res, 2007. 67(1): p. 167-77. 
123. Dillon, R.L., et al., Akt1 and akt2 play distinct roles in the initiation and 
metastatic phases of mammary tumor progression. Cancer Res, 2009. 
69(12): p. 5057-64. 
124. Burgering, B.M., A brief introduction to FOXOlogy. Oncogene, 2008. 
27(16): p. 2258-62. 
125. Weigel, D., et al., The homeotic gene fork head encodes a nuclear protein 
and is expressed in the terminal regions of the Drosophila embryo. Cell, 
1989. 57(4): p. 645-58. 
126. Myatt, S.S. and E.W. Lam, The emerging roles of forkhead box (Fox) 
proteins in cancer. Nat Rev Cancer, 2007. 7(11): p. 847-59. 
127. Kaestner, K.H., W. Knochel, and D.E. Martinez, Unified nomenclature for 
the winged helix/forkhead transcription factors. Genes Dev, 2000. 14(2): p. 
142-6. 
128. Carlsson, P. and M. Mahlapuu, Forkhead transcription factors: key players 
in development and metabolism. Dev Biol, 2002. 250(1): p. 1-23. 
129. Hayashi, H. and T. Kume, Foxc2 transcription factor as a regulator of 
angiogenesis via induction of integrin beta3 expression. Cell Adh Migr, 
2009. 3(1): p. 24-6. 
130. Tammela, T., T.V. Petrova, and K. Alitalo, Molecular lymphangiogenesis: 
new players. Trends Cell Biol, 2005. 15(8): p. 434-41. 
131. Hayashi, H., et al., The Foxc2 transcription factor regulates angiogenesis 
via induction of integrin beta3 expression. J Biol Chem, 2008. 283(35): p. 
23791-800. 
 213 
132. Mani, S.A., et al., Mesenchyme Forkhead 1 (FOXC2) plays a key role in 
metastasis and is associated with aggressive basal-like breast cancers. 
Proc Natl Acad Sci U S A, 2007. 104(24): p. 10069-74. 
133. Alderton, G.K., Metastasis: Regressing to self-renewal. Nat Rev Cancer, 
2008. 8(7): p. 483-483. 
134. Kim, I.M., et al., The Forkhead Box m1 transcription factor stimulates the 
proliferation of tumor cells during development of lung cancer. Cancer 
Res, 2006. 66(4): p. 2153-61. 
135. Costa, R.H., FoxM1 dances with mitosis. Nat Cell Biol, 2005. 7(2): p. 108-
10. 
136. Major, M.L., R. Lepe, and R.H. Costa, Forkhead box M1B transcriptional 
activity requires binding of Cdk-cyclin complexes for phosphorylation-
dependent recruitment of p300/CBP coactivators. Mol Cell Biol, 2004. 
24(7): p. 2649-61. 
137. Wang, X., N.J. Hung, and R.H. Costa, Earlier expression of the 
transcription factor HFH-11B diminishes induction of p21(CIP1/WAF1) 
levels and accelerates mouse hepatocyte entry into S-phase following 
carbon tetrachloride liver injury. Hepatology, 2001. 33(6): p. 1404-14. 
138. Wang, X., et al., Increased hepatic Forkhead Box M1B (FoxM1B) levels in 
old-aged mice stimulated liver regeneration through diminished p27Kip1 
protein levels and increased Cdc25B expression. J Biol Chem, 2002. 
277(46): p. 44310-6. 
139. Ma, R.Y., et al., Raf/MEK/MAPK signaling stimulates the nuclear 
translocation and transactivating activity of FOXM1c. J Cell Sci, 2005. 
118(Pt 4): p. 795-806. 
140. Korver, W., et al., Uncoupling of S phase and mitosis in cardiomyocytes 
and hepatocytes lacking the winged-helix transcription factor Trident. Curr 
Biol, 1998. 8(24): p. 1327-30. 
141. Kwok, J.M., et al., Thiostrepton selectively targets breast cancer cells 
through inhibition of forkhead box M1 expression. Mol Cancer Ther, 2008. 
7(7): p. 2022-32. 
 214 
142. van der Horst, A. and B.M. Burgering, Stressing the role of FoxO proteins 
in lifespan and disease. Nat Rev Mol Cell Biol, 2007. 8(6): p. 440-50. 
143. Greer, E.L. and A. Brunet, FOXO transcription factors at the interface 
between longevity and tumor suppression. Oncogene, 2005. 24(50): p. 
7410-25. 
144. Furuyama, T., et al., Identification of the differential distribution patterns of 
mRNAs and consensus binding sequences for mouse DAF-16 
homologues. Biochem J, 2000. 349(Pt 2): p. 629-34. 
145. Ramaswamy, S., et al., A novel mechanism of gene regulation and tumor 
suppression by the transcription factor FKHR. Cancer Cell, 2002. 2(1): p. 
81-91. 
146. Essers, M.A., et al., FOXO transcription factor activation by oxidative 
stress mediated by the small GTPase Ral and JNK. EMBO J, 2004. 
23(24): p. 4802-12. 
147. Olmos, Y., et al., Mutual dependence of Foxo3a and PGC-1alpha in the 
induction of oxidative stress genes. J Biol Chem, 2009. 284(21): p. 14476-
84. 
148. Benhar, M., D. Engelberg, and A. Levitzki, ROS, stress-activated kinases 
and stress signaling in cancer. EMBO Rep, 2002. 3(5): p. 420-5. 
149. Honda, Y., M. Tanaka, and S. Honda, Redox regulation, gene expression 
and longevity. Geriatr Gerontol Int, 2010. 10 Suppl 1: p. S59-69. 
150. Honda, Y. and S. Honda, The daf-2 gene network for longevity regulates 
oxidative stress resistance and Mn-superoxide dismutase gene 
expression in Caenorhabditis elegans. FASEB J, 1999. 13(11): p. 1385-
93. 
151. Kops, G.J., et al., Forkhead transcription factor FOXO3a protects 
quiescent cells from oxidative stress. Nature, 2002. 419(6904): p. 316-21. 
152. Burgering, B.M. and G.J. Kops, Cell cycle and death control: long live 
Forkheads. Trends Biochem Sci, 2002. 27(7): p. 352-60. 
153. Liu, J.W., et al., Induction of prosurvival molecules by apoptotic stimuli: 
involvement of FOXO3a and ROS. Oncogene, 2005. 24(12): p. 2020-31. 
 215 
154. Taub, J., et al., A cytosolic catalase is needed to extend adult lifespan in 
C. elegans daf-C and clk-1 mutants. Nature, 1999. 399(6732): p. 162-6. 
155. Trachootham, D., J. Alexandre, and P. Huang, Targeting cancer cells by 
ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev 
Drug Discov, 2009. 8(7): p. 579-91. 
156. Nemoto, S. and T. Finkel, Redox regulation of forkhead proteins through a 
p66shc-dependent signaling pathway. Science, 2002. 295(5564): p. 2450-
2. 
157. Brenkman, A.B. and B.M. Burgering, FoxO3a eggs on fertility and aging. 
Trends Mol Med, 2003. 9(11): p. 464-7. 
158. Tothova, Z., et al., FoxOs are critical mediators of hematopoietic stem cell 
resistance to physiologic oxidative stress. Cell, 2007. 128(2): p. 325-39. 
159. Liebermann, D.A. and B. Hoffman, Myeloid differentiation (MyD)/growth 
arrest DNA damage (GADD) genes in tumor suppression, immunity and 
inflammation. Leukemia, 2002. 16(4): p. 527-41. 
160. Alekseyev, A.B., H.P. Liebermann, and R.J. Buenker, Spin-orbit 
configuration interaction study of the ultraviolet photofragmentation of 
XeH+. Phys Chem Chem Phys, 2008. 10(37): p. 5706-13. 
161. Tran, H., et al., DNA repair pathway stimulated by the forkhead 
transcription factor FOXO3a through the Gadd45 protein. Science, 2002. 
296(5567): p. 530-4. 
162. Furukawa-Hibi, Y., et al., FOXO forkhead transcription factors induce 
G(2)-M checkpoint in response to oxidative stress. J Biol Chem, 2002. 
277(30): p. 26729-32. 
163. van der Vos, K.E. and P.J. Coffer, The extending network of FOXO 
transcriptional target genes. Antioxid Redox Signal, 2010. 
164. Seoane, J., et al., Integration of Smad and forkhead pathways in the 
control of neuroepithelial and glioblastoma cell proliferation. Cell, 2004. 
117(2): p. 211-23. 
 216 
165. Medema, R.H., et al., AFX-like Forkhead transcription factors mediate cell-
cycle regulation by Ras and PKB through p27kip1. Nature, 2000. 
404(6779): p. 782-7. 
166. Yang, H., et al., Constitutively active FOXO4 inhibits Akt activity, regulates 
p27 Kip1 stability, and suppresses HER2-mediated tumorigenicity. 
Oncogene, 2005. 24(11): p. 1924-35. 
167. Dansen, T.B. and B.M. Burgering, Unravelling the tumor-suppressive 
functions of FOXO proteins. Trends Cell Biol, 2008. 18(9): p. 421-9. 
168. Dijkers, P.F., et al., Forkhead transcription factor FKHR-L1 modulates 
cytokine-dependent transcriptional regulation of p27(KIP1). Mol Cell Biol, 
2000. 20(24): p. 9138-48. 
169. Stahl, M., et al., The forkhead transcription factor FoxO regulates 
transcription of p27Kip1 and Bim in response to IL-2. J Immunol, 2002. 
168(10): p. 5024-31. 
170. Kops, G.J., et al., Control of cell cycle exit and entry by protein kinase B-
regulated forkhead transcription factors. Mol Cell Biol, 2002. 22(7): p. 
2025-36. 
171. Schmidt, M., et al., Cell cycle inhibition by FoxO forkhead transcription 
factors involves downregulation of cyclin D. Mol Cell Biol, 2002. 22(22): p. 
7842-52. 
172. Hotchkiss, R.S. and D.W. Nicholson, Apoptosis and caspases regulate 
death and inflammation in sepsis. Nat Rev Immunol, 2006. 6(11): p. 813-
22. 
173. Modur, V., et al., FOXO proteins regulate tumor necrosis factor-related 
apoptosis inducing ligand expression. Implications for PTEN mutation in 
prostate cancer. J Biol Chem, 2002. 277(49): p. 47928-37. 
174. Mellier, G., et al., TRAILing death in cancer. Mol Aspects Med, 2010. 
31(1): p. 93-112. 
175. You, H., et al., FOXO3a-dependent regulation of Puma in response to 
cytokine/growth factor withdrawal. J Exp Med, 2006. 203(7): p. 1657-63. 
 217 
176. Dijkers, P.F., et al., Expression of the pro-apoptotic Bcl-2 family member 
Bim is regulated by the forkhead transcription factor FKHR-L1. Curr Biol, 
2000. 10(19): p. 1201-4. 
177. Bouillet, P., et al., Proapoptotic Bcl-2 relative Bim required for certain 
apoptotic responses, leukocyte homeostasis, and to preclude 
autoimmunity. Science, 1999. 286(5445): p. 1735-8. 
178. Gilley, J., P.J. Coffer, and J. Ham, FOXO transcription factors directly 
activate bim gene expression and promote apoptosis in sympathetic 
neurons. J Cell Biol, 2003. 162(4): p. 613-22. 
179. Urbich, C., et al., FOXO-dependent expression of the proapoptotic protein 
Bim: pivotal role for apoptosis signaling in endothelial progenitor cells. 
FASEB J, 2005. 19(8): p. 974-6. 
180. Yang, J.Y., W. Xia, and M.C. Hu, Ionizing radiation activates expression of 
FOXO3a, Fas ligand, and Bim, and induces cell apoptosis. Int J Oncol, 
2006. 29(3): p. 643-8. 
181. Chen, J., O. Odenike, and J.D. Rowley, Leukaemogenesis: more than 
mutant genes. Nat Rev Cancer, 2010. 10(1): p. 23-36. 
182. Essafi, A., et al., Direct transcriptional regulation of Bim by FoxO3a 
mediates STI571-induced apoptosis in Bcr-Abl-expressing cells. 
Oncogene, 2005. 24(14): p. 2317-29. 
183. Sunters, A., et al., FoxO3a transcriptional regulation of Bim controls 
apoptosis in paclitaxel-treated breast cancer cell lines. J Biol Chem, 2003. 
278(50): p. 49795-805. 
184. You, H., K. Yamamoto, and T.W. Mak, Regulation of transactivation-
independent proapoptotic activity of p53 by FOXO3a. Proc Natl Acad Sci 
U S A, 2006. 103(24): p. 9051-6. 
185. Cory, S., D.C. Huang, and J.M. Adams, The Bcl-2 family: roles in cell 
survival and oncogenesis. Oncogene, 2003. 22(53): p. 8590-607. 
186. Yang, J.Y. and M.C. Hung, A new fork for clinical application: targeting 
forkhead transcription factors in cancer. Clin Cancer Res, 2009. 15(3): p. 
752-7. 
 218 
187. Zhao, X., et al., Multiple elements regulate nuclear/cytoplasmic shuttling of 
FOXO1: characterization of phosphorylation- and 14-3-3-dependent and -
independent mechanisms. Biochem J, 2004. 378(Pt 3): p. 839-49. 
188. Rinner, O., et al., An integrated mass spectrometric and computational 
framework for the analysis of protein interaction networks. Nat Biotechnol, 
2007. 25(3): p. 345-52. 
189. Brunet, A., et al., 14-3-3 transits to the nucleus and participates in 
dynamic nucleocytoplasmic transport. J Cell Biol, 2002. 156(5): p. 817-28. 
190. Hu, M.C., et al., IkappaB kinase promotes tumorigenesis through inhibition 
of forkhead FOXO3a. Cell, 2004. 117(2): p. 225-37. 
191. Arden, K.C., FoxO: linking new signaling pathways. Mol Cell, 2004. 14(4): 
p. 416-8. 
192. Novak, K., Right place, wrong time. Nat Rev Cancer, 2004. 4(6): p. 421-
421. 
193. Yang, J.Y., et al., ERK promotes tumorigenesis by inhibiting FOXO3a via 
MDM2-mediated degradation. Nat Cell Biol, 2008. 10(2): p. 138-48. 
194. Vogt, P.K., H. Jiang, and M. Aoki, Triple layer control: phosphorylation, 
acetylation and ubiquitination of FOXO proteins. Cell Cycle, 2005. 4(7): p. 
908-13. 
195. Nakayama, K.I. and K. Nakayama, Ubiquitin ligases: cell-cycle control and 
cancer. Nat Rev Cancer, 2006. 6(5): p. 369-81. 
196. Adams, J., The proteasome: a suitable antineoplastic target. Nat Rev 
Cancer, 2004. 4(5): p. 349-60. 
197. Reits, E.A., et al., Dynamics of proteasome distribution in living cells. 
EMBO J, 1997. 16(20): p. 6087-94. 
198. Huang, H., et al., Skp2 inhibits FOXO1 in tumor suppression through 
ubiquitin-mediated degradation. Proc Natl Acad Sci U S A, 2005. 102(5): 
p. 1649-54. 
199. Plas, D.R. and C.B. Thompson, Akt activation promotes degradation of 
tuberin and FOXO3a via the proteasome. J Biol Chem, 2003. 278(14): p. 
12361-6. 
 219 
200. van der Horst, A., et al., FOXO4 transcriptional activity is regulated by 
monoubiquitination and USP7/HAUSP. Nat Cell Biol, 2006. 8(10): p. 1064-
73. 
201. Li, M., et al., Deubiquitination of p53 by HAUSP is an important pathway 
for p53 stabilization. Nature, 2002. 416(6881): p. 648-53. 
202. Li, M., et al., A dynamic role of HAUSP in the p53-Mdm2 pathway. Mol 
Cell, 2004. 13(6): p. 879-86. 
203. Zhao, Y., et al., Anti-neoplastic activity of the cytosolic FoxO1 results from 
autophagic cell death. Autophagy, 2010. 6(7). 
204. Medema, R.H. and M. Jaattela, Cytosolic FoxO1: alive and killing. Nat Cell 
Biol, 2010. 12(7): p. 642-3. 
205. Lin, H.Y., et al., Targeting histone deacetylase in cancer therapy. Med Res 
Rev, 2006. 26(4): p. 397-413. 
206. Liu, L., et al., Leptin increases in Vogt-Koyanagi-Harada (VKH) disease 
and promotes cell proliferation and inflammatory cytokine secretion. Br J 
Ophthalmol, 2008. 92(4): p. 557-61. 
207. Kornberg, R.D. and Y. Lorch, Twenty-five years of the nucleosome, 
fundamental particle of the eukaryote chromosome. Cell, 1999. 98(3): p. 
285-94. 
208. Gregory, P.D., K. Wagner, and W. Horz, Histone acetylation and 
chromatin remodeling. Exp Cell Res, 2001. 265(2): p. 195-202. 
209. Marks, P., et al., Histone deacetylases and cancer: causes and therapies. 
Nat Rev Cancer, 2001. 1(3): p. 194-202. 
210. Struhl, K., Histone acetylation and transcriptional regulatory mechanisms. 
Genes Dev, 1998. 12(5): p. 599-606. 
211. Kouzarides, T., Chromatin modifications and their function. Cell, 2007. 
128(4): p. 693-705. 
212. Gu, W. and R.G. Roeder, Activation of p53 sequence-specific DNA 
binding by acetylation of the p53 C-terminal domain. Cell, 1997. 90(4): p. 
595-606. 
 220 
213. Stimson, L. and N.B. La Thangue, Biomarkers for predicting clinical 
responses to HDAC inhibitors. Cancer Lett, 2009. 280(2): p. 177-83. 
214. Lei, W.W., et al., Histone deacetylase 1 and 2 differentially regulate 
apoptosis by opposing effects on extracellular signal-regulated kinase 1/2. 
Cell Death and Dis, 2010. 1: p. e44. 
215. Grzenda, A., et al., Sin3: master scaffold and transcriptional corepressor. 
Biochim Biophys Acta, 2009. 1789(6-8): p. 443-50. 
216. Le Guezennec, X., G. Vriend, and H.G. Stunnenberg, Molecular 
determinants of the interaction of Mad with the PAH2 domain of mSin3. J 
Biol Chem, 2004. 279(24): p. 25823-9. 
217. Laherty, C.D., et al., Histone deacetylases associated with the mSin3 
corepressor mediate mad transcriptional repression. Cell, 1997. 89(3): p. 
349-56. 
218. Berger, S.L., The complex language of chromatin regulation during 
transcription. Nature, 2007. 447(7143): p. 407-12. 
219. Yang, X.J. and E. Seto, Collaborative spirit of histone deacetylases in 
regulating chromatin structure and gene expression. Curr Opin Genet 
Dev, 2003. 13(2): p. 143-53. 
220. Gray, S.G. and T.J. Ekstrom, The human histone deacetylase family. Exp 
Cell Res, 2001. 262(2): p. 75-83. 
221. Dalvai, M. and K. Bystricky, The role of histone modifications and variants 
in regulating gene expression in breast cancer. J Mammary Gland Biol 
Neoplasia, 2010. 15(1): p. 19-33. 
222. Luo, J., et al., Negative control of p53 by Sir2alpha promotes cell survival 
under stress. Cell, 2001. 107(2): p. 137-48. 
223. Brunet, A., et al., Stress-dependent regulation of FOXO transcription 
factors by the SIRT1 deacetylase. Science, 2004. 303(5666): p. 2011-5. 
224. Jeong, J., et al., SIRT1 promotes DNA repair activity and deacetylation of 
Ku70. Exp Mol Med, 2007. 39(1): p. 8-13. 
225. Frye, R.A., Characterization of five human cDNAs with homology to the 
yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may 
 221 
have protein ADP-ribosyltransferase activity. Biochem Biophys Res 
Commun, 1999. 260(1): p. 273-9. 
226. Liszt, G., et al., Mouse Sir2 homolog SIRT6 is a nuclear ADP-
ribosyltransferase. J Biol Chem, 2005. 280(22): p. 21313-20. 
227. Dryden, S.C., et al., Role for human SIRT2 NAD-dependent deacetylase 
activity in control of mitotic exit in the cell cycle. Mol Cell Biol, 2003. 23(9): 
p. 3173-85. 
228. Abramov, A.Y., et al., Influence of plant terpenoids on the permeability of 
mitochondria and lipid bilayers. Biochim Biophys Acta, 2001. 1512(1): p. 
98-110. 
229. Michishita, E., et al., Evolutionarily conserved and nonconserved cellular 
localizations and functions of human SIRT proteins. Mol Biol Cell, 2005. 
16(10): p. 4623-35. 
230. Vaquero, A., et al., SIRT1 regulates the histone methyl-transferase 
SUV39H1 during heterochromatin formation. Nature, 2007. 450(7168): p. 
440-4. 
231. Spange, S., et al., Acetylation of non-histone proteins modulates cellular 
signalling at multiple levels. Int J Biochem Cell Biol, 2009. 41(1): p. 185-
98. 
232. Yamamoto, H., K. Schoonjans, and J. Auwerx, Sirtuin functions in health 
and disease. Mol Endocrinol, 2007. 21(8): p. 1745-55. 
233. Kaeberlein, M., M. McVey, and L. Guarente, The SIR2/3/4 complex and 
SIR2 alone promote longevity in Saccharomyces cerevisiae by two 
different mechanisms. Genes Dev, 1999. 13(19): p. 2570-80. 
234. Tissenbaum, H.A. and L. Guarente, Increased dosage of a sir-2 gene 
extends lifespan in Caenorhabditis elegans. Nature, 2001. 410(6825): p. 
227-30. 
235. Bordone, L., et al., SIRT1 transgenic mice show phenotypes resembling 
calorie restriction. Aging Cell, 2007. 6(6): p. 759-67. 
236. Boily, G., et al., SirT1 regulates energy metabolism and response to 
caloric restriction in mice. PLoS One, 2008. 3(3): p. e1759. 
 222 
237. Alcain, F.J. and J.M. Villalba, Sirtuin inhibitors. Expert Opin Ther Pat, 
2009. 19(3): p. 283-94. 
238. Kolas, N.K. and P.E. Cohen, Novel and diverse functions of the DNA 
mismatch repair family in mammalian meiosis and recombination. 
Cytogenet Genome Res, 2004. 107(3-4): p. 216-31. 
239. Shogren-Knaak, M., et al., Histone H4-K16 acetylation controls chromatin 
structure and protein interactions. Science, 2006. 311(5762): p. 844-7. 
240. Hajji, N., et al., Opposing effects of hMOF and SIRT1 on H4K16 
acetylation and the sensitivity to the topoisomerase II inhibitor etoposide. 
Oncogene, 2010. 29(15): p. 2192-204. 
241. Vaziri, H., et al., hSIR2(SIRT1) functions as an NAD-dependent p53 
deacetylase. Cell, 2001. 107(2): p. 149-59. 
242. Yamaguchi, H., et al., p53 acetylation is crucial for its transcription-
independent proapoptotic functions. J Biol Chem, 2009. 284(17): p. 
11171-83. 
243. North, B.J., et al., The human Sir2 ortholog, SIRT2, is an NAD+-
dependent tubulin deacetylase. Mol Cell, 2003. 11(2): p. 437-44. 
244. Vaquero, A., et al., SirT2 is a histone deacetylase with preference for 
histone H4 Lys 16 during mitosis. Genes Dev, 2006. 20(10): p. 1256-61. 
245. Feige, J.N. and J. Auwerx, Transcriptional targets of sirtuins in the 
coordination of mammalian physiology. Curr Opin Cell Biol, 2008. 20(3): p. 
303-9. 
246. Vaquero, A., R. Sternglanz, and D. Reinberg, NAD+-dependent 
deacetylation of H4 lysine 16 by class III HDACs. Oncogene, 2007. 
26(37): p. 5505-20. 
247. Kim, S.C., et al., Substrate and functional diversity of lysine acetylation 
revealed by a proteomics survey. Mol Cell, 2006. 23(4): p. 607-18. 
248. Hallows, W.C., B.N. Albaugh, and J.M. Denu, Where in the cell is SIRT3?-
-functional localization of an NAD+-dependent protein deacetylase. 
Biochem J, 2008. 411(2): p. e11-3. 
 223 
249. Huang, J.Y., et al., Mitochondrial sirtuins. Biochim Biophys Acta, 2010. 
1804(8): p. 1645-51. 
250. Schwer, B., et al., Reversible lysine acetylation controls the activity of the 
mitochondrial enzyme acetyl-CoA synthetase 2. Proc Natl Acad Sci U S A, 
2006. 103(27): p. 10224-9. 
251. Schwer, B. and E. Verdin, Conserved metabolic regulatory functions of 
sirtuins. Cell Metab, 2008. 7(2): p. 104-12. 
252. Ahn, B.H., et al., A role for the mitochondrial deacetylase Sirt3 in 
regulating energy homeostasis. Proc Natl Acad Sci U S A, 2008. 105(38): 
p. 14447-52. 
253. Yang, H., et al., Nutrient-sensitive mitochondrial NAD+ levels dictate cell 
survival. Cell, 2007. 130(6): p. 1095-107. 
254. Ahuja, N., et al., Regulation of insulin secretion by SIRT4, a mitochondrial 
ADP-ribosyltransferase. J Biol Chem, 2007. 282(46): p. 33583-92. 
255. Haigis, M.C., et al., SIRT4 inhibits glutamate dehydrogenase and opposes 
the effects of calorie restriction in pancreatic beta cells. Cell, 2006. 126(5): 
p. 941-54. 
256. North, B.J., et al., Preparation of enzymatically active recombinant class III 
protein deacetylases. Methods, 2005. 36(4): p. 338-45. 
257. Nakagawa, T., et al., SIRT5 Deacetylates carbamoyl phosphate 
synthetase 1 and regulates the urea cycle. Cell, 2009. 137(3): p. 560-70. 
258. Haigis, M.C. and D.A. Sinclair, Mammalian sirtuins: biological insights and 
disease relevance. Annu Rev Pathol, 2010. 5: p. 253-95. 
259. Mostoslavsky, R., et al., Genomic instability and aging-like phenotype in 
the absence of mammalian SIRT6. Cell, 2006. 124(2): p. 315-29. 
260. Michishita, E., et al., SIRT6 is a histone H3 lysine 9 deacetylase that 
modulates telomeric chromatin. Nature, 2008. 452(7186): p. 492-6. 
261. Kawahara, T.L., et al., SIRT6 links histone H3 lysine 9 deacetylation to 
NF-kappaB-dependent gene expression and organismal life span. Cell, 
2009. 136(1): p. 62-74. 
 224 
262. Vakhrusheva, O., et al., Sirt7 increases stress resistance of 
cardiomyocytes and prevents apoptosis and inflammatory cardiomyopathy 
in mice. Circ Res, 2008. 102(6): p. 703-10. 
263. Ford, E., et al., Mammalian Sir2 homolog SIRT7 is an activator of RNA 
polymerase I transcription. Genes Dev, 2006. 20(9): p. 1075-80. 
264. Muth, V., et al., Acetylation of TAF(I)68, a subunit of TIF-IB/SL1, activates 
RNA polymerase I transcription. EMBO J, 2001. 20(6): p. 1353-62. 
265. Motta, M.C., et al., Mammalian SIRT1 represses forkhead transcription 
factors. Cell, 2004. 116(4): p. 551-63. 
266. van der Horst, A., et al., FOXO4 is acetylated upon peroxide stress and 
deacetylated by the longevity protein hSir2(SIRT1). J Biol Chem, 2004. 
279(28): p. 28873-9. 
267. Daitoku, H., et al., Silent information regulator 2 potentiates Foxo1-
mediated transcription through its deacetylase activity. Proc Natl Acad Sci 
U S A, 2004. 101(27): p. 10042-7. 
268. Matsuzaki, H., et al., Acetylation of Foxo1 alters its DNA-binding ability 
and sensitivity to phosphorylation. Proc Natl Acad Sci U S A, 2005. 
102(32): p. 11278-83. 
269. Wang, F., et al., SIRT2 deacetylates FOXO3a in response to oxidative 
stress and caloric restriction. Aging Cell, 2007. 6(4): p. 505-14. 
270. Jacobs, K.M., et al., SIRT3 interacts with the daf-16 homolog FOXO3a in 
the mitochondria, as well as increases FOXO3a dependent gene 
expression. Int J Biol Sci, 2008. 4(5): p. 291-9. 
271. Sundaresan, N.R., et al., Sirt3 blocks the cardiac hypertrophic response 
by augmenting Foxo3a-dependent antioxidant defense mechanisms in 
mice. J Clin Invest, 2009. 119(9): p. 2758-71. 
272. Li, S., et al., p53-induced growth arrest is regulated by the mitochondrial 
SirT3 deacetylase. PLoS One, 2010. 5(5): p. e10486. 
273. Zhang, Y., et al., Identification of a small molecule SIRT2 inhibitor with 
selective tumor cytotoxicity. Biochem Biophys Res Commun, 2009. 
386(4): p. 729-33. 
 225 
274. Langley, E., et al., Human SIR2 deacetylates p53 and antagonizes 
PML/p53-induced cellular senescence. EMBO J, 2002. 21(10): p. 2383-
96. 
275. Yang, Y., et al., Acetylation of FoxO1 activates Bim expression to induce 
apoptosis in response to histone deacetylase inhibitor depsipeptide 
treatment. Neoplasia, 2009. 11(4): p. 313-24. 
276. Kitamura, Y.I., et al., FoxO1 protects against pancreatic beta cell failure 
through NeuroD and MafA induction. Cell Metab, 2005. 2(3): p. 153-63. 
277. Takahashi, Y., et al., PML nuclear bodies and apoptosis. Oncogene, 2004. 
23(16): p. 2819-24. 
278. Smith, G.R. and D.P. Shanley, Modelling the response of FOXO 
transcription factors to multiple post-translational modifications made by 
ageing-related signalling pathways. PLoS One, 2010. 5(6): p. e11092. 
279. Robson, E.J., S.J. He, and M.R. Eccles, A PANorama of PAX genes in 
cancer and development. Nat Rev Cancer, 2006. 6(1): p. 52-62. 
280. van der Vos, K.E. and P.J. Coffer, FOXO-binding partners: it takes two to 
tango. Oncogene, 2008. 27(16): p. 2289-99. 
281. Dong, X.Y., et al., FOXO1A is a candidate for the 13q14 tumor suppressor 
gene inhibiting androgen receptor signaling in prostate cancer. Cancer 
Res, 2006. 66(14): p. 6998-7006. 
282. Linardic, C.M., et al., The PAX3-FKHR fusion gene of rhabdomyosarcoma 
cooperates with loss of p16INK4A to promote bypass of cellular 
senescence. Cancer Res, 2007. 67(14): p. 6691-9. 
283. Paik, J.H., et al., FoxOs are lineage-restricted redundant tumor 
suppressors and regulate endothelial cell homeostasis. Cell, 2007. 128(2): 
p. 309-23. 
284. Zanella, F., et al., Human TRIB2 is a repressor of FOXO that contributes 
to the malignant phenotype of melanoma cells. Oncogene, 2010. 29(20): 
p. 2973-82. 
 226 
285. Mikse, O.R., et al., FOXO3 encodes a carcinogen-activated transcription 
factor frequently deleted in early-stage lung adenocarcinoma. Cancer Res, 
2010. 70(15): p. 6205-15. 
286. Lynch, R.L., et al., The progression of LNCaP human prostate cancer cells 
to androgen independence involves decreased FOXO3a expression and 
reduced p27KIP1 promoter transactivation. Mol Cancer Res, 2005. 3(3): p. 
163-9. 
287. Shukla, S., et al., Deregulation of FOXO3A during prostate cancer 
progression. Int J Oncol, 2009. 34(6): p. 1613-20. 
288. Nakamura, N., et al., Forkhead transcription factors are critical effectors of 
cell death and cell cycle arrest downstream of PTEN. Mol Cell Biol, 2000. 
20(23): p. 8969-82. 
289. Link, K.H. and R.R. Breaker, In vitro selection of glmS ribozymes. 
Methods Mol Biol, 2009. 540: p. 349-64. 
290. Rusnak, D.W., et al., The effects of the novel, reversible epidermal growth 
factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of 
human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer 
Ther, 2001. 1(2): p. 85-94. 
291. Xia, W., et al., A model of acquired autoresistance to a potent ErbB2 
tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in 
breast cancer. Proc Natl Acad Sci U S A, 2006. 103(20): p. 7795-800. 
292. Krol, J., et al., The transcription factor FOXO3a is a crucial cellular target 
of gefitinib (Iressa) in breast cancer cells. Mol Cancer Ther, 2007. 6(12 Pt 
1): p. 3169-79. 
293. Hegde, P.S., et al., Delineation of molecular mechanisms of sensitivity to 
lapatinib in breast cancer cell lines using global gene expression profiles. 
Mol Cancer Ther, 2007. 6(5): p. 1629-40. 
294. Johnston, S., et al., Lapatinib combined with letrozole versus letrozole and 
placebo as first-line therapy for postmenopausal hormone receptor-
positive metastatic breast cancer. J Clin Oncol, 2009. 27(33): p. 5538-46. 
 227 
295. Johnston, S.R., New strategies in estrogen receptor-positive breast 
cancer. Clin Cancer Res, 2010. 16(7): p. 1979-87. 
296. Fraga, M.F., et al., Loss of acetylation at Lys16 and trimethylation at 
Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet, 
2005. 37(4): p. 391-400. 
297. Suzuki, K. and T. Koike, Mammalian Sir2-related protein (SIRT) 2-
mediated modulation of resistance to axonal degeneration in slow 
Wallerian degeneration mice: a crucial role of tubulin deacetylation. 
Neuroscience, 2007. 147(3): p. 599-612. 
298. Imai, S., et al., Transcriptional silencing and longevity protein Sir2 is an 
NAD-dependent histone deacetylase. Nature, 2000. 403(6771): p. 795-
800. 
299. Weichert, W., HDAC expression and clinical prognosis in human 
malignancies. Cancer Lett, 2009. 280(2): p. 168-76. 
300. Saunders, L.R. and E. Verdin, Sirtuins: critical regulators at the crossroads 
between cancer and aging. Oncogene, 2007. 26(37): p. 5489-504. 
301. Wales, M.M., et al., p53 activates expression of HIC-1, a new candidate 
tumour suppressor gene on 17p13.3. Nat Med, 1995. 1(6): p. 570-7. 
302. Chen, W.Y., et al., Tumor suppressor HIC1 directly regulates SIRT1 to 
modulate p53-dependent DNA-damage responses. Cell, 2005. 123(3): p. 
437-48. 
303. Sundararajan, R., et al., Caspase-dependent processing activates the 
proapoptotic activity of deleted in breast cancer-1 during tumor necrosis 
factor-alpha-mediated death signaling. Oncogene, 2005. 24(31): p. 4908-
20. 
304. Kim, J.E., J. Chen, and Z. Lou, DBC1 is a negative regulator of SIRT1. 
Nature, 2008. 451(7178): p. 583-6. 
305. Kim, E.J., et al., Active regulator of SIRT1 cooperates with SIRT1 and 
facilitates suppression of p53 activity. Mol Cell, 2007. 28(2): p. 277-90. 
 228 
306. Yang, Y., et al., SIRT1 sumoylation regulates its deacetylase activity and 
cellular response to genotoxic stress. Nat Cell Biol, 2007. 9(11): p. 1253-
62. 
307. Ashraf, N., et al., Altered sirtuin expression is associated with node-
positive breast cancer. Br J Cancer, 2006. 95(8): p. 1056-61. 
308. Garber, K., HDAC inhibitors overcome first hurdle. Nat Biotechnol, 2007. 
25(1): p. 17-9. 
309. Grozinger, C.M., et al., Identification of a class of small molecule inhibitors 
of the sirtuin family of NAD-dependent deacetylases by phenotypic 
screening. J Biol Chem, 2001. 276(42): p. 38837-43. 
310. Medda, F., et al., Novel cambinol analogs as sirtuin inhibitors: synthesis, 
biological evaluation, and rationalization of activity. J Med Chem, 2009. 
52(9): p. 2673-82. 
311. Heltweg, B., et al., Antitumor activity of a small-molecule inhibitor of 
human silent information regulator 2 enzymes. Cancer Res, 2006. 66(8): 
p. 4368-77. 
312. Lain, S., et al., Discovery, in vivo activity, and mechanism of action of a 
small-molecule p53 activator. Cancer Cell, 2008. 13(5): p. 454-63. 
313. Ota, H., et al., Sirt1 inhibitor, Sirtinol, induces senescence-like growth 
arrest with attenuated Ras-MAPK signaling in human cancer cells. 
Oncogene, 2006. 25(2): p. 176-85. 
314. Kojima, K., et al., A role for SIRT1 in cell growth and chemoresistance in 
prostate cancer PC3 and DU145 cells. Biochem Biophys Res Commun, 
2008. 373(3): p. 423-8. 
315. Solomon, J.M., et al., Inhibition of SIRT1 catalytic activity increases p53 
acetylation but does not alter cell survival following DNA damage. Mol Cell 
Biol, 2006. 26(1): p. 28-38. 
316. Peck, B., et al., SIRT inhibitors induce cell death and p53 acetylation 
through targeting both SIRT1 and SIRT2. Mol Cancer Ther, 2010. 9(4): p. 
844-55. 
 229 
317. Bitterman, K.J., et al., Inhibition of silencing and accelerated aging by 
nicotinamide, a putative negative regulator of yeast sir2 and human 
SIRT1. J Biol Chem, 2002. 277(47): p. 45099-107. 
318. Kelley, L.A. and M.J. Sternberg, Protein structure prediction on the Web: a 
case study using the Phyre server. Nat Protoc, 2009. 4(3): p. 363-71. 
319. Schuttelkopf, A.W. and D.M. van Aalten, PRODRG: a tool for high-
throughput crystallography of protein-ligand complexes. Acta Crystallogr D 
Biol Crystallogr, 2004. 60(Pt 8): p. 1355-63. 
320. Rao, S.N., et al., Validation studies of the site-directed docking program 
LibDock. J Chem Inf Model, 2007. 47(6): p. 2159-71. 
321. Lara, E., et al., Salermide, a Sirtuin inhibitor with a strong cancer-specific 
proapoptotic effect. Oncogene, 2009. 28(6): p. 781-91. 
322. Krammer, A., et al., LigScore: a novel scoring function for predicting 
binding affinities. J Mol Graph Model, 2005. 23(5): p. 395-407. 
323. Vichai, V. and K. Kirtikara, Sulforhodamine B colorimetric assay for 
cytotoxicity screening. Nat Protoc, 2006. 1(3): p. 1112-6. 
324. Krug, U., A. Ganser, and H.P. Koeffler, Tumor suppressor genes in normal 
and malignant hematopoiesis. Oncogene, 2002. 21(21): p. 3475-95. 
325. Blander, G. and L. Guarente, The Sir2 family of protein deacetylases. 
Annu Rev Biochem, 2004. 73: p. 417-35. 
326. Rogina, B. and S.L. Helfand, Sir2 mediates longevity in the fly through a 
pathway related to calorie restriction. Proc Natl Acad Sci U S A, 2004. 
101(45): p. 15998-6003. 
327. Gorospe, M. and R. de Cabo, AsSIRTing the DNA damage response. 
Trends Cell Biol, 2008. 18(2): p. 77-83. 
328. Guarente, L. and F. Picard, Calorie restriction--the SIR2 connection. Cell, 
2005. 120(4): p. 473-82. 
329. Longo, V.D. and B.K. Kennedy, Sirtuins in aging and age-related disease. 
Cell, 2006. 126(2): p. 257-68. 
330. Kennedy, B.K., E.D. Smith, and M. Kaeberlein, The enigmatic role of Sir2 
in aging. Cell, 2005. 123(4): p. 548-50. 
 230 
331. Vaquero, A., et al., Human SirT1 interacts with histone H1 and promotes 
formation of facultative heterochromatin. Mol Cell, 2004. 16(1): p. 93-105. 
332. Luo, J., et al., Deacetylation of p53 modulates its effect on cell growth and 
apoptosis. Nature, 2000. 408(6810): p. 377-81. 
333. Yeung, F., et al., Modulation of NF-kappaB-dependent transcription and 
cell survival by the SIRT1 deacetylase. Embo J, 2004. 23(12): p. 2369-80. 
334. Bouras, T., et al., SIRT1 deacetylation and repression of p300 involves 
lysine residues 1020/1024 within the cell cycle regulatory domain 1. J Biol 
Chem, 2005. 280(11): p. 10264-76. 
335. North, B.J. and E. Verdin, Interphase nucleo-cytoplasmic shuttling and 
localization of SIRT2 during mitosis. PLoS One, 2007. 2(8): p. e784. 
336. Fraga, M.F. and M. Esteller, Epigenetics and aging: the targets and the 
marks. Trends Genet, 2007. 23(8): p. 413-8. 
337. Fraga, M.F., R. Agrelo, and M. Esteller, Cross-talk between aging and 
cancer: the epigenetic language. Ann N Y Acad Sci, 2007. 1100: p. 60-74. 
338. Lim, C.S., Human SIRT1: a potential biomarker for tumorigenesis? Cell 
Biol Int, 2007. 31(6): p. 636-7. 
339. Matsushita, N., et al., Role of NAD-dependent deacetylases SIRT1 and 
SIRT2 in radiation and cisplatin-induced cell death in vertebrate cells. 
Genes Cells, 2005. 10(4): p. 321-32. 
340. Napper, A.D., et al., Discovery of indoles as potent and selective inhibitors 
of the deacetylase SIRT1. J Med Chem, 2005. 48(25): p. 8045-54. 
341. Runnebaum, I.B., et al., Mutations in p53 as potential molecular markers 
for human breast cancer. Proc Natl Acad Sci U S A, 1991. 88(23): p. 
10657-61. 
342. North, B.J. and E. Verdin, Mitotic regulation of SIRT2 by cyclin-dependent 
kinase 1-dependent phosphorylation. J Biol Chem, 2007. 282(27): p. 
19546-55. 
343. Huhtiniemi, T., et al., Comparative and pharmacophore model for 
deacetylase SIRT1. J Comput Aided Mol Des, 2006. 20(9): p. 589-99. 
 231 
344. Pacholec, M., et al., SRT1720, SRT2183, SRT1460, and resveratrol are 
not direct activators of SIRT1. J Biol Chem, 2010. 285(11): p. 8340-51. 
345. Vousden, K.H. and D.P. Lane, p53 in health and disease. Nat Rev Mol 
Cell Biol, 2007. 8(4): p. 275-83. 
346. Kamel, C., et al., SirT1 fails to affect p53-mediated biological functions. 
Aging Cell, 2006. 5(1): p. 81-8. 
347. Mutoh, T., et al., Ion heating and high-energy-particle production by ion-
cyclotron heating in the large helical device. Phys Rev Lett, 2000. 85(21): 
p. 4530-3. 
348. Xia, W., et al., Anti-tumor activity of GW572016: a dual tyrosine kinase 
inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 
and AKT pathways. Oncogene, 2002. 21(41): p. 6255-63. 
349. Geyer, C.E., et al., Lapatinib plus capecitabine for HER2-positive 
advanced breast cancer. N Engl J Med, 2006. 355(26): p. 2733-43. 
350. Johnston, S.R., et al., Integration of signal transduction inhibitors with 
endocrine therapy: an approach to overcoming hormone resistance in 
breast cancer. Clin Cancer Res, 2003. 9(1 Pt 2): p. 524S-32S. 
351. Pasqualone, A., et al., Effectiveness of microsatellite DNA markers in 
checking the identity of protected designation of origin extra virgin olive oil. 
J Agric Food Chem, 2007. 55(10): p. 3857-62. 
352. Lam, E.W., R.E. Francis, and M. Petkovic, FOXO transcription factors: key 
regulators of cell fate. Biochem Soc Trans, 2006. 34(Pt 5): p. 722-6. 
353. Cahill, C.M., et al., Phosphatidylinositol 3-kinase signaling inhibits DAF-16 
DNA binding and function via 14-3-3-dependent and 14-3-3-independent 
pathways. J Biol Chem, 2001. 276(16): p. 13402-10. 
354. Fei, M., et al., Low expression of Foxo3a is associated with poor 
prognosis in ovarian cancer patients. Cancer Invest, 2009. 27(1): p. 52-9. 
355. Kornblau, S.M., et al., Highly Phosphorylated FOXO3A Is an Adverse 
Prognostic Factor in Acute Myeloid Leukemia. Clin Cancer Res. 
 232 
356. Hui, R.C., et al., Doxorubicin activates FOXO3a to induce the expression 
of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells. Mol 
Cancer Ther, 2008. 7(3): p. 670-8. 
357. Arden, K.C., FOXO animal models reveal a variety of diverse roles for 
FOXO transcription factors. Oncogene, 2008. 27(16): p. 2345-50. 
358. Liu, L., et al., Novel mechanism of lapatinib resistance in HER2-positive 
breast tumor cells: activation of AXL. Cancer Res, 2009. 69(17): p. 6871-
8. 
359. Yin, L., L. Huang, and D. Kufe, MUC1 oncoprotein activates the FOXO3a 
transcription factor in a survival response to oxidative stress. J Biol Chem, 
2004. 279(44): p. 45721-7. 
360. Herzog, C.R., et al., FoxO3a gene is a target of deletion in mouse lung 
adenocarcinoma. Oncol Rep, 2009. 22(4): p. 837-43. 
361. Birkenkamp, K.U., et al., FOXO3a induces differentiation of Bcr-Abl-
transformed cells through transcriptional down-regulation of Id1. J Biol 
Chem, 2007. 282(4): p. 2211-20. 
362. Mayer, I.A. and C.L. Arteaga, Does Lapatinib Work against HER2-
negative Breast Cancers? Clin Cancer Res, 2010. 16(5): p. 1355-7. 
363. Untch, M. and G. von Minckwitz, Recent advances in systemic therapy: 
advances in neoadjuvant (primary) systemic therapy with cytotoxic agents. 
Breast Cancer Res, 2009. 11(2): p. 203. 
364. Sunters, A., et al., Paclitaxel-induced nuclear translocation of FOXO3a in 
breast cancer cells is mediated by c-Jun NH2-terminal kinase and Akt. 
Cancer Res, 2006. 66(1): p. 212-20. 
365. Kelland, L., The resurgence of platinum-based cancer chemotherapy. Nat 
Rev Cancer, 2007. 7(8): p. 573-84. 
366. Go, R.S. and A.A. Adjei, Review of the comparative pharmacology and 
clinical activity of cisplatin and carboplatin. J Clin Oncol, 1999. 17(1): p. 
409-22. 
 233 
367. Kreike, B., et al., Gene expression profiling and histopathological 
characterization of triple-negative/basal-like breast carcinomas. Breast 
Cancer Res, 2007. 9(5): p. R65. 
368. Silver, D.P., et al., Efficacy of neoadjuvant Cisplatin in triple-negative 
breast cancer. J Clin Oncol, 2010. 28(7): p. 1145-53. 
369. Koshy, N., et al., Cisplatin-gemcitabine therapy in metastatic breast 
cancer: Improved outcome in triple negative breast cancer patients 
compared to non-triple negative patients. Breast, 2010. 
370. Siddik, Z.H., Cisplatin: mode of cytotoxic action and molecular basis of 
resistance. Oncogene, 2003. 22(47): p. 7265-79. 
371. Stordal, B. and M. Davey, Understanding cisplatin resistance using 
cellular models. IUBMB Life, 2007. 59(11): p. 696-9. 
372. Stewart, D.J., Mechanisms of resistance to cisplatin and carboplatin. Crit 
Rev Oncol Hematol, 2007. 63(1): p. 12-31. 
373. Eckstein, N., et al., Epidermal growth factor receptor pathway analysis 
identifies amphiregulin as a key factor for cisplatin resistance of human 
breast cancer cells. J Biol Chem, 2008. 283(2): p. 739-50. 
374. Bu, Y., et al., Knockdown of Dicer in MCF-7 human breast carcinoma cells 
results in G1 arrest and increased sensitivity to cisplatin. Oncol Rep, 2009. 
21(1): p. 13-7. 
375. Yde, C.W. and O.G. Issinger, Enhancing cisplatin sensitivity in MCF-7 
human breast cancer cells by down-regulation of Bcl-2 and cyclin D1. Int J 
Oncol, 2006. 29(6): p. 1397-404. 
376. Arimoto-Ishida, E., et al., Inhibition of phosphorylation of a forkhead 
transcription factor sensitizes human ovarian cancer cells to cisplatin. 
Endocrinology, 2004. 145(4): p. 2014-22. 
377. Fernández de Mattos, S., et al., FOXO3a mediates the cytotoxic effects of 
cisplatin in colon cancer cells. Mol Cancer Ther, 2008. 7(10): p. 3237-46. 
378. Liang, X.J., et al., SIRT1 contributes in part to cisplatin resistance in 
cancer cells by altering mitochondrial metabolism. Mol Cancer Res, 2008. 
6(9): p. 1499-506. 
 234 
379. Huffman, D.M., et al., SIRT1 is significantly elevated in mouse and human 
prostate cancer. Cancer Res, 2007. 67(14): p. 6612-8. 
380. El-Naggar, S., Y. Liu, and D.C. Dean, Mutation of the Rb1 pathway leads 
to overexpression of mTor, constitutive phosphorylation of Akt on serine 
473, resistance to anoikis, and a block in c-Raf activation. Mol Cell Biol, 
2009. 29(21): p. 5710-7. 
381. Garcia-Echeverria, C. and W.R. Sellers, Drug discovery approaches 
targeting the PI3K/Akt pathway in cancer. Oncogene, 2008. 27(41): p. 
5511-26. 
382. Zhang, H.Y., P.N. Zhang, and H. Sun, Aberration of the PI3K/AKT/mTOR 
signaling in epithelial ovarian cancer and its implication in cisplatin-based 
chemotherapy. Eur J Obstet Gynecol Reprod Biol, 2009. 146(1): p. 81-6. 
383. Kwok, J.M., et al., FOXM1 confers acquired cisplatin resistance in breast 
cancer cells. Mol Cancer Res, 2010. 8(1): p. 24-34. 
384. Jacinto, E., et al., SIN1/MIP1 maintains rictor-mTOR complex integrity and 
regulates Akt phosphorylation and substrate specificity. Cell, 2006. 127(1): 
p. 125-37. 
385. Hiyama, T., et al., p53 Codon 72 polymorphism in gastric cancer 
susceptibility in patients with Helicobacter pylori-associated chronic 
gastritis. Int J Cancer, 2002. 100(3): p. 304-8. 
386. Hergenhahn, M., J.L. Luo, and M. Hollstein, p53 designer genes for the 
modern mouse. Cell Cycle, 2004. 3(6): p. 738-41. 
387. Glozak, M.A., et al., Acetylation and deacetylation of non-histone proteins. 
Gene, 2005. 363: p. 15-23. 
388. Sauve, A.A., et al., The biochemistry of sirtuins. Annu Rev Biochem, 2006. 
75: p. 435-65. 
389. Potente, M., et al., SIRT1 controls endothelial angiogenic functions during 
vascular growth. Genes Dev, 2007. 21(20): p. 2644-58. 
390. Schrump, D.S., Cytotoxicity mediated by histone deacetylase inhibitors in 
cancer cells: mechanisms and potential clinical implications. Clin Cancer 
Res, 2009. 15(12): p. 3947-57. 
 235 
391. Mann, B.S., et al., FDA approval summary: vorinostat for treatment of 
advanced primary cutaneous T-cell lymphoma. Oncologist, 2007. 12(10): 
p. 1247-52. 
392. Johnston, S., et al., Phase II study of predictive biomarker profiles for 
response targeting human epidermal growth factor receptor 2 (HER-2) in 
advanced inflammatory breast cancer with lapatinib monotherapy. J Clin 
Oncol, 2008. 26(7): p. 1066-72. 
393. Fu, W., et al., MDM2 acts downstream of p53 as an E3 ligase to promote 
FOXO ubiquitination and degradation. J Biol Chem, 2009. 284(21): p. 
13987-4000. 
394. Chou, T.C., Theoretical basis, experimental design, and computerized 
simulation of synergism and antagonism in drug combination studies. 
Pharmacol Rev, 2006. 58(3): p. 621-81. 
395. Wang, H., et al., [Research on synergy of combining electrochemical 
oxidation and catalytic wet oxidation]. Huan Jing Ke Xue, 2009. 30(7): p. 
1925-30. 
396. Kalra, J., et al., QLT0267, a small molecule inhibitor targeting integrin-
linked kinase (ILK), and docetaxel can combine to produce synergistic 
interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, 
altered F-actin architecture and improved treatment outcomes in an 
orthotopic breast cancer model. Breast Cancer Res, 2009. 11(3): p. R25. 
397. Zhang, W., et al., Histone deacetylase inhibitor romidepsin enhances anti-
tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines. J 
Thorac Oncol, 2009. 4(2): p. 161-6. 
398. Kopetz, S., et al., Synergistic activity of the SRC family kinase inhibitor 
dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative 
stress. Cancer Res, 2009. 69(9): p. 3842-9. 
399. Zhang, C., et al., Effect of verapamil on the expression of EGFR and 
NM23 in A549 human lung cancer cells. Anticancer Res, 2009. 29(1): p. 
27-32. 
 236 
400. Matsuzaki, H., et al., Regulation of intracellular localization and 
transcriptional activity of FOXO4 by protein kinase B through 
phosphorylation at the motif sites conserved among the FOXO family. J 
Biochem, 2005. 138(4): p. 485-91. 
401. Bartels, M., et al., Histone deacetylase inhibition modulates cell fate 
decisions during myeloid differentiation. Haematologica, 2010. 
402. Black, J.C., et al., The SIRT2 deacetylase regulates autoacetylation of 
p300. Mol Cell, 2008. 32(3): p. 449-55. 
403. Stiehl, D.P., et al., Histone deacetylase inhibitors synergize p300 
autoacetylation that regulates its transactivation activity and complex 
formation. Cancer Res, 2007. 67(5): p. 2256-64. 
404. Bozhanov, S.S., et al., Alterations in p53, BRCA1, ATM, PIK3CA, and 
HER2 genes and their effect in modifying clinicopathological 
characteristics and overall survival of Bulgarian patients with breast 
cancer. J Cancer Res Clin Oncol. 
405. Deal watch: Celgene acquires Gloucester pharmaceuticals, gaining 
approved HDAC inhibitor. Nat Rev Drug Discov, 2010. 9(2): p. 94. 
406. Schug, T.T. and X. Li, Surprising sirtuin crosstalk in the heart. Aging 
(Albany NY), 2010. 2(3): p. 129-32. 
407. Deng, C.X., SIRT1, is it a tumor promoter or tumor suppressor? Int J Biol 
Sci, 2009. 5(2): p. 147-52. 
408. Brooks, C.L. and W. Gu, How does SIRT1 affect metabolism, senescence 
and cancer? Nat Rev Cancer, 2009. 9(2): p. 123-8. 
409. Donmez, G. and L. Guarente, Aging and disease: connections to sirtuins. 
Aging Cell, 2010. 9(2): p. 285-90. 
410. Firestein, R., et al., The SIRT1 deacetylase suppresses intestinal 
tumorigenesis and colon cancer growth. PLoS One, 2008. 3(4): p. e2020. 
411. Spindler, S.R., Rapid and reversible induction of the longevity, anticancer 
and genomic effects of caloric restriction. Mech Ageing Dev, 2005. 126(9): 
p. 960-6. 
 237 
412. Boily, G., et al., SirT1-null mice develop tumors at normal rates but are 
poorly protected by resveratrol. Oncogene, 2009. 28(32): p. 2882-93. 
413. Wang, R.H., et al., Impaired DNA damage response, genome instability, 
and tumorigenesis in SIRT1 mutant mice. Cancer Cell, 2008. 14(4): p. 
312-23. 
414. Shang, L., et al., Serum withdrawal up-regulates human SIRT1 gene 
expression in a p53-dependent manner. J Cell Mol Med, 2008. 
415. Borra, M.T., B.C. Smith, and J.M. Denu, Mechanism of human SIRT1 
activation by resveratrol. J Biol Chem, 2005. 280(17): p. 17187-95. 
416. Beher, D., et al., Resveratrol is not a direct activator of SIRT1 enzyme 
activity. Chem Biol Drug Des, 2009. 74(6): p. 619-24. 
417. Jin, Y.H., et al., Sirt2 interacts with 14-3-3 beta/gamma and down-
regulates the activity of p53. Biochem Biophys Res Commun, 2008. 
368(3): p. 690-5. 
418. Ito, A., et al., p300/CBP-mediated p53 acetylation is commonly induced by 
p53-activating agents and inhibited by MDM2. EMBO J, 2001. 20(6): p. 
1331-40. 
419. Jung-Hynes, B. and N. Ahmad, SIRT1 controls circadian clock circuitry 
and promotes cell survival: a connection with age-related neoplasms. 
FASEB J, 2009. 23(9): p. 2803-9. 
420. Sharma, S.V., et al., A chromatin-mediated reversible drug-tolerant state 
in cancer cell subpopulations. Cell, 2010. 141(1): p. 69-80. 
421. Dannenberg, J.H. and A. Berns, Drugging drug resistance. Cell, 2010. 
141(1): p. 18-20. 
422. Pruitt, K., et al., Inhibition of SIRT1 reactivates silenced cancer genes 
without loss of promoter DNA hypermethylation. PLoS Genet, 2006. 2(3): 
p. e40. 
423. Blackwell, K.L., et al., Randomized study of Lapatinib alone or in 
combination with trastuzumab in women with ErbB2-positive, 
trastuzumab-refractory metastatic breast cancer. J Clin Oncol, 2010. 
28(7): p. 1124-30. 
 238 
424. Cai, X., et al., Discovery of 7-(4-(3-ethynylphenylamino)-7-
methoxyquinazolin-6-yloxy)-N-hydroxyheptanam ide (CUDc-101) as a 
potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of 
cancer. J Med Chem, 2010. 53(5): p. 2000-9. 
425. Lai, C.J., et al., CUDC-101, a multitargeted inhibitor of histone 
deacetylase, epidermal growth factor receptor, and human epidermal 
growth factor receptor 2, exerts potent anticancer activity. Cancer Res, 
2010. 70(9): p. 3647-56. 
426. Evans, A.H., et al., EGFR/HER2 inhibitor AEE788 increases ER-mediated 
transcription in HER2/ER-positive breast cancer cells but functions 
synergistically with endocrine therapy. Br J Cancer, 2010. 102(8): p. 1235-
43. 
427. Reis-Filho, J.S., et al., FGFR1 emerges as a potential therapeutic target 
for lobular breast carcinomas. Clin Cancer Res, 2006. 12(22): p. 6652-62. 
 
 
